
200	The  <e0>fluoroquinolones</e0>  are a rapidly growing class of  <e1>antibiotics</e1>  with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria. "
Other
Comment:

300	These agents, including  <e0>norfloxacin</e0> ,  <e1>ciprofloxacin</e1> ,  ofloxacin ,  enoxacin , and  lomefloxacin , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

301	These agents, including  <e0>norfloxacin</e0> ,  ciprofloxacin ,  <e1>ofloxacin</e1> ,  enoxacin , and  lomefloxacin , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

302	These agents, including  <e0>norfloxacin</e0> ,  ciprofloxacin ,  ofloxacin ,  <e1>enoxacin</e1> , and  lomefloxacin , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

303	These agents, including  <e0>norfloxacin</e0> ,  ciprofloxacin ,  ofloxacin ,  enoxacin , and  <e1>lomefloxacin</e1> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

304	These agents, including  norfloxacin ,  <e0>ciprofloxacin</e0> ,  <e1>ofloxacin</e1> ,  enoxacin , and  lomefloxacin , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

305	These agents, including  norfloxacin ,  <e0>ciprofloxacin</e0> ,  ofloxacin ,  <e1>enoxacin</e1> , and  lomefloxacin , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

306	These agents, including  norfloxacin ,  <e0>ciprofloxacin</e0> ,  ofloxacin ,  enoxacin , and  <e1>lomefloxacin</e1> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

307	These agents, including  norfloxacin ,  ciprofloxacin ,  <e0>ofloxacin</e0> ,  <e1>enoxacin</e1> , and  lomefloxacin , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

308	These agents, including  norfloxacin ,  ciprofloxacin ,  <e0>ofloxacin</e0> ,  enoxacin , and  <e1>lomefloxacin</e1> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

309	These agents, including  norfloxacin ,  ciprofloxacin ,  ofloxacin ,  <e0>enoxacin</e0> , and  <e1>lomefloxacin</e1> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. "
Other
Comment:

400	Advantages offered by this class of  <e0>antibiotics</e0>  include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral  <e1>antibiotics</e1>  are generally used. "
Other
Comment:


200	In order to provide information for the appropriate package insert labeling of  <e0>progestin-only oral contraceptives</e0>  ( <e1>POC</e1> ) in the US, a comprehensive review was made of  norgestrel  (0.075 mg) and  norethindrone  (0.35 mg), with the clinical differences indicated where applicable.  "
Other
Comment:

201	In order to provide information for the appropriate package insert labeling of  <e0>progestin-only oral contraceptives</e0>  ( POC ) in the US, a comprehensive review was made of  <e1>norgestrel</e1>  (0.075 mg) and  norethindrone  (0.35 mg), with the clinical differences indicated where applicable.  "
Other
Comment:

202	In order to provide information for the appropriate package insert labeling of  <e0>progestin-only oral contraceptives</e0>  ( POC ) in the US, a comprehensive review was made of  norgestrel  (0.075 mg) and  <e1>norethindrone</e1>  (0.35 mg), with the clinical differences indicated where applicable.  "
Other
Comment:

203	In order to provide information for the appropriate package insert labeling of  progestin-only oral contraceptives  ( <e0>POC</e0> ) in the US, a comprehensive review was made of  <e1>norgestrel</e1>  (0.075 mg) and  norethindrone  (0.35 mg), with the clinical differences indicated where applicable.  "
Other
Comment:

204	In order to provide information for the appropriate package insert labeling of  progestin-only oral contraceptives  ( <e0>POC</e0> ) in the US, a comprehensive review was made of  norgestrel  (0.075 mg) and  <e1>norethindrone</e1>  (0.35 mg), with the clinical differences indicated where applicable.  "
Other
Comment:

205	In order to provide information for the appropriate package insert labeling of  progestin-only oral contraceptives  ( POC ) in the US, a comprehensive review was made of  <e0>norgestrel</e0>  (0.075 mg) and  <e1>norethindrone</e1>  (0.35 mg), with the clinical differences indicated where applicable.  "
Other
Comment:


100	Antimicrobial activity of  <e0>Ganoderma lucidum extract</e0>  alone and in combination with some  <e1>antibiotics</e1> .
"
Other
Comment:

400	To investigate the effects of antimicrobial combinations of  <e0>GL</e0>  with four kinds of  <e1>antibiotics</e1>  ( ampicillin ,  cefazolin ,  oxytetracycline  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

401	To investigate the effects of antimicrobial combinations of  <e0>GL</e0>  with four kinds of  antibiotics  ( <e1>ampicillin</e1> ,  cefazolin ,  oxytetracycline  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

402	To investigate the effects of antimicrobial combinations of  <e0>GL</e0>  with four kinds of  antibiotics  ( ampicillin ,  <e1>cefazolin</e1> ,  oxytetracycline  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

403	To investigate the effects of antimicrobial combinations of  <e0>GL</e0>  with four kinds of  antibiotics  ( ampicillin ,  cefazolin ,  <e1>oxytetracycline</e1>  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

404	To investigate the effects of antimicrobial combinations of  <e0>GL</e0>  with four kinds of  antibiotics  ( ampicillin ,  cefazolin ,  oxytetracycline  and  <e1>chloramphenicol</e1> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

405	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  <e0>antibiotics</e0>  ( <e1>ampicillin</e1> ,  cefazolin ,  oxytetracycline  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

406	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  <e0>antibiotics</e0>  ( ampicillin ,  <e1>cefazolin</e1> ,  oxytetracycline  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

407	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  <e0>antibiotics</e0>  ( ampicillin ,  cefazolin ,  <e1>oxytetracycline</e1>  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

408	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  <e0>antibiotics</e0>  ( ampicillin ,  cefazolin ,  oxytetracycline  and  <e1>chloramphenicol</e1> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

409	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  antibiotics  ( <e0>ampicillin</e0> ,  <e1>cefazolin</e1> ,  oxytetracycline  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

410	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  antibiotics  ( <e0>ampicillin</e0> ,  cefazolin ,  <e1>oxytetracycline</e1>  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

411	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  antibiotics  ( <e0>ampicillin</e0> ,  cefazolin ,  oxytetracycline  and  <e1>chloramphenicol</e1> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

412	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  antibiotics  ( ampicillin ,  <e0>cefazolin</e0> ,  <e1>oxytetracycline</e1>  and  chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

413	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  antibiotics  ( ampicillin ,  <e0>cefazolin</e0> ,  oxytetracycline  and  <e1>chloramphenicol</e1> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

414	To investigate the effects of antimicrobial combinations of  GL  with four kinds of  antibiotics  ( ampicillin ,  cefazolin ,  <e0>oxytetracycline</e0>  and  <e1>chloramphenicol</e1> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. "
Other
Comment:

500	The antimicrobial combinations of  <e0>GL</e0>  with four  <e1>antibiotics</e1>  resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. "
effect(e0,e1)Comment:

600	Synergism was observed when  <e0>GL</e0>  was combined with  <e1>cefazolin</e1>  against Bacillus subtilis and Klebsiella oxytoca."
effect(e0,e1)Comment:


800	On the basis of the estimated number of regular users of intravenous  <e0>amphetamine</e0>  in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and  <e1>heroin</e1>  addicts. "
Other
Comment:

900	However, the absolute number of  <e0>alcohol</e0> -related deaths is far greater than the number of deaths in  <e1>amphetamine</e1>  or  heroin  users."
Other
Comment:

901	However, the absolute number of  <e0>alcohol</e0> -related deaths is far greater than the number of deaths in  amphetamine  or  <e1>heroin</e1>  users."
Other
Comment:

902	However, the absolute number of  alcohol -related deaths is far greater than the number of deaths in  <e0>amphetamine</e0>  or  <e1>heroin</e1>  users."
Other
Comment:




100	Differential regulation of tyrosine phosphorylation in tumor cells by  <e0>contortrostatin</e0> , a homodimeric disintegrin, and monomeric disintegrins  <e1>echistatin</e1>  and  flavoridin ."
Other
Comment:

101	Differential regulation of tyrosine phosphorylation in tumor cells by  <e0>contortrostatin</e0> , a homodimeric disintegrin, and monomeric disintegrins  echistatin  and  <e1>flavoridin</e1> ."
Other
Comment:

102	Differential regulation of tyrosine phosphorylation in tumor cells by  contortrostatin , a homodimeric disintegrin, and monomeric disintegrins  <e0>echistatin</e0>  and  <e1>flavoridin</e1> ."
Other
Comment:

200	The homodimeric disintegrin  <e0>contortrostatin</e0>  was compared directly to the monomeric disintegrins  <e1>echistatin</e1>  and  flavoridin  for the ability to affect protein tyrosine phosphorylation in tumor cells. "
Other
Comment:

201	The homodimeric disintegrin  <e0>contortrostatin</e0>  was compared directly to the monomeric disintegrins  echistatin  and  <e1>flavoridin</e1>  for the ability to affect protein tyrosine phosphorylation in tumor cells. "
Other
Comment:

202	The homodimeric disintegrin  contortrostatin  was compared directly to the monomeric disintegrins  <e0>echistatin</e0>  and  <e1>flavoridin</e1>  for the ability to affect protein tyrosine phosphorylation in tumor cells. "
Other
Comment:

400	 <e0>Echistatin</e0>  alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of  <e1>contortrostatin</e1>  when both are added simultaneously. "
effect(e0,e1)Comment:

600	 <e0>Flavoridin</e0>  alone was found to have no effect on CAS, but can completely block  <e1>contortrostatin</e1> -induced phosphorylation of this protein in MDA-MB-435 cells. "
effect(e0,e1)Comment:


400	 <e0>Diethyl pyrocarbonate</e0> , at pH 7.0, was used to chemically modify exposed histidine residues on  <e1>toxin A</e1> . "
Other
Comment:

500	Modification of  <e0>toxin A</e0>  with  <e1>diethyl pyrocarbonate</e1>  abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. "
Other
Comment:

600	Treatment of  <e0>toxin A</e0>  with [(14)C]- <e1>diethyl pyrocarbonate</e1>  revealed concentration dependent labelling of histidine residues on the toxin molecules. "
Other
Comment:

700	The effects of  <e0>diethyl pyrocarbonate</e0>  could be reversed by  <e1>hydroxylamine</e1>  treatment. "
Other
Comment:

1200	Exposed histidines on  <e0>toxin A</e0>  are available for  <e1>zinc</e1>  chelation, and these have been exploited in the development of a novel purification protocol for  toxin A  using  zinc -chelating chromatography."
Other
Comment:

1201	Exposed histidines on  <e0>toxin A</e0>  are available for  zinc  chelation, and these have been exploited in the development of a novel purification protocol for  <e1>toxin A</e1>  using  zinc -chelating chromatography."
Other
Comment:

1202	Exposed histidines on  <e0>toxin A</e0>  are available for  zinc  chelation, and these have been exploited in the development of a novel purification protocol for  toxin A  using  <e1>zinc</e1> -chelating chromatography."
Other
Comment:

1203	Exposed histidines on  toxin A  are available for  <e0>zinc</e0>  chelation, and these have been exploited in the development of a novel purification protocol for  <e1>toxin A</e1>  using  zinc -chelating chromatography."
Other
Comment:

1204	Exposed histidines on  toxin A  are available for  <e0>zinc</e0>  chelation, and these have been exploited in the development of a novel purification protocol for  toxin A  using  <e1>zinc</e1> -chelating chromatography."
Other
Comment:

1205	Exposed histidines on  toxin A  are available for  zinc  chelation, and these have been exploited in the development of a novel purification protocol for  <e0>toxin A</e0>  using  <e1>zinc</e1> -chelating chromatography."
Other
Comment:


100	Note: dissolution of aerosol particles of  <e0>budesonide</e0>  in  <e1>Survanta</e1> , a model  lung surfactant .
"
Other
Comment:

101	Note: dissolution of aerosol particles of  <e0>budesonide</e0>  in  Survanta , a model  <e1>lung surfactant</e1> .
"
Other
Comment:

102	Note: dissolution of aerosol particles of  budesonide  in  <e0>Survanta</e0> , a model  <e1>lung surfactant</e1> .
"
Other
Comment:

200	The effect of a  <e0>pulmonary surfactant</e0>  extract from bovine lung,  <e1>Survanta</e1> , on the dissolution rate of aerosol particles of  budesonide  was determined. "
Other
Comment:

201	The effect of a  <e0>pulmonary surfactant</e0>  extract from bovine lung,  Survanta , on the dissolution rate of aerosol particles of  <e1>budesonide</e1>  was determined. "
Other
Comment:

202	The effect of a  pulmonary surfactant  extract from bovine lung,  <e0>Survanta</e0> , on the dissolution rate of aerosol particles of  <e1>budesonide</e1>  was determined. "
Other
Comment:

300	Aerosol particles of  <e0>budesonide</e0>  were generated from an  <e1>ethanol</e1>  solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. "
Other
Comment:

700	 <e0>Survanta</e0>  increased the extent of dissolution of  <e1>budesonide</e1>  in proportion to the added concentration, which was also verified by equilibrium solubilization studies. "
Other
Comment:

800	 <e0>Survanta</e0>  also increased rate of dissolution, in a manner similar to  <e1>sodium dodecyl sulfate</e1> . "
Other
Comment:

900	Analysis of the concentration of  <e0>budesonide</e0>  following ultracentrifugation indicated that there is rapid equilibration of  <e1>budesonide</e1>  between the  Survanta  and aqueous phase. "
Other
Comment:

901	Analysis of the concentration of  <e0>budesonide</e0>  following ultracentrifugation indicated that there is rapid equilibration of  budesonide  between the  <e1>Survanta</e1>  and aqueous phase. "
Other
Comment:

902	Analysis of the concentration of  budesonide  following ultracentrifugation indicated that there is rapid equilibration of  <e0>budesonide</e0>  between the  <e1>Survanta</e1>  and aqueous phase. "
Other
Comment:


200	As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by  <e0>methamphetamine</e0>  ( <e1>METH</e1> ) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. "
Other
Comment:

500	Using in situ hybridization, we observed that  <e0>METH</e0>  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  <e1>SCH-23390</e1>  but not by an  atypical neuroleptic   clozapine . "
effect(e0,e1)Comment:

501	Using in situ hybridization, we observed that  <e0>METH</e0>  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  SCH-23390  but not by an  <e1>atypical neuroleptic</e1>   clozapine . "
Other
Comment:

502	Using in situ hybridization, we observed that  <e0>METH</e0>  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  SCH-23390  but not by an  atypical neuroleptic   <e1>clozapine</e1> . "
Other
Comment:

503	Using in situ hybridization, we observed that  METH  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  <e0>SCH-23390</e0>  but not by an  <e1>atypical neuroleptic</e1>   clozapine . "
Other
Comment:

504	Using in situ hybridization, we observed that  METH  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  <e0>SCH-23390</e0>  but not by an  atypical neuroleptic   <e1>clozapine</e1> . "
Other
Comment:

505	Using in situ hybridization, we observed that  METH  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  SCH-23390  but not by an  <e0>atypical neuroleptic</e0>   <e1>clozapine</e1> . "
Other
Comment:


100	The effects of  <e0>DCG-IV</e0>  and  <e1>L-CCG-1</e1>  upon  phencyclidine  ( PCP )-induced locomotion and behavioral changes in mice.
"
Other
Comment:

101	The effects of  <e0>DCG-IV</e0>  and  L-CCG-1  upon  <e1>phencyclidine</e1>  ( PCP )-induced locomotion and behavioral changes in mice.
"
Other
Comment:

102	The effects of  <e0>DCG-IV</e0>  and  L-CCG-1  upon  phencyclidine  ( <e1>PCP</e1> )-induced locomotion and behavioral changes in mice.
"
Other
Comment:

103	The effects of  DCG-IV  and  <e0>L-CCG-1</e0>  upon  <e1>phencyclidine</e1>  ( PCP )-induced locomotion and behavioral changes in mice.
"
Other
Comment:

104	The effects of  DCG-IV  and  <e0>L-CCG-1</e0>  upon  phencyclidine  ( <e1>PCP</e1> )-induced locomotion and behavioral changes in mice.
"
Other
Comment:

105	The effects of  DCG-IV  and  L-CCG-1  upon  <e0>phencyclidine</e0>  ( <e1>PCP</e1> )-induced locomotion and behavioral changes in mice.
"
Other
Comment:

300	injection of  <e0>phencyclidine</e0>  ( <e1>PCP</e1> ) were observed by measuring locomotor activity and stereotyped behavior. "
Other
Comment:

400	Then, the effects of metabotropic glutamate receptor (mGluR) agonists,  <e0>DCG-IV</e0>  and  <e1>L-CCG-1</e1> , on the above behavioral changes induced by  PCP  were found. "
Other
Comment:

401	Then, the effects of metabotropic glutamate receptor (mGluR) agonists,  <e0>DCG-IV</e0>  and  L-CCG-1 , on the above behavioral changes induced by  <e1>PCP</e1>  were found. "
Other
Comment:

402	Then, the effects of metabotropic glutamate receptor (mGluR) agonists,  DCG-IV  and  <e0>L-CCG-1</e0> , on the above behavioral changes induced by  <e1>PCP</e1>  were found. "
Other
Comment:

500	The effects of  <e0>DCG-IV</e0>  were very strong and completely depressed the  <e1>PCP</e1> -induced hyperlocomotion. "
effect(e0,e1)Comment:

900	In order to examine some molecular mechanisms of  <e0>PCP</e0> -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  <e1>PCP</e1> ,  DCG-IV , and  L-CCG-1  was carried out."
Other
Comment:

901	In order to examine some molecular mechanisms of  <e0>PCP</e0> -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  PCP ,  <e1>DCG-IV</e1> , and  L-CCG-1  was carried out."
Other
Comment:

902	In order to examine some molecular mechanisms of  <e0>PCP</e0> -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  PCP ,  DCG-IV , and  <e1>L-CCG-1</e1>  was carried out."
Other
Comment:

903	In order to examine some molecular mechanisms of  PCP -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  <e0>PCP</e0> ,  <e1>DCG-IV</e1> , and  L-CCG-1  was carried out."
Other
Comment:

904	In order to examine some molecular mechanisms of  PCP -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  <e0>PCP</e0> ,  DCG-IV , and  <e1>L-CCG-1</e1>  was carried out."
Other
Comment:

905	In order to examine some molecular mechanisms of  PCP -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  PCP ,  <e0>DCG-IV</e0> , and  <e1>L-CCG-1</e1>  was carried out."
Other
Comment:


100	Behavioral responses to repeated  <e0>cocaine</e0>  exposure in mice selectively bred for differential sensitivity to  <e1>pentobarbital</e1> .
"
Other
Comment:

200	Mice from the 20th generation of three lines divergently selected for response to  <e0>pentobarbital</e0> -induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study  <e1>cocaine</e1> -induced behavioral sensitization. "
Other
Comment:


100	 <e0>18-Methoxycoronaridine</e0>  ( <e1>18-MC</e1> ) and  ibogaine : comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"
Other
Comment:

101	 <e0>18-Methoxycoronaridine</e0>  ( 18-MC ) and  <e1>ibogaine</e1> : comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"
Other
Comment:

102	 18-Methoxycoronaridine  ( <e0>18-MC</e0> ) and  <e1>ibogaine</e1> : comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"
Other
Comment:

300	Like  <e0>ibogaine</e0>  (40 mg/kg),  <e1>18-MC</e1>  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  cocaine  and the oral self-administration of  ethanol  and  nicotine  in rats; "
Other
Comment:

301	Like  <e0>ibogaine</e0>  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  <e1>morphine</e1>  and  cocaine  and the oral self-administration of  ethanol  and  nicotine  in rats; "
Other
Comment:

302	Like  <e0>ibogaine</e0>  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  <e1>cocaine</e1>  and the oral self-administration of  ethanol  and  nicotine  in rats; "
Other
Comment:

303	Like  <e0>ibogaine</e0>  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  cocaine  and the oral self-administration of  <e1>ethanol</e1>  and  nicotine  in rats; "
Other
Comment:

304	Like  <e0>ibogaine</e0>  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  cocaine  and the oral self-administration of  ethanol  and  <e1>nicotine</e1>  in rats; "
Other
Comment:

305	Like  ibogaine  (40 mg/kg),  <e0>18-MC</e0>  (40 mg/kg) decreases the intravenous self-administration of  <e1>morphine</e1>  and  cocaine  and the oral self-administration of  ethanol  and  nicotine  in rats; "
Other
Comment:

306	Like  ibogaine  (40 mg/kg),  <e0>18-MC</e0>  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  <e1>cocaine</e1>  and the oral self-administration of  ethanol  and  nicotine  in rats; "
Other
Comment:

307	Like  ibogaine  (40 mg/kg),  <e0>18-MC</e0>  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  cocaine  and the oral self-administration of  <e1>ethanol</e1>  and  nicotine  in rats; "
Other
Comment:

308	Like  ibogaine  (40 mg/kg),  <e0>18-MC</e0>  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  cocaine  and the oral self-administration of  ethanol  and  <e1>nicotine</e1>  in rats; "
Other
Comment:

309	Like  ibogaine  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  <e0>morphine</e0>  and  <e1>cocaine</e1>  and the oral self-administration of  ethanol  and  nicotine  in rats; "
Other
Comment:

310	Like  ibogaine  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  <e0>morphine</e0>  and  cocaine  and the oral self-administration of  <e1>ethanol</e1>  and  nicotine  in rats; "
Other
Comment:

311	Like  ibogaine  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  <e0>morphine</e0>  and  cocaine  and the oral self-administration of  ethanol  and  <e1>nicotine</e1>  in rats; "
Other
Comment:

312	Like  ibogaine  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  <e0>cocaine</e0>  and the oral self-administration of  <e1>ethanol</e1>  and  nicotine  in rats; "
Other
Comment:

313	Like  ibogaine  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  <e0>cocaine</e0>  and the oral self-administration of  ethanol  and  <e1>nicotine</e1>  in rats; "
Other
Comment:

314	Like  ibogaine  (40 mg/kg),  18-MC  (40 mg/kg) decreases the intravenous self-administration of  morphine  and  cocaine  and the oral self-administration of  <e0>ethanol</e0>  and  <e1>nicotine</e1>  in rats; "
Other
Comment:

400	unlike  <e0>ibogaine</e0> ,  <e1>18-MC</e1>  does not affect responding for a nondrug reinforcer (water). "
Other
Comment:

500	Both  <e0>ibogaine</e0>  and  <e1>18-MC</e1>  ameliorate  opioid  withdrawal signs. "
Other
Comment:

501	Both  <e0>ibogaine</e0>  and  18-MC  ameliorate  <e1>opioid</e1>  withdrawal signs. "
Other
Comment:

502	Both  ibogaine  and  <e0>18-MC</e0>  ameliorate  <e1>opioid</e1>  withdrawal signs. "
Other
Comment:

600	Both  <e0>ibogaine</e0>  and  <e1>18-MC</e1>  decrease extracellular levels of dopamine in the nucleus accumbens, but only  ibogaine  increases extracellular levels of serotonin in the nucleus accumbens. "
Other
Comment:

601	Both  <e0>ibogaine</e0>  and  18-MC  decrease extracellular levels of dopamine in the nucleus accumbens, but only  <e1>ibogaine</e1>  increases extracellular levels of serotonin in the nucleus accumbens. "
Other
Comment:

602	Both  ibogaine  and  <e0>18-MC</e0>  decrease extracellular levels of dopamine in the nucleus accumbens, but only  <e1>ibogaine</e1>  increases extracellular levels of serotonin in the nucleus accumbens. "
Other
Comment:

700	Both  <e0>ibogaine</e0>  and  <e1>18-MC</e1>  block  morphine -induced and  nicotine -induced dopamine release in the nucleus accumbens; "
Other
Comment:

701	Both  <e0>ibogaine</e0>  and  18-MC  block  <e1>morphine</e1> -induced and  nicotine -induced dopamine release in the nucleus accumbens; "
effect(e0,e1)Comment:

702	Both  <e0>ibogaine</e0>  and  18-MC  block  morphine -induced and  <e1>nicotine</e1> -induced dopamine release in the nucleus accumbens; "
effect(e0,e1)Comment:

703	Both  ibogaine  and  <e0>18-MC</e0>  block  <e1>morphine</e1> -induced and  nicotine -induced dopamine release in the nucleus accumbens; "
effect(e0,e1)Comment:

704	Both  ibogaine  and  <e0>18-MC</e0>  block  morphine -induced and  <e1>nicotine</e1> -induced dopamine release in the nucleus accumbens; "
effect(e0,e1)Comment:

705	Both  ibogaine  and  18-MC  block  <e0>morphine</e0> -induced and  <e1>nicotine</e1> -induced dopamine release in the nucleus accumbens; "
Other
Comment:

800	only  <e0>ibogaine</e0>  enhances  <e1>cocaine</e1> -induced increases in accumbal dopamine. "
effect(e0,e1)Comment:

900	Both  <e0>ibogaine</e0>  and  <e1>18-MC</e1>  enhance the locomotor and/or stereotypic effects of stimulants. "
Other
Comment:

1000	 <e0>Ibogaine</e0>  attenuates, but  <e1>18-MC</e1>  potentiates, the acute locomotor effects of  morphine ; "
Other
Comment:

1001	 <e0>Ibogaine</e0>  attenuates, but  18-MC  potentiates, the acute locomotor effects of  <e1>morphine</e1> ; "
effect(e0,e1)Comment:

1002	 Ibogaine  attenuates, but  <e0>18-MC</e0>  potentiates, the acute locomotor effects of  <e1>morphine</e1> ; "
effect(e0,e1)Comment:

1100	both compounds attenuate  <e0>morphine</e0> -induced locomotion in  <e1>morphine</e1> -experienced rats. "
Other
Comment:

1400	 <e0>Ibogaine</e0> , but not  <e1>18-MC</e1> , decreases heart rate at high doses. "
Other
Comment:

1500	While  <e0>18-MC</e0>  and  <e1>ibogaine</e1>  have similar affinities for kappa opioid and possibly nicotinic receptors,  18-MC  has much lower affinities than  ibogaine  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. "
Other
Comment:

1501	While  <e0>18-MC</e0>  and  ibogaine  have similar affinities for kappa opioid and possibly nicotinic receptors,  <e1>18-MC</e1>  has much lower affinities than  ibogaine  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. "
Other
Comment:

1502	While  <e0>18-MC</e0>  and  ibogaine  have similar affinities for kappa opioid and possibly nicotinic receptors,  18-MC  has much lower affinities than  <e1>ibogaine</e1>  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. "
Other
Comment:

1503	While  18-MC  and  <e0>ibogaine</e0>  have similar affinities for kappa opioid and possibly nicotinic receptors,  <e1>18-MC</e1>  has much lower affinities than  ibogaine  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. "
Other
Comment:

1504	While  18-MC  and  <e0>ibogaine</e0>  have similar affinities for kappa opioid and possibly nicotinic receptors,  18-MC  has much lower affinities than  <e1>ibogaine</e1>  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. "
Other
Comment:

1505	While  18-MC  and  ibogaine  have similar affinities for kappa opioid and possibly nicotinic receptors,  <e0>18-MC</e0>  has much lower affinities than  <e1>ibogaine</e1>  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. "
Other
Comment:

1600	Both  <e0>18-MC</e0>  and  <e1>ibogaine</e1>  are sequestered in fat and, like  ibogaine ,  18-MC  probably has an active metabolite. "
Other
Comment:

1601	Both  <e0>18-MC</e0>  and  ibogaine  are sequestered in fat and, like  <e1>ibogaine</e1> ,  18-MC  probably has an active metabolite. "
Other
Comment:

1602	Both  <e0>18-MC</e0>  and  ibogaine  are sequestered in fat and, like  ibogaine ,  <e1>18-MC</e1>  probably has an active metabolite. "
Other
Comment:

1603	Both  18-MC  and  <e0>ibogaine</e0>  are sequestered in fat and, like  <e1>ibogaine</e1> ,  18-MC  probably has an active metabolite. "
Other
Comment:

1604	Both  18-MC  and  <e0>ibogaine</e0>  are sequestered in fat and, like  ibogaine ,  <e1>18-MC</e1>  probably has an active metabolite. "
Other
Comment:

1605	Both  18-MC  and  ibogaine  are sequestered in fat and, like  <e0>ibogaine</e0> ,  <e1>18-MC</e1>  probably has an active metabolite. "
Other
Comment:

1700	The data suggest that  <e0>18-MC</e0>  has a narrower spectrum of actions and will have a substantially greater therapeutic index than  <e1>ibogaine</e1> ."
Other
Comment:


100	Clinical implications of  <e0>warfarin</e0>  interactions with five  <e1>sedatives</e1> .
"
int(e0,e1)Comment:

200	The intensity, uniformity and time course of  <e0>anticoagulant</e0>  interference by  <e1>phenobarbital</e1> ,  secobarbital ,  glutethimide ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

201	The intensity, uniformity and time course of  <e0>anticoagulant</e0>  interference by  phenobarbital ,  <e1>secobarbital</e1> ,  glutethimide ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

202	The intensity, uniformity and time course of  <e0>anticoagulant</e0>  interference by  phenobarbital ,  secobarbital ,  <e1>glutethimide</e1> ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

203	The intensity, uniformity and time course of  <e0>anticoagulant</e0>  interference by  phenobarbital ,  secobarbital ,  glutethimide ,  <e1>chloral hydrate</e1>  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

204	The intensity, uniformity and time course of  <e0>anticoagulant</e0>  interference by  phenobarbital ,  secobarbital ,  glutethimide ,  chloral hydrate  and  <e1>methaqualone</e1>  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

205	The intensity, uniformity and time course of  <e0>anticoagulant</e0>  interference by  phenobarbital ,  secobarbital ,  glutethimide ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  <e1>coumarin</e1>  therapy. "
Other
Comment:

206	The intensity, uniformity and time course of  anticoagulant  interference by  <e0>phenobarbital</e0> ,  <e1>secobarbital</e1> ,  glutethimide ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

207	The intensity, uniformity and time course of  anticoagulant  interference by  <e0>phenobarbital</e0> ,  secobarbital ,  <e1>glutethimide</e1> ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

208	The intensity, uniformity and time course of  anticoagulant  interference by  <e0>phenobarbital</e0> ,  secobarbital ,  glutethimide ,  <e1>chloral hydrate</e1>  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

209	The intensity, uniformity and time course of  anticoagulant  interference by  <e0>phenobarbital</e0> ,  secobarbital ,  glutethimide ,  chloral hydrate  and  <e1>methaqualone</e1>  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

210	The intensity, uniformity and time course of  anticoagulant  interference by  <e0>phenobarbital</e0> ,  secobarbital ,  glutethimide ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  <e1>coumarin</e1>  therapy. "
Other
Comment:

211	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  <e0>secobarbital</e0> ,  <e1>glutethimide</e1> ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

212	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  <e0>secobarbital</e0> ,  glutethimide ,  <e1>chloral hydrate</e1>  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

213	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  <e0>secobarbital</e0> ,  glutethimide ,  chloral hydrate  and  <e1>methaqualone</e1>  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

214	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  <e0>secobarbital</e0> ,  glutethimide ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  <e1>coumarin</e1>  therapy. "
Other
Comment:

215	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  secobarbital ,  <e0>glutethimide</e0> ,  <e1>chloral hydrate</e1>  and  methaqualone  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

216	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  secobarbital ,  <e0>glutethimide</e0> ,  chloral hydrate  and  <e1>methaqualone</e1>  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

217	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  secobarbital ,  <e0>glutethimide</e0> ,  chloral hydrate  and  methaqualone  were systematically investigated in 16 patients receiving  <e1>coumarin</e1>  therapy. "
Other
Comment:

218	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  secobarbital ,  glutethimide ,  <e0>chloral hydrate</e0>  and  <e1>methaqualone</e1>  were systematically investigated in 16 patients receiving  coumarin  therapy. "
Other
Comment:

219	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  secobarbital ,  glutethimide ,  <e0>chloral hydrate</e0>  and  methaqualone  were systematically investigated in 16 patients receiving  <e1>coumarin</e1>  therapy. "
Other
Comment:

220	The intensity, uniformity and time course of  anticoagulant  interference by  phenobarbital ,  secobarbital ,  glutethimide ,  chloral hydrate  and  <e0>methaqualone</e0>  were systematically investigated in 16 patients receiving  <e1>coumarin</e1>  therapy. "
Other
Comment:

500	Anticoagulant inhibition was observed during the administration of  <e0>phenobarbital</e0> ,  <e1>secobarbital</e1>  and  glutethimide ; "
Other
Comment:

501	Anticoagulant inhibition was observed during the administration of  <e0>phenobarbital</e0> ,  secobarbital  and  <e1>glutethimide</e1> ; "
Other
Comment:

502	Anticoagulant inhibition was observed during the administration of  phenobarbital ,  <e0>secobarbital</e0>  and  <e1>glutethimide</e1> ; "
Other
Comment:

600	there was no significant change in prothrombin test results during the trials of  <e0>chloral hydrate</e0>  and  <e1>methaqualone</e1> . "
Other
Comment:

700	 <e0>Barbiturates</e0>  and  <e1>glutethimide</e1>  should not be administered to patients receiving  coumarin drugs . "
Other
Comment:

701	 <e0>Barbiturates</e0>  and  glutethimide  should not be administered to patients receiving  <e1>coumarin drugs</e1> . "
advise(e0,e1)Comment:

702	 Barbiturates  and  <e0>glutethimide</e0>  should not be administered to patients receiving  <e1>coumarin drugs</e1> . "
advise(e0,e1)Comment:

900	 <e0>Chloral hydrate</e0>  and  <e1>methaqualone</e1>  interact pharmacologically with orally administered  anticoagulant agents , but the effect is not clinically significant. "
Other
Comment:

901	 <e0>Chloral hydrate</e0>  and  methaqualone  interact pharmacologically with orally administered  <e1>anticoagulant agents</e1> , but the effect is not clinically significant. "
int(e0,e1)Comment:

902	 Chloral hydrate  and  <e0>methaqualone</e0>  interact pharmacologically with orally administered  <e1>anticoagulant agents</e1> , but the effect is not clinically significant. "
int(e0,e1)Comment:

1000	It is concluded that  <e0>chloral hydrate</e0>  and  <e1>methaqualone</e1>  may be administered safely without additional caution in prothrombin test monitoring during oral  anticoagulant  therapy."
Other
Comment:

1001	It is concluded that  <e0>chloral hydrate</e0>  and  methaqualone  may be administered safely without additional caution in prothrombin test monitoring during oral  <e1>anticoagulant</e1>  therapy."
Other
Comment:

1002	It is concluded that  chloral hydrate  and  <e0>methaqualone</e0>  may be administered safely without additional caution in prothrombin test monitoring during oral  <e1>anticoagulant</e1>  therapy."
Other
Comment:



700	Concomitantly given  <e0>thiazide diuretics</e0>  did not interfere with the absorption of a tablet of  <e1>digoxin</e1> . "
Other
Comment:


100	Combinations of  <e0>clozapine</e0>  and  <e1>phencyclidine</e1> : effects on drug discrimination and behavioral inhibition in rats.
"
Other
Comment:

200	 <e0>Phencyclidine</e0>  ( <e1>PCP</e1> ) produces psychotomimetic effects in humans that resemble schizophrenia symptoms. "
Other
Comment:

400	In the present study, the  <e0>atypical antipsychotic</e0>   <e1>clozapine</e1>  was tested in combination with an active dose of  PCP  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. "
Other
Comment:

401	In the present study, the  <e0>atypical antipsychotic</e0>   clozapine  was tested in combination with an active dose of  <e1>PCP</e1>  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. "
Other
Comment:

402	In the present study, the  atypical antipsychotic   <e0>clozapine</e0>  was tested in combination with an active dose of  <e1>PCP</e1>  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. "
Other
Comment:

500	 <e0>PCP</e0>  produced distinctive effects in each task: it substituted for the training dose in  <e1>PCP</e1>  discrimination and it increased the number of responses with short (lt;3 s) interresponse times as well as increasing overall response rates in the DRL schedule. "
Other
Comment:

600	Acute dosing with  <e0>clozapine</e0>  failed to alter the behavioral effects of  <e1>PCP</e1>  in either procedure even when tested up to doses that produced pharmacological effects alone. "
Other
Comment:

700	These results suggest that acute dosing with  <e0>clozapine</e0>  would not affect behaviors most closely associated with  <e1>PCP</e1>  intoxication. "
Other
Comment:

900	Since chronic dosing is required for therapeutic efficacy of  <e0>antipsychotics</e0> , future studies should focus on investigation of chronic dosing effects of these drugs in combination with  <e1>PCP</e1> ."
Other
Comment:


500	 <e0>Resveratrol</e0>  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  <e1>noradrenaline</e1>  (8 micromol/l) or  KCl  (125 mmol/l) from both lean and dietary-obese rats. "
Other
Comment:

501	 <e0>Resveratrol</e0>  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  noradrenaline  (8 micromol/l) or  <e1>KCl</e1>  (125 mmol/l) from both lean and dietary-obese rats. "
Other
Comment:

502	 Resveratrol  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  <e0>noradrenaline</e0>  (8 micromol/l) or  <e1>KCl</e1>  (125 mmol/l) from both lean and dietary-obese rats. "
Other
Comment:

700	However,  <e0>L-NAME</e0>  (100 and 300 micromol/l) did not alter the effects of  <e1>reseveratrol</e1>  on arteries from dietary-obese rats, giving superimposed concentration-responses curves. "
Other
Comment:

800	 <e0>Indomethacin</e0>  was also ineffective in altering  <e1>resveratrol</e1>  activity in arteries from both lean and dietary-obese rats. "
Other
Comment:

900	In  <e0>noradrenaline</e0> -precontracted arteries from dietary-obese rats, responses to  <e1>resveratrol</e1>  were not attenuated by endothelial denudation, indicating an action independent of the endothelium. "
Other
Comment:

1000	This study indicates that: (a) the maximal effects of  <e0>resveratrol</e0>  on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of  <e1>resveratrol</e1>  in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO."
Other
Comment:


100	If taken 1 hour before  <e0>indinavir</e0>  ( <e1>IDV</e1> ),  didanosine  does not affect  IDV  exposure, despite persistent buffering effects.
"
Other
Comment:

101	If taken 1 hour before  <e0>indinavir</e0>  ( IDV ),  <e1>didanosine</e1>  does not affect  IDV  exposure, despite persistent buffering effects.
"
Other
Comment:

102	If taken 1 hour before  <e0>indinavir</e0>  ( IDV ),  didanosine  does not affect  <e1>IDV</e1>  exposure, despite persistent buffering effects.
"
Other
Comment:

103	If taken 1 hour before  indinavir  ( <e0>IDV</e0> ),  <e1>didanosine</e1>  does not affect  IDV  exposure, despite persistent buffering effects.
"
Other
Comment:

104	If taken 1 hour before  indinavir  ( <e0>IDV</e0> ),  didanosine  does not affect  <e1>IDV</e1>  exposure, despite persistent buffering effects.
"
Other
Comment:

105	If taken 1 hour before  indinavir  ( IDV ),  <e0>didanosine</e0>  does not affect  <e1>IDV</e1>  exposure, despite persistent buffering effects.
"
Other
Comment:

200	Concurrent administration of  <e0>indinavir</e0>  and  <e1>didanosine</e1>  significantly reduces the level of exposure to  indinavir , but it is unclear how soon after  didanosine  administration  indinavir  may be given safely. "
mechanism(e0,e1)Comment:

201	Concurrent administration of  <e0>indinavir</e0>  and  didanosine  significantly reduces the level of exposure to  <e1>indinavir</e1> , but it is unclear how soon after  didanosine  administration  indinavir  may be given safely. "
Other
Comment:

202	Concurrent administration of  <e0>indinavir</e0>  and  didanosine  significantly reduces the level of exposure to  indinavir , but it is unclear how soon after  <e1>didanosine</e1>  administration  indinavir  may be given safely. "
Other
Comment:

203	Concurrent administration of  <e0>indinavir</e0>  and  didanosine  significantly reduces the level of exposure to  indinavir , but it is unclear how soon after  didanosine  administration  <e1>indinavir</e1>  may be given safely. "
Other
Comment:

204	Concurrent administration of  indinavir  and  <e0>didanosine</e0>  significantly reduces the level of exposure to  <e1>indinavir</e1> , but it is unclear how soon after  didanosine  administration  indinavir  may be given safely. "
Other
Comment:

205	Concurrent administration of  indinavir  and  <e0>didanosine</e0>  significantly reduces the level of exposure to  indinavir , but it is unclear how soon after  <e1>didanosine</e1>  administration  indinavir  may be given safely. "
Other
Comment:

206	Concurrent administration of  indinavir  and  <e0>didanosine</e0>  significantly reduces the level of exposure to  indinavir , but it is unclear how soon after  didanosine  administration  <e1>indinavir</e1>  may be given safely. "
Other
Comment:

207	Concurrent administration of  indinavir  and  didanosine  significantly reduces the level of exposure to  <e0>indinavir</e0> , but it is unclear how soon after  <e1>didanosine</e1>  administration  indinavir  may be given safely. "
Other
Comment:

208	Concurrent administration of  indinavir  and  didanosine  significantly reduces the level of exposure to  <e0>indinavir</e0> , but it is unclear how soon after  didanosine  administration  <e1>indinavir</e1>  may be given safely. "
Other
Comment:

209	Concurrent administration of  indinavir  and  didanosine  significantly reduces the level of exposure to  indinavir , but it is unclear how soon after  <e0>didanosine</e0>  administration  <e1>indinavir</e1>  may be given safely. "
Other
Comment:

300	We compared  <e0>indinavir</e0>  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  <e1>indinavir</e1>  alone versus 800 mg of  indinavir  administered 1 h after  didanosine  administration. "
Other
Comment:

301	We compared  <e0>indinavir</e0>  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  indinavir  alone versus 800 mg of  <e1>indinavir</e1>  administered 1 h after  didanosine  administration. "
Other
Comment:

302	We compared  <e0>indinavir</e0>  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  indinavir  alone versus 800 mg of  indinavir  administered 1 h after  <e1>didanosine</e1>  administration. "
Other
Comment:

303	We compared  indinavir  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  <e0>indinavir</e0>  alone versus 800 mg of  <e1>indinavir</e1>  administered 1 h after  didanosine  administration. "
Other
Comment:

304	We compared  indinavir  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  <e0>indinavir</e0>  alone versus 800 mg of  indinavir  administered 1 h after  <e1>didanosine</e1>  administration. "
Other
Comment:

305	We compared  indinavir  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  indinavir  alone versus 800 mg of  <e0>indinavir</e0>  administered 1 h after  <e1>didanosine</e1>  administration. "
Other
Comment:

400	Median gastric pH was significantly higher when  <e0>indinavir</e0>  was taken after  <e1>didanosine</e1>  administration; "
mechanism(e0,e1)Comment:

600	 <e0>Indinavir</e0>  may be taken with a light meal 1 h following the administration of 400 mg of  <e1>didanosine</e1> ."
advise(e0,e1)Comment:


500	 <e0>Cytochalasin D</e0>  at 10 microM preferentially blocked the secretory effect of  <e1>carbachol</e1>  and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. "
effect(e0,e1)Comment:

600	 <e0>Cytochalasin D</e0>  inhibited the  <e1>carbachol</e1> -stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. "
effect(e0,e1)Comment:


400	The percentage of neurons hyperpolarized by  <e0>mu- selective opioids</e0> ,  <e1>delta(1)- selective opioids</e1> , and  kappa-selective opioids  was significantly reduced when 1% but not lt; "
Other
Comment:

401	The percentage of neurons hyperpolarized by  <e0>mu- selective opioids</e0> ,  delta(1)- selective opioids , and  <e1>kappa-selective opioids</e1>  was significantly reduced when 1% but not lt; "
Other
Comment:

402	The percentage of neurons hyperpolarized by  mu- selective opioids ,  <e0>delta(1)- selective opioids</e0> , and  <e1>kappa-selective opioids</e1>  was significantly reduced when 1% but not lt; "
Other
Comment:



100	Suppression by  <e0>verapamil</e0>  of  <e1>bombesin</e1> -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  in wistar rats.
"
effect(e0,e1)Comment:

101	Suppression by  <e0>verapamil</e0>  of  bombesin -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by  <e1>azoxymethane</e1>  in wistar rats.
"
Other
Comment:

102	Suppression by  verapamil  of  <e0>bombesin</e0> -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by  <e1>azoxymethane</e1>  in wistar rats.
"
Other
Comment:

200	BACKGROUND: The effects of combined administration of  <e0>bombesin</e0>  and  <e1>verapamil hydrochloride</e1>  ( verapamil ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

201	BACKGROUND: The effects of combined administration of  <e0>bombesin</e0>  and  verapamil hydrochloride  ( <e1>verapamil</e1> ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

202	BACKGROUND: The effects of combined administration of  <e0>bombesin</e0>  and  verapamil hydrochloride  ( verapamil ), a  <e1>calcium channel blocker</e1> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

203	BACKGROUND: The effects of combined administration of  <e0>bombesin</e0>  and  verapamil hydrochloride  ( verapamil ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e1>azoxymethane</e1>  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

204	BACKGROUND: The effects of combined administration of  <e0>bombesin</e0>  and  verapamil hydrochloride  ( verapamil ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( <e1>AOM</e1> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

205	BACKGROUND: The effects of combined administration of  bombesin  and  <e0>verapamil hydrochloride</e0>  ( <e1>verapamil</e1> ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

206	BACKGROUND: The effects of combined administration of  bombesin  and  <e0>verapamil hydrochloride</e0>  ( verapamil ), a  <e1>calcium channel blocker</e1> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

207	BACKGROUND: The effects of combined administration of  bombesin  and  <e0>verapamil hydrochloride</e0>  ( verapamil ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e1>azoxymethane</e1>  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

208	BACKGROUND: The effects of combined administration of  bombesin  and  <e0>verapamil hydrochloride</e0>  ( verapamil ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( <e1>AOM</e1> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

209	BACKGROUND: The effects of combined administration of  bombesin  and  verapamil hydrochloride  ( <e0>verapamil</e0> ), a  <e1>calcium channel blocker</e1> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

210	BACKGROUND: The effects of combined administration of  bombesin  and  verapamil hydrochloride  ( <e0>verapamil</e0> ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e1>azoxymethane</e1>  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

211	BACKGROUND: The effects of combined administration of  bombesin  and  verapamil hydrochloride  ( <e0>verapamil</e0> ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( <e1>AOM</e1> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

212	BACKGROUND: The effects of combined administration of  bombesin  and  verapamil hydrochloride  ( verapamil ), a  <e0>calcium channel blocker</e0> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e1>azoxymethane</e1>  ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

213	BACKGROUND: The effects of combined administration of  bombesin  and  verapamil hydrochloride  ( verapamil ), a  <e0>calcium channel blocker</e0> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  azoxymethane  ( <e1>AOM</e1> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

214	BACKGROUND: The effects of combined administration of  bombesin  and  verapamil hydrochloride  ( verapamil ), a  calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e0>azoxymethane</e0>  ( <e1>AOM</e1> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. "
Other
Comment:

300	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of  <e0>AOM</e0>  (7.4 mg/kg body weight) and subcutaneous injections of  <e1>bombesin</e1>  (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of  verapamil  (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. "
Other
Comment:

301	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of  <e0>AOM</e0>  (7.4 mg/kg body weight) and subcutaneous injections of  bombesin  (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of  <e1>verapamil</e1>  (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. "
Other
Comment:

302	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of  AOM  (7.4 mg/kg body weight) and subcutaneous injections of  <e0>bombesin</e0>  (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of  <e1>verapamil</e1>  (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. "
Other
Comment:

500	Although  <e0>verapamil</e0>  administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by  <e1>bombesin</e1>  or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. "
Other
Comment:

600	 <e0>Verapamil</e0>  also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by  <e1>bombesin</e1> . "
effect(e0,e1)Comment:


100	In vitro interaction of  <e0>prostaglandin F2alpha</e0>  and  <e1>oxytocin</e1>  in placental vessels.
"
int(e0,e1)Comment:

200	The interaction of  <e0>prostaglandin F2alpha</e0>  and synthetic  <e1>oxytocin</e1>  on placental vessels was studied in vitro. "
Other
Comment:

400	In seven experiments reactions to  <e0>norepinephrine</e0>  and  <e1>oxytocin</e1>  were  PGF2alpha . "
Other
Comment:

401	In seven experiments reactions to  <e0>norepinephrine</e0>  and  oxytocin  were  <e1>PGF2alpha</e1> . "
Other
Comment:

402	In seven experiments reactions to  norepinephrine  and  <e0>oxytocin</e0>  were  <e1>PGF2alpha</e1> . "
Other
Comment:

500	 <e0>PGF2alpha</e0>  produced significantly increased vasoconstriction after a single administration of  <e1>oxytocin</e1> . "
effect(e0,e1)Comment:

1000	There is thus an enhancement effect of  <e0>PGF2alpha</e0>  upon the reaction of placental vessels to  <e1>oxytocin</e1>  in vitro."
effect(e0,e1)Comment:


100	 <e0>Carbamazepine</e0>  overdose recognized by a  <e1>tricyclic antidepressant</e1>  assay.
"
Other
Comment:

300	We report the case of an adolescent with altered consciousness caused by  <e0>carbamazepine</e0>  overdose with a positive  <e1>tricyclic antidepressant</e1>  level to alert clinicians to the cross-reactivity of  carbamazepine  with a toxicology screen for  tricyclic antidepressants ."
effect(e0,e1)Comment:

301	We report the case of an adolescent with altered consciousness caused by  <e0>carbamazepine</e0>  overdose with a positive  tricyclic antidepressant  level to alert clinicians to the cross-reactivity of  <e1>carbamazepine</e1>  with a toxicology screen for  tricyclic antidepressants ."
Other
Comment:

302	We report the case of an adolescent with altered consciousness caused by  <e0>carbamazepine</e0>  overdose with a positive  tricyclic antidepressant  level to alert clinicians to the cross-reactivity of  carbamazepine  with a toxicology screen for  <e1>tricyclic antidepressants</e1> ."
Other
Comment:

303	We report the case of an adolescent with altered consciousness caused by  carbamazepine  overdose with a positive  <e0>tricyclic antidepressant</e0>  level to alert clinicians to the cross-reactivity of  <e1>carbamazepine</e1>  with a toxicology screen for  tricyclic antidepressants ."
Other
Comment:

304	We report the case of an adolescent with altered consciousness caused by  carbamazepine  overdose with a positive  <e0>tricyclic antidepressant</e0>  level to alert clinicians to the cross-reactivity of  carbamazepine  with a toxicology screen for  <e1>tricyclic antidepressants</e1> ."
Other
Comment:

305	We report the case of an adolescent with altered consciousness caused by  carbamazepine  overdose with a positive  tricyclic antidepressant  level to alert clinicians to the cross-reactivity of  <e0>carbamazepine</e0>  with a toxicology screen for  <e1>tricyclic antidepressants</e1> ."
advise(e0,e1)Comment:


100	 <e0>Cypermethrin</e0> -induced oxidative stress in rat brain and liver is prevented by  <e1>vitamin E</e1>  or  allopurinol .
"
effect(e0,e1)Comment:

101	 <e0>Cypermethrin</e0> -induced oxidative stress in rat brain and liver is prevented by  vitamin E  or  <e1>allopurinol</e1> .
"
effect(e0,e1)Comment:

102	 Cypermethrin -induced oxidative stress in rat brain and liver is prevented by  <e0>vitamin E</e0>  or  <e1>allopurinol</e1> .
"
Other
Comment:

200	Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by  <e0>cypermethrin</e0> , a  <e1>Type II pyrethroid</e1> . "
Other
Comment:

700	Pretreatment of rats with  <e0>allopurinol</e0>  (100 mg/kg, ip) or  <e1>Vitamin E</e1>  (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral  cypermethrin  administration within 4 h. "
Other
Comment:

701	Pretreatment of rats with  <e0>allopurinol</e0>  (100 mg/kg, ip) or  Vitamin E  (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral  <e1>cypermethrin</e1>  administration within 4 h. "
effect(e0,e1)Comment:

702	Pretreatment of rats with  allopurinol  (100 mg/kg, ip) or  <e0>Vitamin E</e0>  (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral  <e1>cypermethrin</e1>  administration within 4 h. "
effect(e0,e1)Comment:

800	Thus, the results suggest that  <e0>cypermethrin</e0>  exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by  <e1>allopurinol</e1>  and  Vitamin E ."
effect(e0,e1)Comment:

801	Thus, the results suggest that  <e0>cypermethrin</e0>  exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by  allopurinol  and  <e1>Vitamin E</e1> ."
effect(e0,e1)Comment:

802	Thus, the results suggest that  cypermethrin  exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by  <e0>allopurinol</e0>  and  <e1>Vitamin E</e1> ."
Other
Comment:


400	In this study we investigated the effect of  <e0>ginsenosides</e0>  on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e1>selective Ca(2+) channel blockers</e1>   nimodipine  (L-type),  omega-conotoxin GVIA  (N-type), or  omega-agatoxin IVA  (P-type) in bovine chromaffin cells. "
Other
Comment:

401	In this study we investigated the effect of  <e0>ginsenosides</e0>  on high threshold voltage-dependent Ca(2+) channel subtypes using their  selective Ca(2+) channel blockers   <e1>nimodipine</e1>  (L-type),  omega-conotoxin GVIA  (N-type), or  omega-agatoxin IVA  (P-type) in bovine chromaffin cells. "
Other
Comment:

402	In this study we investigated the effect of  <e0>ginsenosides</e0>  on high threshold voltage-dependent Ca(2+) channel subtypes using their  selective Ca(2+) channel blockers   nimodipine  (L-type),  <e1>omega-conotoxin GVIA</e1>  (N-type), or  omega-agatoxin IVA  (P-type) in bovine chromaffin cells. "
Other
Comment:

403	In this study we investigated the effect of  <e0>ginsenosides</e0>  on high threshold voltage-dependent Ca(2+) channel subtypes using their  selective Ca(2+) channel blockers   nimodipine  (L-type),  omega-conotoxin GVIA  (N-type), or  <e1>omega-agatoxin IVA</e1>  (P-type) in bovine chromaffin cells. "
Other
Comment:

404	In this study we investigated the effect of  ginsenosides  on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e0>selective Ca(2+) channel blockers</e0>   <e1>nimodipine</e1>  (L-type),  omega-conotoxin GVIA  (N-type), or  omega-agatoxin IVA  (P-type) in bovine chromaffin cells. "
Other
Comment:

405	In this study we investigated the effect of  ginsenosides  on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e0>selective Ca(2+) channel blockers</e0>   nimodipine  (L-type),  <e1>omega-conotoxin GVIA</e1>  (N-type), or  omega-agatoxin IVA  (P-type) in bovine chromaffin cells. "
Other
Comment:

406	In this study we investigated the effect of  ginsenosides  on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e0>selective Ca(2+) channel blockers</e0>   nimodipine  (L-type),  omega-conotoxin GVIA  (N-type), or  <e1>omega-agatoxin IVA</e1>  (P-type) in bovine chromaffin cells. "
Other
Comment:

407	In this study we investigated the effect of  ginsenosides  on high threshold voltage-dependent Ca(2+) channel subtypes using their  selective Ca(2+) channel blockers   <e0>nimodipine</e0>  (L-type),  <e1>omega-conotoxin GVIA</e1>  (N-type), or  omega-agatoxin IVA  (P-type) in bovine chromaffin cells. "
Other
Comment:

408	In this study we investigated the effect of  ginsenosides  on high threshold voltage-dependent Ca(2+) channel subtypes using their  selective Ca(2+) channel blockers   <e0>nimodipine</e0>  (L-type),  omega-conotoxin GVIA  (N-type), or  <e1>omega-agatoxin IVA</e1>  (P-type) in bovine chromaffin cells. "
Other
Comment:

409	In this study we investigated the effect of  ginsenosides  on high threshold voltage-dependent Ca(2+) channel subtypes using their  selective Ca(2+) channel blockers   nimodipine  (L-type),  <e0>omega-conotoxin GVIA</e0>  (N-type), or  <e1>omega-agatoxin IVA</e1>  (P-type) in bovine chromaffin cells. "
Other
Comment:

700	 <e0>Nimodipine</e0>  had no effect on  <e1>ginsenosides</e1>  response. "
Other
Comment:

800	These data suggest that  <e0>ginsenosides</e0>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e1>omega-conotoxin GVIA</e1> -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  nimodipine / omega-conotoxin GVIA / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

801	These data suggest that  <e0>ginsenosides</e0>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  <e1>omega-agatoxin IVA</e1> -sensitive (P-type) channel and  nimodipine / omega-conotoxin GVIA / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

802	These data suggest that  <e0>ginsenosides</e0>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  <e1>nimodipine</e1> / omega-conotoxin GVIA / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

803	These data suggest that  <e0>ginsenosides</e0>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  nimodipine / <e1>omega-conotoxin GVIA</e1> / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

804	These data suggest that  <e0>ginsenosides</e0>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  nimodipine / omega-conotoxin GVIA / <e1>omega-agatoxin VIA</e1> -resistant (presumptive Q-type) channel. "
Other
Comment:

805	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e0>omega-conotoxin GVIA</e0> -sensitive (N-type) channel, an  <e1>omega-agatoxin IVA</e1> -sensitive (P-type) channel and  nimodipine / omega-conotoxin GVIA / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

806	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e0>omega-conotoxin GVIA</e0> -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  <e1>nimodipine</e1> / omega-conotoxin GVIA / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

807	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e0>omega-conotoxin GVIA</e0> -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  nimodipine / <e1>omega-conotoxin GVIA</e1> / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

808	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e0>omega-conotoxin GVIA</e0> -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  nimodipine / omega-conotoxin GVIA / <e1>omega-agatoxin VIA</e1> -resistant (presumptive Q-type) channel. "
Other
Comment:

809	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  <e0>omega-agatoxin IVA</e0> -sensitive (P-type) channel and  <e1>nimodipine</e1> / omega-conotoxin GVIA / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

810	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  <e0>omega-agatoxin IVA</e0> -sensitive (P-type) channel and  nimodipine / <e1>omega-conotoxin GVIA</e1> / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

811	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  <e0>omega-agatoxin IVA</e0> -sensitive (P-type) channel and  nimodipine / omega-conotoxin GVIA / <e1>omega-agatoxin VIA</e1> -resistant (presumptive Q-type) channel. "
Other
Comment:

812	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  <e0>nimodipine</e0> / <e1>omega-conotoxin GVIA</e1> / omega-agatoxin VIA -resistant (presumptive Q-type) channel. "
Other
Comment:

813	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  <e0>nimodipine</e0> / omega-conotoxin GVIA / <e1>omega-agatoxin VIA</e1> -resistant (presumptive Q-type) channel. "
Other
Comment:

814	These data suggest that  ginsenosides  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  omega-conotoxin GVIA -sensitive (N-type) channel, an  omega-agatoxin IVA -sensitive (P-type) channel and  nimodipine / <e0>omega-conotoxin GVIA</e0> / <e1>omega-agatoxin VIA</e1> -resistant (presumptive Q-type) channel. "
Other
Comment:

900	Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by  <e0>ginsenosides</e0>  in bovine chromaffin cell could be the cellular basis of antistress effects induced by  <e1>ginseng</e1> ."
Other
Comment:


100	In vitro activity of  <e0>KRM-1648</e0> , either singly or in combination with  <e1>ofloxacin</e1> , against Mycobacterium ulcerans.
"
Other
Comment:

200	The antimicrobial effect of a  <e0>benzoxazinorifamycin</e0> ,  <e1>KRM-1648</e1> , either alone or in combination with  ofloxacin , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. "
Other
Comment:

201	The antimicrobial effect of a  <e0>benzoxazinorifamycin</e0> ,  KRM-1648 , either alone or in combination with  <e1>ofloxacin</e1> , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. "
Other
Comment:

202	The antimicrobial effect of a  benzoxazinorifamycin ,  <e0>KRM-1648</e0> , either alone or in combination with  <e1>ofloxacin</e1> , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. "
Other
Comment:

600	ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for  <e0>rifampicin</e0>  and  <e1>rifabutin</e1>  were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. "
Other
Comment:

700	When combined with  <e0>ofloxacin</e0> ,  <e1>KRM-1648</e1>  exhibited strong synergistic activity while only additive effects were observed with the combination of  rifampicin  (or  rifabutin ) and  ofloxacin . "
effect(e0,e1)Comment:

701	When combined with  <e0>ofloxacin</e0> ,  KRM-1648  exhibited strong synergistic activity while only additive effects were observed with the combination of  <e1>rifampicin</e1>  (or  rifabutin ) and  ofloxacin . "
Other
Comment:

702	When combined with  <e0>ofloxacin</e0> ,  KRM-1648  exhibited strong synergistic activity while only additive effects were observed with the combination of  rifampicin  (or  <e1>rifabutin</e1> ) and  ofloxacin . "
Other
Comment:

703	When combined with  <e0>ofloxacin</e0> ,  KRM-1648  exhibited strong synergistic activity while only additive effects were observed with the combination of  rifampicin  (or  rifabutin ) and  <e1>ofloxacin</e1> . "
Other
Comment:

704	When combined with  ofloxacin ,  <e0>KRM-1648</e0>  exhibited strong synergistic activity while only additive effects were observed with the combination of  <e1>rifampicin</e1>  (or  rifabutin ) and  ofloxacin . "
Other
Comment:

705	When combined with  ofloxacin ,  <e0>KRM-1648</e0>  exhibited strong synergistic activity while only additive effects were observed with the combination of  rifampicin  (or  <e1>rifabutin</e1> ) and  ofloxacin . "
Other
Comment:

706	When combined with  ofloxacin ,  <e0>KRM-1648</e0>  exhibited strong synergistic activity while only additive effects were observed with the combination of  rifampicin  (or  rifabutin ) and  <e1>ofloxacin</e1> . "
Other
Comment:

707	When combined with  ofloxacin ,  KRM-1648  exhibited strong synergistic activity while only additive effects were observed with the combination of  <e0>rifampicin</e0>  (or  <e1>rifabutin</e1> ) and  ofloxacin . "
Other
Comment:

708	When combined with  ofloxacin ,  KRM-1648  exhibited strong synergistic activity while only additive effects were observed with the combination of  <e0>rifampicin</e0>  (or  rifabutin ) and  <e1>ofloxacin</e1> . "
effect(e0,e1)Comment:

709	When combined with  ofloxacin ,  KRM-1648  exhibited strong synergistic activity while only additive effects were observed with the combination of  rifampicin  (or  <e0>rifabutin</e0> ) and  <e1>ofloxacin</e1> . "
effect(e0,e1)Comment:


200	The effects of  <e0>ruthenium red</e0>  ( <e1>RR</e1> ) on  inositol 1,4,5-trisphosphate  ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. "
Other
Comment:

201	The effects of  <e0>ruthenium red</e0>  ( RR ) on  <e1>inositol 1,4,5-trisphosphate</e1>  ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. "
Other
Comment:

202	The effects of  <e0>ruthenium red</e0>  ( RR ) on  inositol 1,4,5-trisphosphate  ( <e1>InsP(3)</e1> )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. "
Other
Comment:

203	The effects of  ruthenium red  ( <e0>RR</e0> ) on  <e1>inositol 1,4,5-trisphosphate</e1>  ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. "
Other
Comment:

204	The effects of  ruthenium red  ( <e0>RR</e0> ) on  inositol 1,4,5-trisphosphate  ( <e1>InsP(3)</e1> )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. "
Other
Comment:

205	The effects of  ruthenium red  ( RR ) on  <e0>inositol 1,4,5-trisphosphate</e0>  ( <e1>InsP(3)</e1> )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. "
Other
Comment:

400	Administering  <e0>InsP(3)</e0>  together with  <e1>RR</e1>  (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. "
effect(e0,e1)Comment:

500	Pretreatment of megakaryocytes with extracellular  <e0>RR</e0>  (50 microM) also inhibited  <e1>InsP(3)</e1> -induced responses. "
effect(e0,e1)Comment:

700	In contrast, in isolated single pancreatic acinar cells,  <e0>RR</e0>  had no effect on  <e1>InsP(3)</e1> -induced responses. "
Other
Comment:

900	In addition, we have shown that  <e0>RR</e0>  is a useful pharmacological tool with which to examine the  <e1>InsP(3)</e1> -mediated responses of megakaryocytes."
Other
Comment:


100	Effect of  <e0>rofecoxib</e0>  on the pharmacokinetics of  <e1>digoxin</e1>  in healthy volunteers.
"
Other
Comment:

200	The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor,  <e0>rofecoxib</e0> , at steady state on the pharmacokinetics of  <e1>digoxin</e1>  following a single dose in healthy subjects. "
Other
Comment:

600	Samples for plasma and urine immunoreactive  <e0>digoxin</e0>  concentrations were collected through 120 hours following the  <e1>digoxin</e1>  dose. "
Other
Comment:

800	For  <e0>digoxin</e0>  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( <e1>rofecoxib</e1>  +  digoxin /placebo +  digoxin ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. "
Other
Comment:

801	For  <e0>digoxin</e0>  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( rofecoxib  +  <e1>digoxin</e1> /placebo +  digoxin ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. "
Other
Comment:

802	For  <e0>digoxin</e0>  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( rofecoxib  +  digoxin /placebo +  <e1>digoxin</e1> ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. "
Other
Comment:

803	For  digoxin  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( <e0>rofecoxib</e0>  +  <e1>digoxin</e1> /placebo +  digoxin ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. "
Other
Comment:

804	For  digoxin  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( <e0>rofecoxib</e0>  +  digoxin /placebo +  <e1>digoxin</e1> ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. "
Other
Comment:

805	For  digoxin  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( rofecoxib  +  <e0>digoxin</e0> /placebo +  <e1>digoxin</e1> ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. "
Other
Comment:

1000	The harmonic mean elimination half-life was 45.7 and 43.4 hours for  <e0>rofecoxib</e0>  +  <e1>digoxin</e1>  and placebo +  digoxin  treatments, respectively. "
Other
Comment:

1001	The harmonic mean elimination half-life was 45.7 and 43.4 hours for  <e0>rofecoxib</e0>  +  digoxin  and placebo +  <e1>digoxin</e1>  treatments, respectively. "
Other
Comment:

1002	The harmonic mean elimination half-life was 45.7 and 43.4 hours for  rofecoxib  +  <e0>digoxin</e0>  and placebo +  <e1>digoxin</e1>  treatments, respectively. "
Other
Comment:

1200	The mean (SD) cumulative urinary excretion of immunoreactive  <e0>digoxin</e0>  after concurrent treatment with  <e1>rofecoxib</e1>  or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. "
Other
Comment:

1400	 <e0>Rofecoxib</e0>  did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of  <e1>digoxin</e1> ."
Other
Comment:


100	Concomitant  <e0>cyclophosphamide</e0> ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  chemotherapy plus  highly active antiretroviral  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

101	Concomitant  <e0>cyclophosphamide</e0> ,  doxorubicin ,  <e1>vincristine</e1> , and  prednisone  chemotherapy plus  highly active antiretroviral  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

102	Concomitant  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  <e1>prednisone</e1>  chemotherapy plus  highly active antiretroviral  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

103	Concomitant  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  chemotherapy plus  <e1>highly active antiretroviral</e1>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

104	Concomitant  cyclophosphamide ,  <e0>doxorubicin</e0> ,  <e1>vincristine</e1> , and  prednisone  chemotherapy plus  highly active antiretroviral  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

105	Concomitant  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  <e1>prednisone</e1>  chemotherapy plus  highly active antiretroviral  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

106	Concomitant  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  chemotherapy plus  <e1>highly active antiretroviral</e1>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

107	Concomitant  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  <e1>prednisone</e1>  chemotherapy plus  highly active antiretroviral  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

108	Concomitant  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  chemotherapy plus  <e1>highly active antiretroviral</e1>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

109	Concomitant  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  chemotherapy plus  <e1>highly active antiretroviral</e1>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
Other
Comment:

300	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

301	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  <e1>vincristine</e1> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

302	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  <e1>prednisone</e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

303	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1>cyclophosphamide</e1> ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

304	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e1>doxorubicin</e1> ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

305	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e1>teniposide</e1> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

306	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

307	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

308	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

309	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e0>cyclophosphamide</e0> ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

310	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  <e1>vincristine</e1> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

311	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  <e1>prednisone</e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

312	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1>cyclophosphamide</e1> ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

313	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e1>doxorubicin</e1> ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

314	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e1>teniposide</e1> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

315	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

316	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

317	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

318	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e0>doxorubicin</e0> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

319	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  <e1>prednisone</e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

320	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1>cyclophosphamide</e1> ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

321	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e1>doxorubicin</e1> ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

322	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e1>teniposide</e1> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

323	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

324	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

325	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

326	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  <e0>vincristine</e0> , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

327	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1>cyclophosphamide</e1> ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

328	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e1>doxorubicin</e1> ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

329	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e1>teniposide</e1> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

330	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

331	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

332	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

333	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  <e0>prednisone</e0>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

334	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e0>cyclophosphamide</e0> ,  <e1>doxorubicin</e1> ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

335	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e0>cyclophosphamide</e0> ,  doxorubicin ,  <e1>teniposide</e1> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

336	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e0>cyclophosphamide</e0> ,  doxorubicin ,  teniposide , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

337	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e0>cyclophosphamide</e0> ,  doxorubicin ,  teniposide , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

338	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e0>cyclophosphamide</e0> ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

339	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e0>cyclophosphamide</e0> ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

340	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e0>doxorubicin</e0> ,  <e1>teniposide</e1> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

341	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e0>doxorubicin</e0> ,  teniposide , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

342	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e0>doxorubicin</e0> ,  teniposide , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

343	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e0>doxorubicin</e0> ,  teniposide , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

344	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  <e0>doxorubicin</e0> ,  teniposide , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

345	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e0>teniposide</e0> , and  <e1>prednisone</e1>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

346	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e0>teniposide</e0> , and  prednisone  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

347	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e0>teniposide</e0> , and  prednisone  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

348	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  <e0>teniposide</e0> , and  prednisone  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

349	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e0>prednisone</e0>  with  <e1>vincristine</e1>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

350	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e0>prednisone</e0>  with  vincristine  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

351	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  <e0>prednisone</e0>  with  vincristine  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

352	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  doxorubicin ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  <e0>vincristine</e0>  plus  <e1>bleomycin</e1> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

353	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  <e0>vincristine</e0>  plus  bleomycin ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

354	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  cyclophosphamide ,  <e1>doxorubicin</e1> ,  vincristine , and  prednisone  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  cyclophosphamide ,  doxorubicin ,  teniposide , and  prednisone  with  vincristine  plus  <e0>bleomycin</e0> ) without receiving  <ne10>antiretroviral</ne10>  therapy. "
Other
Comment:

600	 <e0>Antiretroviral</e0>  regimens consisted of two  <e1>reverse transcriptase inhibitors</e1>  and one  protease inhibitor . "
Other
Comment:

601	 <e0>Antiretroviral</e0>  regimens consisted of two  reverse transcriptase inhibitors  and one  <e1>protease inhibitor</e1> . "
Other
Comment:

602	 Antiretroviral  regimens consisted of two  <e0>reverse transcriptase inhibitors</e0>  and one  <e1>protease inhibitor</e1> . "
Other
Comment:

1500	However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between  <e0>antiretroviral drugs</e0>  and  <e1>antineoplastic drugs</e1> . "
advise(e0,e1)Comment:


300	Treatment with  <e0>antidepressant drugs</e0>  can directly interfere with blood glucose levels or may interact with  <e1>hypoglycemic agents</e1> . "
int(e0,e1)Comment:

700	 <e0>Imipramine</e0>  (5 mg/kg),  <e1>moclobemide</e1>  (30 mg/kg),  clonazepam  (0.25 mg/kg),  fluoxetine  (20 mg/kg)  sertraline  (30 mg/kg) or vehicle was administered. "
Other
Comment:

701	 <e0>Imipramine</e0>  (5 mg/kg),  moclobemide  (30 mg/kg),  <e1>clonazepam</e1>  (0.25 mg/kg),  fluoxetine  (20 mg/kg)  sertraline  (30 mg/kg) or vehicle was administered. "
Other
Comment:

702	 <e0>Imipramine</e0>  (5 mg/kg),  moclobemide  (30 mg/kg),  clonazepam  (0.25 mg/kg),  <e1>fluoxetine</e1>  (20 mg/kg)  sertraline  (30 mg/kg) or vehicle was administered. "
Other
Comment:

703	 <e0>Imipramine</e0>  (5 mg/kg),  moclobemide  (30 mg/kg),  clonazepam  (0.25 mg/kg),  fluoxetine  (20 mg/kg)  <e1>sertraline</e1>  (30 mg/kg) or vehicle was administered. "
Other
Comment:

704	 Imipramine  (5 mg/kg),  <e0>moclobemide</e0>  (30 mg/kg),  <e1>clonazepam</e1>  (0.25 mg/kg),  fluoxetine  (20 mg/kg)  sertraline  (30 mg/kg) or vehicle was administered. "
Other
Comment:

705	 Imipramine  (5 mg/kg),  <e0>moclobemide</e0>  (30 mg/kg),  clonazepam  (0.25 mg/kg),  <e1>fluoxetine</e1>  (20 mg/kg)  sertraline  (30 mg/kg) or vehicle was administered. "
Other
Comment:

706	 Imipramine  (5 mg/kg),  <e0>moclobemide</e0>  (30 mg/kg),  clonazepam  (0.25 mg/kg),  fluoxetine  (20 mg/kg)  <e1>sertraline</e1>  (30 mg/kg) or vehicle was administered. "
Other
Comment:

707	 Imipramine  (5 mg/kg),  moclobemide  (30 mg/kg),  <e0>clonazepam</e0>  (0.25 mg/kg),  <e1>fluoxetine</e1>  (20 mg/kg)  sertraline  (30 mg/kg) or vehicle was administered. "
Other
Comment:

708	 Imipramine  (5 mg/kg),  moclobemide  (30 mg/kg),  <e0>clonazepam</e0>  (0.25 mg/kg),  fluoxetine  (20 mg/kg)  <e1>sertraline</e1>  (30 mg/kg) or vehicle was administered. "
Other
Comment:

709	 Imipramine  (5 mg/kg),  moclobemide  (30 mg/kg),  clonazepam  (0.25 mg/kg),  <e0>fluoxetine</e0>  (20 mg/kg)  <e1>sertraline</e1>  (30 mg/kg) or vehicle was administered. "
Other
Comment:

900	An oral  <e0>glucose</e0>  overload of 1 ml of a 50%  <e1>glucose</e1>  solution was given to rats and blood glucose was determined after 30, 60 and 90 min. "
Other
Comment:

1000	 <e0>Imipramine</e0>  and  <e1>clonazepam</e1>  did not change fasting or overload glycemia. "
Other
Comment:

1100	 <e0>Fluoxetine</e0>  and  <e1>moclobemide</e1>  increased blood  glucose  at different times after the glucose overload. "
Other
Comment:

1101	 <e0>Fluoxetine</e0>  and  moclobemide  increased blood  <e1>glucose</e1>  at different times after the glucose overload. "
Other
Comment:

1102	 Fluoxetine  and  <e0>moclobemide</e0>  increased blood  <e1>glucose</e1>  at different times after the glucose overload. "
Other
Comment:

1200	 <e0>Sertraline</e0>  neutralized the increase of glycemia induced by oral  <e1>glucose</e1>  overload. "
Other
Comment:

1300	In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of  <e0>glucose</e0>  tolerance 30 min after  <e1>glucose</e1>  overload. "
Other
Comment:

1400	Again,  <e0>sertraline</e0>  neutralized the increase in glycemia after  <e1>glucose</e1>  overload both in diabetic and non-diabetic rats. "
Other
Comment:


100	Activity of  <e0>buforin II</e0>  alone and in combination with  <e1>azithromycin</e1>  and  minocycline  against Cryptosporidium parvum in cell culture.
"
Other
Comment:

101	Activity of  <e0>buforin II</e0>  alone and in combination with  azithromycin  and  <e1>minocycline</e1>  against Cryptosporidium parvum in cell culture.
"
Other
Comment:

102	Activity of  buforin II  alone and in combination with  <e0>azithromycin</e0>  and  <e1>minocycline</e1>  against Cryptosporidium parvum in cell culture.
"
Other
Comment:

200	The in vitro anti-cryptosporidial activity of  <e0>buforin II</e0>  alone and in combination with  <e1>azithromycin</e1>  and  minocycline  was investigated. "
Other
Comment:

201	The in vitro anti-cryptosporidial activity of  <e0>buforin II</e0>  alone and in combination with  azithromycin  and  <e1>minocycline</e1>  was investigated. "
Other
Comment:

202	The in vitro anti-cryptosporidial activity of  buforin II  alone and in combination with  <e0>azithromycin</e0>  and  <e1>minocycline</e1>  was investigated. "
Other
Comment:

400	Moreover, its activity was enhanced when it was combined with either  <e0>azithromycin</e0>  or  <e1>minocycline</e1>  with 90% parasite reduction at the highest concentration tested. "
Other
Comment:

500	 <e0>Buforin II</e0>  may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either  <e1>azithromycin</e1>  or  minocycline ."
effect(e0,e1)Comment:

501	 <e0>Buforin II</e0>  may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either  azithromycin  or  <e1>minocycline</e1> ."
effect(e0,e1)Comment:

502	 Buforin II  may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either  <e0>azithromycin</e0>  or  <e1>minocycline</e1> ."
Other
Comment:


100	Effect of  <e0>dofetillide</e0>  on the pharmacokinetics of  <e1>digoxin</e1> .
"
Other
Comment:

200	The effect of  <e0>dofetilide</e0>  on the steady-state pharmacokinetics of  <e1>digoxin</e1>  was evaluated in a randomized, double-blind study. "
Other
Comment:

300	Five days of  <e0>dofetilide</e0>  treatment did not significantly affect steady-state pharmacokinetic variables of  <e1>digoxin</e1>  compared with placebo; "
Other
Comment:

400	therefore, the use of  <e0>dofetilide</e0>  does not necessitate an adjustment in  <e1>digoxin</e1>  dose to maintain therapeutic digoxin levels."
Other
Comment:


500	Numerous drug interactions are possible with some  <e0>anticonvulsant agents</e0> , such as  <e1>phenobarbitone</e1>  and  phenytoin , which affect hepatic microsomal enzyme systems. "
Other
Comment:

501	Numerous drug interactions are possible with some  <e0>anticonvulsant agents</e0> , such as  phenobarbitone  and  <e1>phenytoin</e1> , which affect hepatic microsomal enzyme systems. "
Other
Comment:

502	Numerous drug interactions are possible with some  anticonvulsant agents , such as  <e0>phenobarbitone</e0>  and  <e1>phenytoin</e1> , which affect hepatic microsomal enzyme systems. "
Other
Comment:


100	Interaction of  <e0>ketamine</e0>  and  <e1>halothane</e1>  in rats.
"
int(e0,e1)Comment:

200	The interaction of intramuscularly injected  <e0>ketamine</e0>  and its N-demethylated metabolite (metabolite I) with  <e1>halothane</e1>  was evaluated in rats. "
Other
Comment:

400	However,  <e0>halothane</e0>  anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of  <e1>ketamine</e1> , 50 mg/kg, im. "
mechanism(e0,e1)Comment:

500	The reduction in MAC was correlated with brain levels of  <e0>ketamine</e0>  or metabolite I, suggesting a  <e1>ketamine</e1> :metabolite I potency ration of 3:1. "
Other
Comment:

600	The half-life of  <e0>ketamine</e0>  in plasma and brain was longer in the presence of  <e1>halothane</e1>  than when  ketamine  was given alone. "
mechanism(e0,e1)Comment:

601	The half-life of  <e0>ketamine</e0>  in plasma and brain was longer in the presence of  halothane  than when  <e1>ketamine</e1>  was given alone. "
Other
Comment:

602	The half-life of  ketamine  in plasma and brain was longer in the presence of  <e0>halothane</e0>  than when  <e1>ketamine</e1>  was given alone. "
Other
Comment:

700	It is concluded that  <e0>ketamine</e0>  is not a short-acting drug and that concomitant use with  <e1>halothane</e1>  would be expected to prolong further the duration of its action on the central nervous system."
effect(e0,e1)Comment:


100	 <e0>Rifampin</e0>  and  <e1>warfarin</e1> : a drug interaction.
"
int(e0,e1)Comment:

200	The drug interaction between  <e0>warfarin</e0>  and  <e1>rifampin</e1>  is not well known. "
int(e0,e1)Comment:

300	 <e0>Rifampin</e0>  has been reported to increase the  <e1>warfarin</e1>  requirements in human subjects ingesting these agents simultaneously. "
mechanism(e0,e1)Comment:

400	The concomitant administration of  <e0>rifampin</e0>  and  <e1>warfarin</e1>  resulted in the need for an unusually high maintenance dose of  warfarin  (20 mg per day) in order to produce a therapeutic effect. "
mechanism(e0,e1)Comment:

401	The concomitant administration of  <e0>rifampin</e0>  and  warfarin  resulted in the need for an unusually high maintenance dose of  <e1>warfarin</e1>  (20 mg per day) in order to produce a therapeutic effect. "
Other
Comment:

402	The concomitant administration of  rifampin  and  <e0>warfarin</e0>  resulted in the need for an unusually high maintenance dose of  <e1>warfarin</e1>  (20 mg per day) in order to produce a therapeutic effect. "
Other
Comment:

500	Withdrawal of  <e0>rifampin</e0>  decreased the  <e1>warfarin</e1>  requirement by 50%. "
mechanism(e0,e1)Comment:

600	This effect may be mediated by the ability of  <e0>rifampin</e0>  to induce microsomal enzymes and, thus, the catabolism of  <e1>warfarin</e1> . "
mechanism(e0,e1)Comment:

700	The effect of  <e0>rifampin</e0>  on the  <e1>warfarin</e1>  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  rifampin  and extended a similar length of time after  rifampin  withdrawal. "
effect(e0,e1)Comment:

701	The effect of  <e0>rifampin</e0>  on the  warfarin  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  <e1>rifampin</e1>  and extended a similar length of time after  rifampin  withdrawal. "
Other
Comment:

702	The effect of  <e0>rifampin</e0>  on the  warfarin  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  rifampin  and extended a similar length of time after  <e1>rifampin</e1>  withdrawal. "
Other
Comment:

703	The effect of  rifampin  on the  <e0>warfarin</e0>  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  <e1>rifampin</e1>  and extended a similar length of time after  rifampin  withdrawal. "
Other
Comment:

704	The effect of  rifampin  on the  <e0>warfarin</e0>  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  rifampin  and extended a similar length of time after  <e1>rifampin</e1>  withdrawal. "
Other
Comment:

705	The effect of  rifampin  on the  warfarin  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  <e0>rifampin</e0>  and extended a similar length of time after  <e1>rifampin</e1>  withdrawal. "
Other
Comment:


200	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( <e1>NaCMC</e1> ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

201	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( NaCMC ) and  <e1>carboxymethylcellulose-cysteine</e1>  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

202	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( <e1>CMC-Cys</e1> ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

203	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  <e1>sodium fluorescein</e1>  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

204	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( <e1>NaFlu</e1> ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

205	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  <e1>bacitracin</e1>  and  insulin . "
Other
Comment:

206	The purpose of this study was to evaluate the effect of  <e0>sodium carboxymethylcellulose</e0>  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  <e1>insulin</e1> . "
Other
Comment:

207	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( <e0>NaCMC</e0> ) and  <e1>carboxymethylcellulose-cysteine</e1>  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

208	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( <e0>NaCMC</e0> ) and  carboxymethylcellulose-cysteine  ( <e1>CMC-Cys</e1> ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

209	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( <e0>NaCMC</e0> ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  <e1>sodium fluorescein</e1>  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

210	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( <e0>NaCMC</e0> ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( <e1>NaFlu</e1> ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

211	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( <e0>NaCMC</e0> ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  <e1>bacitracin</e1>  and  insulin . "
Other
Comment:

212	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( <e0>NaCMC</e0> ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  <e1>insulin</e1> . "
Other
Comment:

213	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  <e0>carboxymethylcellulose-cysteine</e0>  ( <e1>CMC-Cys</e1> ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

214	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  <e0>carboxymethylcellulose-cysteine</e0>  ( CMC-Cys ) conjugates on the intestinal permeation of  <e1>sodium fluorescein</e1>  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

215	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  <e0>carboxymethylcellulose-cysteine</e0>  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( <e1>NaFlu</e1> ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

216	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  <e0>carboxymethylcellulose-cysteine</e0>  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  <e1>bacitracin</e1>  and  insulin . "
Other
Comment:

217	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  <e0>carboxymethylcellulose-cysteine</e0>  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  <e1>insulin</e1> . "
Other
Comment:

218	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( <e0>CMC-Cys</e0> ) conjugates on the intestinal permeation of  <e1>sodium fluorescein</e1>  ( NaFlu ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

219	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( <e0>CMC-Cys</e0> ) conjugates on the intestinal permeation of  sodium fluorescein  ( <e1>NaFlu</e1> ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

220	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( <e0>CMC-Cys</e0> ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  <e1>bacitracin</e1>  and  insulin . "
Other
Comment:

221	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( <e0>CMC-Cys</e0> ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  bacitracin  and  <e1>insulin</e1> . "
Other
Comment:

222	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  <e0>sodium fluorescein</e0>  ( <e1>NaFlu</e1> ) and model peptide drugs,  bacitracin  and  insulin . "
Other
Comment:

223	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  <e0>sodium fluorescein</e0>  ( NaFlu ) and model peptide drugs,  <e1>bacitracin</e1>  and  insulin . "
Other
Comment:

224	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  <e0>sodium fluorescein</e0>  ( NaFlu ) and model peptide drugs,  bacitracin  and  <e1>insulin</e1> . "
Other
Comment:

225	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( <e0>NaFlu</e0> ) and model peptide drugs,  <e1>bacitracin</e1>  and  insulin . "
Other
Comment:

226	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( <e0>NaFlu</e0> ) and model peptide drugs,  bacitracin  and  <e1>insulin</e1> . "
Other
Comment:

227	The purpose of this study was to evaluate the effect of  sodium carboxymethylcellulose  ( NaCMC ) and  carboxymethylcellulose-cysteine  ( CMC-Cys ) conjugates on the intestinal permeation of  sodium fluorescein  ( NaFlu ) and model peptide drugs,  <e0>bacitracin</e0>  and  <e1>insulin</e1> . "
Other
Comment:

300	 <e0>Cysteine</e0>  was covalently linked to carbodiimide activated  <e1>NaCMC</e1> . "
Other
Comment:

600	Unmodified  <e0>NaCMC</e0>  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  <e1>NaFlu</e1>  to 1.3 and 1% (m/v)  NaCMC  conjugated with  cysteine  further enhanced the permeation. "
Other
Comment:

601	Unmodified  <e0>NaCMC</e0>  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  NaFlu  to 1.3 and 1% (m/v)  <e1>NaCMC</e1>  conjugated with  cysteine  further enhanced the permeation. "
Other
Comment:

602	Unmodified  <e0>NaCMC</e0>  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  NaFlu  to 1.3 and 1% (m/v)  NaCMC  conjugated with  <e1>cysteine</e1>  further enhanced the permeation. "
Other
Comment:

603	Unmodified  NaCMC  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  <e0>NaFlu</e0>  to 1.3 and 1% (m/v)  <e1>NaCMC</e1>  conjugated with  cysteine  further enhanced the permeation. "
Other
Comment:

604	Unmodified  NaCMC  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  <e0>NaFlu</e0>  to 1.3 and 1% (m/v)  NaCMC  conjugated with  <e1>cysteine</e1>  further enhanced the permeation. "
Other
Comment:

605	Unmodified  NaCMC  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  NaFlu  to 1.3 and 1% (m/v)  <e0>NaCMC</e0>  conjugated with  <e1>cysteine</e1>  further enhanced the permeation. "
Other
Comment:

800	Decreasing the concentration of  <e0>CMC-Cys</e0> , exhibiting 7.3% (m/m) of immobilised  <e1>cysteine</e1>  (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of  NaFlu  from 1.8 to 1.2. "
Other
Comment:

801	Decreasing the concentration of  <e0>CMC-Cys</e0> , exhibiting 7.3% (m/m) of immobilised  cysteine  (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of  <e1>NaFlu</e1>  from 1.8 to 1.2. "
Other
Comment:

802	Decreasing the concentration of  CMC-Cys , exhibiting 7.3% (m/m) of immobilised  <e0>cysteine</e0>  (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of  <e1>NaFlu</e1>  from 1.8 to 1.2. "
Other
Comment:

900	 <e0>NaCMC</e0>  at 1% (m/v) in the presence of free  <e1>cysteine</e1>  had no significant effect on the R-value of  NaFlu  compared to  NaCMC  alone. "
Other
Comment:

901	 <e0>NaCMC</e0>  at 1% (m/v) in the presence of free  cysteine  had no significant effect on the R-value of  <e1>NaFlu</e1>  compared to  NaCMC  alone. "
Other
Comment:

902	 <e0>NaCMC</e0>  at 1% (m/v) in the presence of free  cysteine  had no significant effect on the R-value of  NaFlu  compared to  <e1>NaCMC</e1>  alone. "
Other
Comment:

903	 NaCMC  at 1% (m/v) in the presence of free  <e0>cysteine</e0>  had no significant effect on the R-value of  <e1>NaFlu</e1>  compared to  NaCMC  alone. "
Other
Comment:

904	 NaCMC  at 1% (m/v) in the presence of free  <e0>cysteine</e0>  had no significant effect on the R-value of  NaFlu  compared to  <e1>NaCMC</e1>  alone. "
Other
Comment:

905	 NaCMC  at 1% (m/v) in the presence of free  cysteine  had no significant effect on the R-value of  <e0>NaFlu</e0>  compared to  <e1>NaCMC</e1>  alone. "
Other
Comment:

1000	Formulation of fluorescence labelled  <e0>bacitracin</e0>  and  <e1>insulin</e1>  in unconjugated  NaCMC  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  CMC-Cys 7.3 a significantly improved permeation was observed (R= 1.3). "
Other
Comment:

1001	Formulation of fluorescence labelled  <e0>bacitracin</e0>  and  insulin  in unconjugated  <e1>NaCMC</e1>  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  CMC-Cys 7.3 a significantly improved permeation was observed (R= 1.3). "
Other
Comment:

1002	Formulation of fluorescence labelled  <e0>bacitracin</e0>  and  insulin  in unconjugated  NaCMC  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  <e1>CMC-Cys</e1> 7.3 a significantly improved permeation was observed (R= 1.3). "
Other
Comment:

1003	Formulation of fluorescence labelled  bacitracin  and  <e0>insulin</e0>  in unconjugated  <e1>NaCMC</e1>  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  CMC-Cys 7.3 a significantly improved permeation was observed (R= 1.3). "
Other
Comment:

1004	Formulation of fluorescence labelled  bacitracin  and  <e0>insulin</e0>  in unconjugated  NaCMC  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  <e1>CMC-Cys</e1> 7.3 a significantly improved permeation was observed (R= 1.3). "
Other
Comment:

1005	Formulation of fluorescence labelled  bacitracin  and  insulin  in unconjugated  <e0>NaCMC</e0>  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  <e1>CMC-Cys</e1> 7.3 a significantly improved permeation was observed (R= 1.3). "
Other
Comment:

1100	Conjugation at  <e0>NaCMC</e0>  with  <e1>cysteine</e1>  moieties significantly improves the intestinal permeation of the hydrophilic molecule  NaFlu  and the model peptide drugs  bacitracin  and  insulin  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1101	Conjugation at  <e0>NaCMC</e0>  with  cysteine  moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e1>NaFlu</e1>  and the model peptide drugs  bacitracin  and  insulin  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1102	Conjugation at  <e0>NaCMC</e0>  with  cysteine  moieties significantly improves the intestinal permeation of the hydrophilic molecule  NaFlu  and the model peptide drugs  <e1>bacitracin</e1>  and  insulin  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1103	Conjugation at  <e0>NaCMC</e0>  with  cysteine  moieties significantly improves the intestinal permeation of the hydrophilic molecule  NaFlu  and the model peptide drugs  bacitracin  and  <e1>insulin</e1>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1104	Conjugation at  NaCMC  with  <e0>cysteine</e0>  moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e1>NaFlu</e1>  and the model peptide drugs  bacitracin  and  insulin  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1105	Conjugation at  NaCMC  with  <e0>cysteine</e0>  moieties significantly improves the intestinal permeation of the hydrophilic molecule  NaFlu  and the model peptide drugs  <e1>bacitracin</e1>  and  insulin  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1106	Conjugation at  NaCMC  with  <e0>cysteine</e0>  moieties significantly improves the intestinal permeation of the hydrophilic molecule  NaFlu  and the model peptide drugs  bacitracin  and  <e1>insulin</e1>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1107	Conjugation at  NaCMC  with  cysteine  moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e0>NaFlu</e0>  and the model peptide drugs  <e1>bacitracin</e1>  and  insulin  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1108	Conjugation at  NaCMC  with  cysteine  moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e0>NaFlu</e0>  and the model peptide drugs  bacitracin  and  <e1>insulin</e1>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:

1109	Conjugation at  NaCMC  with  cysteine  moieties significantly improves the intestinal permeation of the hydrophilic molecule  NaFlu  and the model peptide drugs  <e0>bacitracin</e0>  and  <e1>insulin</e1>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
Other
Comment:




100	Pharmacokinetic Interaction between  <e0>amprenavir</e0>  and  <e1>rifabutin</e1>  or  rifampin  in healthy males.
"
Other
Comment:

101	Pharmacokinetic Interaction between  <e0>amprenavir</e0>  and  rifabutin  or  <e1>rifampin</e1>  in healthy males.
"
Other
Comment:

102	Pharmacokinetic Interaction between  amprenavir  and  <e0>rifabutin</e0>  or  <e1>rifampin</e1>  in healthy males.
"
Other
Comment:

200	The objective of this study was to determine if there is a pharmacokinetic interaction when  <e0>amprenavir</e0>  is given with  <e1>rifabutin</e1>  or  rifampin  and to determine the effects of these drugs on the erythromycin breath test (ERMBT). "
Other
Comment:

201	The objective of this study was to determine if there is a pharmacokinetic interaction when  <e0>amprenavir</e0>  is given with  rifabutin  or  <e1>rifampin</e1>  and to determine the effects of these drugs on the erythromycin breath test (ERMBT). "
Other
Comment:

202	The objective of this study was to determine if there is a pharmacokinetic interaction when  amprenavir  is given with  <e0>rifabutin</e0>  or  <e1>rifampin</e1>  and to determine the effects of these drugs on the erythromycin breath test (ERMBT). "
Other
Comment:

400	All subjects received  <e0>amprenavir</e0>  (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either  <e1>rifabutin</e1>  (300 mg once a day [QD]) (cohort 1) or  rifampin  (600 mg QD) (cohort 2) for 14 days. "
Other
Comment:

401	All subjects received  <e0>amprenavir</e0>  (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either  rifabutin  (300 mg once a day [QD]) (cohort 1) or  <e1>rifampin</e1>  (600 mg QD) (cohort 2) for 14 days. "
Other
Comment:

402	All subjects received  amprenavir  (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either  <e0>rifabutin</e0>  (300 mg once a day [QD]) (cohort 1) or  <e1>rifampin</e1>  (600 mg QD) (cohort 2) for 14 days. "
Other
Comment:

500	Cohort 1 then received  <e0>amprenavir</e0>  plus  <e1>rifabutin</e1>  for 10 days, and cohort 2 received  amprenavir  plus  rifampin  for 4 days. "
Other
Comment:

501	Cohort 1 then received  <e0>amprenavir</e0>  plus  rifabutin  for 10 days, and cohort 2 received  <e1>amprenavir</e1>  plus  rifampin  for 4 days. "
Other
Comment:

502	Cohort 1 then received  <e0>amprenavir</e0>  plus  rifabutin  for 10 days, and cohort 2 received  amprenavir  plus  <e1>rifampin</e1>  for 4 days. "
Other
Comment:

503	Cohort 1 then received  amprenavir  plus  <e0>rifabutin</e0>  for 10 days, and cohort 2 received  <e1>amprenavir</e1>  plus  rifampin  for 4 days. "
Other
Comment:

504	Cohort 1 then received  amprenavir  plus  <e0>rifabutin</e0>  for 10 days, and cohort 2 received  amprenavir  plus  <e1>rifampin</e1>  for 4 days. "
Other
Comment:

505	Cohort 1 then received  amprenavir  plus  rifabutin  for 10 days, and cohort 2 received  <e0>amprenavir</e0>  plus  <e1>rifampin</e1>  for 4 days. "
Other
Comment:

600	Serial plasma and urine samples for measurement of  <e0>amprenavir</e0> ,  <e1>rifabutin</e1> , and  rifampin  and their  25-O-desacetyl metabolites , were measured by high-performance liquid chromatography. "
Other
Comment:

601	Serial plasma and urine samples for measurement of  <e0>amprenavir</e0> ,  rifabutin , and  <e1>rifampin</e1>  and their  25-O-desacetyl metabolites , were measured by high-performance liquid chromatography. "
Other
Comment:

602	Serial plasma and urine samples for measurement of  <e0>amprenavir</e0> ,  rifabutin , and  rifampin  and their  <e1>25-O-desacetyl metabolites</e1> , were measured by high-performance liquid chromatography. "
Other
Comment:

603	Serial plasma and urine samples for measurement of  amprenavir ,  <e0>rifabutin</e0> , and  <e1>rifampin</e1>  and their  25-O-desacetyl metabolites , were measured by high-performance liquid chromatography. "
Other
Comment:

604	Serial plasma and urine samples for measurement of  amprenavir ,  <e0>rifabutin</e0> , and  rifampin  and their  <e1>25-O-desacetyl metabolites</e1> , were measured by high-performance liquid chromatography. "
Other
Comment:

605	Serial plasma and urine samples for measurement of  amprenavir ,  rifabutin , and  <e0>rifampin</e0>  and their  <e1>25-O-desacetyl metabolites</e1> , were measured by high-performance liquid chromatography. "
Other
Comment:

700	 <e0>Rifabutin</e0>  did not significantly affect  <e1>amprenavir</e1> 's pharmacokinetics. "
Other
Comment:

800	 <e0>Amprenavir</e0>  significantly increased the area under the curve at steady state (AUC(ss)) of  <e1>rifabutin</e1>  by 2.93-fold and the AUC(ss) of  25-O-desacetylrifabutin  by 13.3-fold. "
mechanism(e0,e1)Comment:

801	 <e0>Amprenavir</e0>  significantly increased the area under the curve at steady state (AUC(ss)) of  rifabutin  by 2.93-fold and the AUC(ss) of  <e1>25-O-desacetylrifabutin</e1>  by 13.3-fold. "
mechanism(e0,e1)Comment:

802	 Amprenavir  significantly increased the area under the curve at steady state (AUC(ss)) of  <e0>rifabutin</e0>  by 2.93-fold and the AUC(ss) of  <e1>25-O-desacetylrifabutin</e1>  by 13.3-fold. "
Other
Comment:

900	 <e0>Rifampin</e0>  significantly decreased the AUC(ss) of  <e1>amprenavir</e1>  by 82%, but  amprenavir  had no effect on  rifampin  pharmacokinetics. "
mechanism(e0,e1)Comment:

901	 <e0>Rifampin</e0>  significantly decreased the AUC(ss) of  amprenavir  by 82%, but  <e1>amprenavir</e1>  had no effect on  rifampin  pharmacokinetics. "
Other
Comment:

902	 <e0>Rifampin</e0>  significantly decreased the AUC(ss) of  amprenavir  by 82%, but  amprenavir  had no effect on  <e1>rifampin</e1>  pharmacokinetics. "
Other
Comment:

903	 Rifampin  significantly decreased the AUC(ss) of  <e0>amprenavir</e0>  by 82%, but  <e1>amprenavir</e1>  had no effect on  rifampin  pharmacokinetics. "
Other
Comment:

904	 Rifampin  significantly decreased the AUC(ss) of  <e0>amprenavir</e0>  by 82%, but  amprenavir  had no effect on  <e1>rifampin</e1>  pharmacokinetics. "
Other
Comment:

905	 Rifampin  significantly decreased the AUC(ss) of  amprenavir  by 82%, but  <e0>amprenavir</e0>  had no effect on  <e1>rifampin</e1>  pharmacokinetics. "
Other
Comment:

1100	The results of the ERMBT after 2 weeks of  <e0>rifabutin</e0>  and  <e1>rifampin</e1>  therapy were increased 187 and 156%, respectively. "
Other
Comment:

1200	 <e0>Amprenavir</e0>  plus  <e1>rifampin</e1>  was well tolerated. "
Other
Comment:

1300	 <e0>Amprenavir</e0>  plus  <e1>rifabutin</e1>  was poorly tolerated, and 5 of 11 subjects discontinued therapy. "
effect(e0,e1)Comment:

1400	 <e0>Rifampin</e0>  markedly increases the metabolic clearance of  <e1>amprenavir</e1> , and coadministration is contraindicated. "
mechanism(e0,e1)Comment:

1500	 <e0>Amprenavir</e0>  significantly decreases clearance of  <e1>rifabutin</e1>  and  25-O-desacetylrifabutin , and the combination is poorly tolerated. "
mechanism(e0,e1)Comment:

1501	 <e0>Amprenavir</e0>  significantly decreases clearance of  rifabutin  and  <e1>25-O-desacetylrifabutin</e1> , and the combination is poorly tolerated. "
mechanism(e0,e1)Comment:

1502	 Amprenavir  significantly decreases clearance of  <e0>rifabutin</e0>  and  <e1>25-O-desacetylrifabutin</e1> , and the combination is poorly tolerated. "
Other
Comment:

1600	 <e0>Amprenavir</e0>  inhibits the ERMBT, and  <e1>rifampin</e1>  and  rifabutin  are equipotent inducers of the ERMBT."
Other
Comment:

1601	 <e0>Amprenavir</e0>  inhibits the ERMBT, and  rifampin  and  <e1>rifabutin</e1>  are equipotent inducers of the ERMBT."
Other
Comment:

1602	 Amprenavir  inhibits the ERMBT, and  <e0>rifampin</e0>  and  <e1>rifabutin</e1>  are equipotent inducers of the ERMBT."
Other
Comment:


800	The  <e0>thiazolidinediones</e0>  ( <e1>rosiglitazone</e1>  and  pioglitazone ), a new class of oral  antidiabetic agents , are "insulin sensitizers" "
Other
Comment:

801	The  <e0>thiazolidinediones</e0>  ( rosiglitazone  and  <e1>pioglitazone</e1> ), a new class of oral  antidiabetic agents , are "insulin sensitizers" "
Other
Comment:

802	The  <e0>thiazolidinediones</e0>  ( rosiglitazone  and  pioglitazone ), a new class of oral  <e1>antidiabetic agents</e1> , are "insulin sensitizers" "
Other
Comment:

803	The  thiazolidinediones  ( <e0>rosiglitazone</e0>  and  <e1>pioglitazone</e1> ), a new class of oral  antidiabetic agents , are "insulin sensitizers" "
Other
Comment:

804	The  thiazolidinediones  ( <e0>rosiglitazone</e0>  and  pioglitazone ), a new class of oral  <e1>antidiabetic agents</e1> , are "insulin sensitizers" "
Other
Comment:

805	The  thiazolidinediones  ( rosiglitazone  and  <e0>pioglitazone</e0> ), a new class of oral  <e1>antidiabetic agents</e1> , are "insulin sensitizers" "
Other
Comment:


300	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of  <e0>arginine</e0>  (20mM),  <e1>glucose</e1>  (100 or 150 mg. per 100 ml.), and  theophylline  (10 mM). "
Other
Comment:

301	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of  <e0>arginine</e0>  (20mM),  glucose  (100 or 150 mg. per 100 ml.), and  <e1>theophylline</e1>  (10 mM). "
Other
Comment:

302	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of  arginine  (20mM),  <e0>glucose</e0>  (100 or 150 mg. per 100 ml.), and  <e1>theophylline</e1>  (10 mM). "
Other
Comment:

500	 <e0>Glucose</e0> , alone and in the presence of  <e1>theophylline</e1> , caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. "
Other
Comment:

600	 <e0>Arginine</e0> , in the presence of  <e1>glucose</e1>  and  theophylline , caused excessive glucagon release but nearly normal insulin release in the diabetics. "
Other
Comment:

601	 <e0>Arginine</e0> , in the presence of  glucose  and  <e1>theophylline</e1> , caused excessive glucagon release but nearly normal insulin release in the diabetics. "
Other
Comment:

602	 Arginine , in the presence of  <e0>glucose</e0>  and  <e1>theophylline</e1> , caused excessive glucagon release but nearly normal insulin release in the diabetics. "
Other
Comment:

700	 <e0>Arginine</e0> , in the absence of  <e1>glucose</e1>  or  theophylline , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. "
Other
Comment:

701	 <e0>Arginine</e0> , in the absence of  glucose  or  <e1>theophylline</e1> , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. "
Other
Comment:

702	 Arginine , in the absence of  <e0>glucose</e0>  or  <e1>theophylline</e1> , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. "
Other
Comment:

1200	Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to  <e0>theophylline</e0> , but are relatively insensitive to  <e1>glucose</e1> ."
Other
Comment:


300	In this study, the effects of  <e0>etofibrate</e0>  upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day  <e1>etofibrate</e1>  or placebo for 1-month. "
Other
Comment:

700	 <e0>Etofibrate</e0>  elicited 62% enhancement of post- <e1>heparin</e1>  lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. "
effect(e0,e1)Comment:


100	The mode of toxic action of the pesticide  <e0>gliftor</e0> : the metabolism of  <e1>1,3-difluoroacetone</e1>  to  (-)-erythro-fluorocitrate .
"
Other
Comment:

101	The mode of toxic action of the pesticide  <e0>gliftor</e0> : the metabolism of  1,3-difluoroacetone  to  <e1>(-)-erythro-fluorocitrate</e1> .
"
Other
Comment:

102	The mode of toxic action of the pesticide  gliftor : the metabolism of  <e0>1,3-difluoroacetone</e0>  to  <e1>(-)-erythro-fluorocitrate</e1> .
"
Other
Comment:

200	The biochemical toxicology of  <e0>1,3-difluoroacetone</e0> , a known metabolite of the major ingredient of the pesticide  <e1>Gliftor</e1>  ( 1,3-difluoro-2-propanol ), was investigated in vivo and in vitro. "
Other
Comment:

201	The biochemical toxicology of  <e0>1,3-difluoroacetone</e0> , a known metabolite of the major ingredient of the pesticide  Gliftor  ( <e1>1,3-difluoro-2-propanol</e1> ), was investigated in vivo and in vitro. "
Other
Comment:

202	The biochemical toxicology of  1,3-difluoroacetone , a known metabolite of the major ingredient of the pesticide  <e0>Gliftor</e0>  ( <e1>1,3-difluoro-2-propanol</e1> ), was investigated in vivo and in vitro. "
Other
Comment:

300	Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted  <e0>1,3-difluoroacetone</e0>  to  <e1>(-)-erythro-fluorocitrate</e1>  in vitro. "
Other
Comment:

400	Administration of  <e0>1,3-difluoroacetone</e0>  (100 mg kg(-1) body weight) to rats in vivo resulted in  <e1>(-)-erythro-fluorocitrate</e1>  synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. "
Other
Comment:

500	Animals dosed with  <e0>1,3-difluoroacetone</e0>  did not display the 2-3 hour lag phase in either  <e1>(-)-erythro-fluorocitrate</e1>  synthesis or in citrate and fluoride accumulation characteristic of animals dosed with  1,3-difluoro-2-propanol . "
Other
Comment:

501	Animals dosed with  <e0>1,3-difluoroacetone</e0>  did not display the 2-3 hour lag phase in either  (-)-erythro-fluorocitrate  synthesis or in citrate and fluoride accumulation characteristic of animals dosed with  <e1>1,3-difluoro-2-propanol</e1> . "
Other
Comment:

502	Animals dosed with  1,3-difluoroacetone  did not display the 2-3 hour lag phase in either  <e0>(-)-erythro-fluorocitrate</e0>  synthesis or in citrate and fluoride accumulation characteristic of animals dosed with  <e1>1,3-difluoro-2-propanol</e1> . "
Other
Comment:

600	We demonstrate that the conversion of  <e0>1,3-difluoro-2-propanol</e0>  to  <e1>1,3-difluoroacetone</e1>  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  (-)-erythro-fluorocitrate  from  1,3-difluoro-2-propanol . "
Other
Comment:

601	We demonstrate that the conversion of  <e0>1,3-difluoro-2-propanol</e0>  to  1,3-difluoroacetone  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  <e1>(-)-erythro-fluorocitrate</e1>  from  1,3-difluoro-2-propanol . "
Other
Comment:

602	We demonstrate that the conversion of  <e0>1,3-difluoro-2-propanol</e0>  to  1,3-difluoroacetone  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  (-)-erythro-fluorocitrate  from  <e1>1,3-difluoro-2-propanol</e1> . "
Other
Comment:

603	We demonstrate that the conversion of  1,3-difluoro-2-propanol  to  <e0>1,3-difluoroacetone</e0>  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  <e1>(-)-erythro-fluorocitrate</e1>  from  1,3-difluoro-2-propanol . "
Other
Comment:

604	We demonstrate that the conversion of  1,3-difluoro-2-propanol  to  <e0>1,3-difluoroacetone</e0>  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  (-)-erythro-fluorocitrate  from  <e1>1,3-difluoro-2-propanol</e1> . "
Other
Comment:

605	We demonstrate that the conversion of  1,3-difluoro-2-propanol  to  1,3-difluoroacetone  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  <e0>(-)-erythro-fluorocitrate</e0>  from  <e1>1,3-difluoro-2-propanol</e1> . "
Other
Comment:

700	Prior administration of  <e0>4-methylpyrazole</e0>  (90 mg kg(-1) body weight) was shown to prevent the conversion of  <e1>1,3-difluoro-2-propanol</e1>  (100 mg kg(-1) body weight) to  (-)-erythro-fluorocitrate  in vivo and to eliminate the fluoride and citrate elevations seen in  1,3-difluoro-2-propanol -intoxicated animals. "
effect(e0,e1)Comment:

701	Prior administration of  <e0>4-methylpyrazole</e0>  (90 mg kg(-1) body weight) was shown to prevent the conversion of  1,3-difluoro-2-propanol  (100 mg kg(-1) body weight) to  <e1>(-)-erythro-fluorocitrate</e1>  in vivo and to eliminate the fluoride and citrate elevations seen in  1,3-difluoro-2-propanol -intoxicated animals. "
Other
Comment:

702	Prior administration of  <e0>4-methylpyrazole</e0>  (90 mg kg(-1) body weight) was shown to prevent the conversion of  1,3-difluoro-2-propanol  (100 mg kg(-1) body weight) to  (-)-erythro-fluorocitrate  in vivo and to eliminate the fluoride and citrate elevations seen in  <e1>1,3-difluoro-2-propanol</e1> -intoxicated animals. "
Other
Comment:

703	Prior administration of  4-methylpyrazole  (90 mg kg(-1) body weight) was shown to prevent the conversion of  <e0>1,3-difluoro-2-propanol</e0>  (100 mg kg(-1) body weight) to  <e1>(-)-erythro-fluorocitrate</e1>  in vivo and to eliminate the fluoride and citrate elevations seen in  1,3-difluoro-2-propanol -intoxicated animals. "
Other
Comment:

704	Prior administration of  4-methylpyrazole  (90 mg kg(-1) body weight) was shown to prevent the conversion of  <e0>1,3-difluoro-2-propanol</e0>  (100 mg kg(-1) body weight) to  (-)-erythro-fluorocitrate  in vivo and to eliminate the fluoride and citrate elevations seen in  <e1>1,3-difluoro-2-propanol</e1> -intoxicated animals. "
Other
Comment:

705	Prior administration of  4-methylpyrazole  (90 mg kg(-1) body weight) was shown to prevent the conversion of  1,3-difluoro-2-propanol  (100 mg kg(-1) body weight) to  <e0>(-)-erythro-fluorocitrate</e0>  in vivo and to eliminate the fluoride and citrate elevations seen in  <e1>1,3-difluoro-2-propanol</e1> -intoxicated animals. "
Other
Comment:

800	However, administration of  <e0>4-methylpyrazole</e0>  (90 mg kg(-1) body weight) to rats 2 hours prior to  <e1>1,3-difluoroacetone</e1>  (100 mg kg(-1) body weight) was ineffective in preventing  (-)-erythro-fluorocitrate  synthesis and did not diminish fluoride or citrate accumulation in vivo. "
Other
Comment:

801	However, administration of  <e0>4-methylpyrazole</e0>  (90 mg kg(-1) body weight) to rats 2 hours prior to  1,3-difluoroacetone  (100 mg kg(-1) body weight) was ineffective in preventing  <e1>(-)-erythro-fluorocitrate</e1>  synthesis and did not diminish fluoride or citrate accumulation in vivo. "
Other
Comment:

802	However, administration of  4-methylpyrazole  (90 mg kg(-1) body weight) to rats 2 hours prior to  <e0>1,3-difluoroacetone</e0>  (100 mg kg(-1) body weight) was ineffective in preventing  <e1>(-)-erythro-fluorocitrate</e1>  synthesis and did not diminish fluoride or citrate accumulation in vivo. "
Other
Comment:

900	We conclude that the prophylactic and antidotal properties of  <e0>4-methylpyrazole</e0>  seen in animals treated with  <e1>1,3-difluoro-2-propanol</e1>  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  1,3-difluoro-2-propanol  to  1,3-difluoroacetone  in the committed step of the toxic pathway."
effect(e0,e1)Comment:

901	We conclude that the prophylactic and antidotal properties of  <e0>4-methylpyrazole</e0>  seen in animals treated with  1,3-difluoro-2-propanol  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  <e1>1,3-difluoro-2-propanol</e1>  to  1,3-difluoroacetone  in the committed step of the toxic pathway."
Other
Comment:

902	We conclude that the prophylactic and antidotal properties of  <e0>4-methylpyrazole</e0>  seen in animals treated with  1,3-difluoro-2-propanol  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  1,3-difluoro-2-propanol  to  <e1>1,3-difluoroacetone</e1>  in the committed step of the toxic pathway."
Other
Comment:

903	We conclude that the prophylactic and antidotal properties of  4-methylpyrazole  seen in animals treated with  <e0>1,3-difluoro-2-propanol</e0>  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  <e1>1,3-difluoro-2-propanol</e1>  to  1,3-difluoroacetone  in the committed step of the toxic pathway."
Other
Comment:

904	We conclude that the prophylactic and antidotal properties of  4-methylpyrazole  seen in animals treated with  <e0>1,3-difluoro-2-propanol</e0>  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  1,3-difluoro-2-propanol  to  <e1>1,3-difluoroacetone</e1>  in the committed step of the toxic pathway."
Other
Comment:

905	We conclude that the prophylactic and antidotal properties of  4-methylpyrazole  seen in animals treated with  1,3-difluoro-2-propanol  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  <e0>1,3-difluoro-2-propanol</e0>  to  <e1>1,3-difluoroacetone</e1>  in the committed step of the toxic pathway."
Other
Comment:



100	 <e0>Green tea polyphenols</e0>  as potent  <e1>enhancers</e1>  of glucocorticoid-induced mouse mammary tumor virus gene expression.
"
Other
Comment:

400	 <e0>n-dodecyl gallate</e0>  showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude  <e1>tannic acid</e1> . "
Other
Comment:


100	Pharmacokinetic interaction between single oral doses of  <e0>diltiazem</e0>  and  <e1>sirolimus</e1>  in healthy volunteers.
"
mechanism(e0,e1)Comment:

200	AIM AND BACKGROUND: The pharmacokinetic interaction between  <e0>sirolimus</e0> , a  <e1>macrolide immunosuppressant</e1>  metabolized by CYP3A4, and the  calcium channel blocker   diltiazem  was studied in 18 healthy subjects. "
Other
Comment:

201	AIM AND BACKGROUND: The pharmacokinetic interaction between  <e0>sirolimus</e0> , a  macrolide immunosuppressant  metabolized by CYP3A4, and the  <e1>calcium channel blocker</e1>   diltiazem  was studied in 18 healthy subjects. "
Other
Comment:

202	AIM AND BACKGROUND: The pharmacokinetic interaction between  <e0>sirolimus</e0> , a  macrolide immunosuppressant  metabolized by CYP3A4, and the  calcium channel blocker   <e1>diltiazem</e1>  was studied in 18 healthy subjects. "
Other
Comment:

203	AIM AND BACKGROUND: The pharmacokinetic interaction between  sirolimus , a  <e0>macrolide immunosuppressant</e0>  metabolized by CYP3A4, and the  <e1>calcium channel blocker</e1>   diltiazem  was studied in 18 healthy subjects. "
Other
Comment:

204	AIM AND BACKGROUND: The pharmacokinetic interaction between  sirolimus , a  <e0>macrolide immunosuppressant</e0>  metabolized by CYP3A4, and the  calcium channel blocker   <e1>diltiazem</e1>  was studied in 18 healthy subjects. "
Other
Comment:

205	AIM AND BACKGROUND: The pharmacokinetic interaction between  sirolimus , a  macrolide immunosuppressant  metabolized by CYP3A4, and the  <e0>calcium channel blocker</e0>   <e1>diltiazem</e1>  was studied in 18 healthy subjects. "
Other
Comment:

300	Several clinically important interactions have previously been reported for other  <e0>immunosuppressive drugs</e0>  that are metabolized by the same enzyme and for  <e1>calcium antagonists</e1> . "
Other
Comment:

400	METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of  <e0>sirolimus</e0> , a single oral 120-mg dose of  <e1>diltiazem</e1> , and the two drugs given together. "
Other
Comment:

600	RESULTS: The geometric mean (90% confidence interval) whole blood  <e0>sirolimus</e0>  area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with  <e1>diltiazem</e1>  coadministration, whereas the mean elimination half-life of  sirolimus  decreased slightly, from 79 to 67 hours. "
mechanism(e0,e1)Comment:

601	RESULTS: The geometric mean (90% confidence interval) whole blood  <e0>sirolimus</e0>  area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with  diltiazem  coadministration, whereas the mean elimination half-life of  <e1>sirolimus</e1>  decreased slightly, from 79 to 67 hours. "
Other
Comment:

602	RESULTS: The geometric mean (90% confidence interval) whole blood  sirolimus  area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with  <e0>diltiazem</e0>  coadministration, whereas the mean elimination half-life of  <e1>sirolimus</e1>  decreased slightly, from 79 to 67 hours. "
Other
Comment:

700	Apparent oral clearance and volume of distribution of  <e0>sirolimus</e0>  decreased with 38% and 45%, respectively, when  <e1>sirolimus</e1>  was given with  diltiazem . "
Other
Comment:

701	Apparent oral clearance and volume of distribution of  <e0>sirolimus</e0>  decreased with 38% and 45%, respectively, when  sirolimus  was given with  <e1>diltiazem</e1> . "
Other
Comment:

702	Apparent oral clearance and volume of distribution of  sirolimus  decreased with 38% and 45%, respectively, when  <e0>sirolimus</e0>  was given with  <e1>diltiazem</e1> . "
mechanism(e0,e1)Comment:

800	The plasma maximum concentration and area under the plasma concentration-time curve of  <e0>diltiazem</e0> ,  <e1>desacetyldiltiazem</e1> , and  desmethyldiltiazem  were unchanged after coadministration of  sirolimus , and no potentiation of the effects of  diltiazem  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

801	The plasma maximum concentration and area under the plasma concentration-time curve of  <e0>diltiazem</e0> ,  desacetyldiltiazem , and  <e1>desmethyldiltiazem</e1>  were unchanged after coadministration of  sirolimus , and no potentiation of the effects of  diltiazem  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

802	The plasma maximum concentration and area under the plasma concentration-time curve of  <e0>diltiazem</e0> ,  desacetyldiltiazem , and  desmethyldiltiazem  were unchanged after coadministration of  <e1>sirolimus</e1> , and no potentiation of the effects of  diltiazem  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

803	The plasma maximum concentration and area under the plasma concentration-time curve of  <e0>diltiazem</e0> ,  desacetyldiltiazem , and  desmethyldiltiazem  were unchanged after coadministration of  sirolimus , and no potentiation of the effects of  <e1>diltiazem</e1>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

804	The plasma maximum concentration and area under the plasma concentration-time curve of  diltiazem ,  <e0>desacetyldiltiazem</e0> , and  <e1>desmethyldiltiazem</e1>  were unchanged after coadministration of  sirolimus , and no potentiation of the effects of  diltiazem  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

805	The plasma maximum concentration and area under the plasma concentration-time curve of  diltiazem ,  <e0>desacetyldiltiazem</e0> , and  desmethyldiltiazem  were unchanged after coadministration of  <e1>sirolimus</e1> , and no potentiation of the effects of  diltiazem  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

806	The plasma maximum concentration and area under the plasma concentration-time curve of  diltiazem ,  <e0>desacetyldiltiazem</e0> , and  desmethyldiltiazem  were unchanged after coadministration of  sirolimus , and no potentiation of the effects of  <e1>diltiazem</e1>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

807	The plasma maximum concentration and area under the plasma concentration-time curve of  diltiazem ,  desacetyldiltiazem , and  <e0>desmethyldiltiazem</e0>  were unchanged after coadministration of  <e1>sirolimus</e1> , and no potentiation of the effects of  diltiazem  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

808	The plasma maximum concentration and area under the plasma concentration-time curve of  diltiazem ,  desacetyldiltiazem , and  <e0>desmethyldiltiazem</e0>  were unchanged after coadministration of  sirolimus , and no potentiation of the effects of  <e1>diltiazem</e1>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

809	The plasma maximum concentration and area under the plasma concentration-time curve of  diltiazem ,  desacetyldiltiazem , and  desmethyldiltiazem  were unchanged after coadministration of  <e0>sirolimus</e0> , and no potentiation of the effects of  <e1>diltiazem</e1>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. "
Other
Comment:

900	CONCLUSIONS: Single-dose  <e0>diltiazem</e0>  coadministration leads to higher  <e1>sirolimus</e1>  exposure, presumably by inhibition of the first-pass metabolism of  sirolimus . "
mechanism(e0,e1)Comment:

901	CONCLUSIONS: Single-dose  <e0>diltiazem</e0>  coadministration leads to higher  sirolimus  exposure, presumably by inhibition of the first-pass metabolism of  <e1>sirolimus</e1> . "
Other
Comment:

902	CONCLUSIONS: Single-dose  diltiazem  coadministration leads to higher  <e0>sirolimus</e0>  exposure, presumably by inhibition of the first-pass metabolism of  <e1>sirolimus</e1> . "
Other
Comment:

1000	Because of the pronounced intersubject variability in the extent of the  <e0>sirolimus</e0> - <e1>diltiazem</e1>  interaction, whole blood  sirolimus  concentrations should be monitored closely in patients treated with the two drugs."
advise(e0,e1)Comment:

1001	Because of the pronounced intersubject variability in the extent of the  <e0>sirolimus</e0> - diltiazem  interaction, whole blood  <e1>sirolimus</e1>  concentrations should be monitored closely in patients treated with the two drugs."
Other
Comment:

1002	Because of the pronounced intersubject variability in the extent of the  sirolimus - <e0>diltiazem</e0>  interaction, whole blood  <e1>sirolimus</e1>  concentrations should be monitored closely in patients treated with the two drugs."
Other
Comment:


100	 <e0>Fluvoxamine</e0>  inhibits the CYP2C9 catalyzed biotransformation of  <e1>tolbutamide</e1> .
"
mechanism(e0,e1)Comment:

200	OBJECTIVE: Our objective was to examine the interaction between  <e0>fluvoxamine</e0>  and  <e1>tolbutamide</e1>  to confirm that  fluvoxamine  inhibits CYP2C9. "
Other
Comment:

201	OBJECTIVE: Our objective was to examine the interaction between  <e0>fluvoxamine</e0>  and  tolbutamide  to confirm that  <e1>fluvoxamine</e1>  inhibits CYP2C9. "
Other
Comment:

202	OBJECTIVE: Our objective was to examine the interaction between  fluvoxamine  and  <e0>tolbutamide</e0>  to confirm that  <e1>fluvoxamine</e1>  inhibits CYP2C9. "
Other
Comment:

900	Plasma was analyzed for  <e0>tolbutamide</e0> , and urine was analyzed for  <e1>tolbutamide</e1>  and its two metabolites,  4-hydroxytolbutamide  and  carboxytolbutamide  by means of HPLC. "
Other
Comment:

901	Plasma was analyzed for  <e0>tolbutamide</e0> , and urine was analyzed for  tolbutamide  and its two metabolites,  <e1>4-hydroxytolbutamide</e1>  and  carboxytolbutamide  by means of HPLC. "
Other
Comment:

902	Plasma was analyzed for  <e0>tolbutamide</e0> , and urine was analyzed for  tolbutamide  and its two metabolites,  4-hydroxytolbutamide  and  <e1>carboxytolbutamide</e1>  by means of HPLC. "
Other
Comment:

903	Plasma was analyzed for  tolbutamide , and urine was analyzed for  <e0>tolbutamide</e0>  and its two metabolites,  <e1>4-hydroxytolbutamide</e1>  and  carboxytolbutamide  by means of HPLC. "
Other
Comment:

904	Plasma was analyzed for  tolbutamide , and urine was analyzed for  <e0>tolbutamide</e0>  and its two metabolites,  4-hydroxytolbutamide  and  <e1>carboxytolbutamide</e1>  by means of HPLC. "
Other
Comment:

905	Plasma was analyzed for  tolbutamide , and urine was analyzed for  tolbutamide  and its two metabolites,  <e0>4-hydroxytolbutamide</e0>  and  <e1>carboxytolbutamide</e1>  by means of HPLC. "
Other
Comment:

1000	RESULTS: During treatment with  <e0>fluvoxamine</e0> , there was a statistically significant decrease in the median of the total clearance of  <e1>tolbutamide</e1> , from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. "
mechanism(e0,e1)Comment:

1200	The clearance by means of  <e0>4-hydroxytolbutamide</e0>  and  <e1>carboxytolbutamide</e1>  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  tolbutamide  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  tolbutamide  per day). "
Other
Comment:

1201	The clearance by means of  <e0>4-hydroxytolbutamide</e0>  and  carboxytolbutamide  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  <e1>tolbutamide</e1>  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  tolbutamide  per day). "
Other
Comment:

1202	The clearance by means of  <e0>4-hydroxytolbutamide</e0>  and  carboxytolbutamide  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  tolbutamide  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  <e1>tolbutamide</e1>  per day). "
Other
Comment:

1203	The clearance by means of  4-hydroxytolbutamide  and  <e0>carboxytolbutamide</e0>  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  <e1>tolbutamide</e1>  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  tolbutamide  per day). "
Other
Comment:

1204	The clearance by means of  4-hydroxytolbutamide  and  <e0>carboxytolbutamide</e0>  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  tolbutamide  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  <e1>tolbutamide</e1>  per day). "
Other
Comment:

1205	The clearance by means of  4-hydroxytolbutamide  and  carboxytolbutamide  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  <e0>tolbutamide</e0>  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  <e1>tolbutamide</e1>  per day). "
Other
Comment:


100	Longitudinal assessment of  <e0>everolimus</e0>  in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on  <e1>cyclosporine</e1> .
"
Other
Comment:

200	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of  <e0>everolimus</e0>  and  <e1>cyclosporine</e1>  (INN,  ciclosporin ) when coadministered in de novo kidney allograft recipients during the first year after transplantation. "
Other
Comment:

201	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of  <e0>everolimus</e0>  and  cyclosporine  (INN,  <e1>ciclosporin</e1> ) when coadministered in de novo kidney allograft recipients during the first year after transplantation. "
Other
Comment:

202	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of  everolimus  and  <e0>cyclosporine</e0>  (INN,  <e1>ciclosporin</e1> ) when coadministered in de novo kidney allograft recipients during the first year after transplantation. "
Other
Comment:

300	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive  <e0>everolimus</e0>  tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with  <e1>cyclosporine</e1>  and  prednisone . "
Other
Comment:

301	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive  <e0>everolimus</e0>  tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with  cyclosporine  and  <e1>prednisone</e1> . "
Other
Comment:

302	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive  everolimus  tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with  <e0>cyclosporine</e0>  and  <e1>prednisone</e1> . "
Other
Comment:

400	Blood sampling for the pharmacokinetics of  <e0>everolimus</e0>  and  <e1>cyclosporine</e1>  was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. "
Other
Comment:

700	Potential differences in  <e0>cyclosporine</e0>  dosing and pharmacokinetics at different levels of  <e1>everolimus</e1>  exposure were assessed in the context of ANOVA. "
Other
Comment:

1400	 <e0>Cyclosporine</e0>  doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered  <e1>everolimus</e1>  dose level (P = .13, .82, and .76, respectively). "
Other
Comment:

1600	For a 4-fold range of  <e0>everolimus</e0>  doses there were no differential effects on  <e1>cyclosporine</e1>  dosing or pharmacokinetics."
Other
Comment:


100	 <e0>ADL 8-2698</e0> , a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous  <e1>morphine</e1>  without affecting analgesia.
"
effect(e0,e1)Comment:

200	 <e0>ADL-8-2698</e0>  is a novel  <e1>peripherally restricted opioid antagonist</e1>  that may selectively prevent  opioid -induced gastrointestinal effects without reversing analgesia. "
Other
Comment:

201	 <e0>ADL-8-2698</e0>  is a novel  peripherally restricted opioid antagonist  that may selectively prevent  <e1>opioid</e1> -induced gastrointestinal effects without reversing analgesia. "
effect(e0,e1)Comment:

202	 ADL-8-2698  is a novel  <e0>peripherally restricted opioid antagonist</e0>  that may selectively prevent  <e1>opioid</e1> -induced gastrointestinal effects without reversing analgesia. "
Other
Comment:

300	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous  <e0>morphine</e0>  (0.05 mg x kg(-1)), and oral  <e1>ADL 8-2698</e1>  (4 mg) and intravenous  morphine  (0.05 mg x kg(-1)) in a double blind, cross-over study. "
Other
Comment:

301	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous  <e0>morphine</e0>  (0.05 mg x kg(-1)), and oral  ADL 8-2698  (4 mg) and intravenous  <e1>morphine</e1>  (0.05 mg x kg(-1)) in a double blind, cross-over study. "
Other
Comment:

302	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous  morphine  (0.05 mg x kg(-1)), and oral  <e0>ADL 8-2698</e0>  (4 mg) and intravenous  <e1>morphine</e1>  (0.05 mg x kg(-1)) in a double blind, cross-over study. "
Other
Comment:

500	 <e0>Morphine</e0>  prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by  <e1>ADL 8-2698</e1>  (P = .004). "
effect(e0,e1)Comment:

600	Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive  <e0>ADL 8-2698</e0>  (4 mg) or placebo and intravenous  <e1>morphine</e1>  (0.15 mg/kg) or to receive oral and intravenous placebo. "
Other
Comment:

800	 <e0>Morphine</e0>  analgesia and pupil constriction were unaffected by  <e1>ADL 8-2698</e1>  and differed from placebo (P lt; .002). "
Other
Comment:

900	We conclude that  <e0>ADL 8-2698</e0>  prevents  <e1>morphine</e1> -induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia."
effect(e0,e1)Comment:



100	Rhabdomyolysis secondary to a drug interaction between  <e0>simvastatin</e0>  and  <e1>clarithromycin</e1> .
"
effect(e0,e1)Comment:

200	OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of  <e0>clarithromycin</e0>  and  <e1>simvastatin</e1> . "
Other
Comment:

1000	DISCUSSION:  <e0>Clarithromycin</e0>  is a potent inhibitor of CYP3A4, the major enzyme responsible for  <e1>simvastatin</e1>  metabolism. "
mechanism(e0,e1)Comment:

1100	The concomitant administration of  <e0>macrolide antibiotics</e0>  and other  <e1>hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors</e1>  have resulted in previous reports of rhabdomyolysis. "
effect(e0,e1)Comment:

1300	CONCLUSIONS:  <e0>Macrolide antibiotics</e0>  inhibit the metabolism of  <e1>HMG-CoA reductase inhibitors</e1>  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  cerivastatin ,  lovastatin ,  simvastatin ). "
Other
Comment:

1301	CONCLUSIONS:  <e0>Macrolide antibiotics</e0>  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  <e1>atorvastatin</e1> ,  cerivastatin ,  lovastatin ,  simvastatin ). "
mechanism(e0,e1)Comment:

1302	CONCLUSIONS:  <e0>Macrolide antibiotics</e0>  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  <e1>cerivastatin</e1> ,  lovastatin ,  simvastatin ). "
mechanism(e0,e1)Comment:

1303	CONCLUSIONS:  <e0>Macrolide antibiotics</e0>  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  cerivastatin ,  <e1>lovastatin</e1> ,  simvastatin ). "
mechanism(e0,e1)Comment:

1304	CONCLUSIONS:  <e0>Macrolide antibiotics</e0>  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  cerivastatin ,  lovastatin ,  <e1>simvastatin</e1> ). "
mechanism(e0,e1)Comment:

1305	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  <e0>HMG-CoA reductase inhibitors</e0>  that are metabolized by CYP3A4 (i.e.,  <e1>atorvastatin</e1> ,  cerivastatin ,  lovastatin ,  simvastatin ). "
Other
Comment:

1306	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  <e0>HMG-CoA reductase inhibitors</e0>  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  <e1>cerivastatin</e1> ,  lovastatin ,  simvastatin ). "
Other
Comment:

1307	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  <e0>HMG-CoA reductase inhibitors</e0>  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  cerivastatin ,  <e1>lovastatin</e1> ,  simvastatin ). "
Other
Comment:

1308	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  <e0>HMG-CoA reductase inhibitors</e0>  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  cerivastatin ,  lovastatin ,  <e1>simvastatin</e1> ). "
Other
Comment:

1309	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  <e0>atorvastatin</e0> ,  <e1>cerivastatin</e1> ,  lovastatin ,  simvastatin ). "
Other
Comment:

1310	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  <e0>atorvastatin</e0> ,  cerivastatin ,  <e1>lovastatin</e1> ,  simvastatin ). "
Other
Comment:

1311	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  <e0>atorvastatin</e0> ,  cerivastatin ,  lovastatin ,  <e1>simvastatin</e1> ). "
Other
Comment:

1312	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  <e0>cerivastatin</e0> ,  <e1>lovastatin</e1> ,  simvastatin ). "
Other
Comment:

1313	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  <e0>cerivastatin</e0> ,  lovastatin ,  <e1>simvastatin</e1> ). "
Other
Comment:

1314	CONCLUSIONS:  Macrolide antibiotics  inhibit the metabolism of  HMG-CoA reductase inhibitors  that are metabolized by CYP3A4 (i.e.,  atorvastatin ,  cerivastatin ,  <e0>lovastatin</e0> ,  <e1>simvastatin</e1> ). "
Other
Comment:





100	The effects of concomitant  <e0>phenytoin</e0>  administration on the steady-state pharmacokinetics of  <e1>quetiapine</e1> .
"
Other
Comment:

200	 <e0>Quetiapine fumarate</e0>  (' <e1>Seroquel</e1> ') is a newly introduced  atypical antipsychotic  with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. "
Other
Comment:

201	 <e0>Quetiapine fumarate</e0>  (' Seroquel ') is a newly introduced  <e1>atypical antipsychotic</e1>  with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. "
Other
Comment:

202	 Quetiapine fumarate  (' <e0>Seroquel</e0> ') is a newly introduced  <e1>atypical antipsychotic</e1>  with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. "
Other
Comment:

500	This study demonstrated that the potent cytochrome P450 enzyme-inducer  <e0>phenytoin</e0>  did indeed have a marked effect on the metabolism of  <e1>quetiapine</e1> , resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. "
mechanism(e0,e1)Comment:


300	 <e0>Acetaminophen</e0> ,  <e1>lidocaine</e1> ,  phenobarbital ,  quinidine ,  theophylline , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

301	 <e0>Acetaminophen</e0> ,  lidocaine ,  <e1>phenobarbital</e1> ,  quinidine ,  theophylline , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

302	 <e0>Acetaminophen</e0> ,  lidocaine ,  phenobarbital ,  <e1>quinidine</e1> ,  theophylline , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

303	 <e0>Acetaminophen</e0> ,  lidocaine ,  phenobarbital ,  quinidine ,  <e1>theophylline</e1> , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

304	 <e0>Acetaminophen</e0> ,  lidocaine ,  phenobarbital ,  quinidine ,  theophylline , and  <e1>valproic acid</e1>  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

305	 Acetaminophen ,  <e0>lidocaine</e0> ,  <e1>phenobarbital</e1> ,  quinidine ,  theophylline , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

306	 Acetaminophen ,  <e0>lidocaine</e0> ,  phenobarbital ,  <e1>quinidine</e1> ,  theophylline , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

307	 Acetaminophen ,  <e0>lidocaine</e0> ,  phenobarbital ,  quinidine ,  <e1>theophylline</e1> , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

308	 Acetaminophen ,  <e0>lidocaine</e0> ,  phenobarbital ,  quinidine ,  theophylline , and  <e1>valproic acid</e1>  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

309	 Acetaminophen ,  lidocaine ,  <e0>phenobarbital</e0> ,  <e1>quinidine</e1> ,  theophylline , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

310	 Acetaminophen ,  lidocaine ,  <e0>phenobarbital</e0> ,  quinidine ,  <e1>theophylline</e1> , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

311	 Acetaminophen ,  lidocaine ,  <e0>phenobarbital</e0> ,  quinidine ,  theophylline , and  <e1>valproic acid</e1>  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

312	 Acetaminophen ,  lidocaine ,  phenobarbital ,  <e0>quinidine</e0> ,  <e1>theophylline</e1> , and  valproic acid  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

313	 Acetaminophen ,  lidocaine ,  phenobarbital ,  <e0>quinidine</e0> ,  theophylline , and  <e1>valproic acid</e1>  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

314	 Acetaminophen ,  lidocaine ,  phenobarbital ,  quinidine ,  <e0>theophylline</e0> , and  <e1>valproic acid</e1>  were added to pooled human serum at therapeutic concentrations. "
Other
Comment:

500	The following eight target drug/added drug combinations were studied:  <e0>acetaminophen</e0> / <e1>phenobarbital</e1> . "
Other
Comment:

600	 <e0>acetaminophen</e0> / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

601	 <e0>acetaminophen</e0> / theophylline ,  <e1>lidocaine</e1> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

602	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / <e1>quinidine</e1> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

603	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / quinidine ,  <e1>phenobarbital</e1> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

604	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / quinidine ,  phenobarbital / <e1>acetaminophen</e1> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

605	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e1>phenobarbital</e1> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

606	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

607	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

608	 <e0>acetaminophen</e0> / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

609	 <e0>acetaminophen</e0> / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

610	 <e0>acetaminophen</e0> / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

611	 <e0>acetaminophen</e0> / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

612	 <e0>acetaminophen</e0> / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

613	 acetaminophen / <e0>theophylline</e0> ,  <e1>lidocaine</e1> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

614	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / <e1>quinidine</e1> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

615	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  <e1>phenobarbital</e1> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

616	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / <e1>acetaminophen</e1> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

617	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e1>phenobarbital</e1> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

618	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

619	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

620	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

621	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

622	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

623	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

624	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

625	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / <e1>quinidine</e1> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

626	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / quinidine ,  <e1>phenobarbital</e1> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

627	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / <e1>acetaminophen</e1> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

628	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  <e1>phenobarbital</e1> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

629	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

630	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

631	 acetaminophen / theophylline ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

632	 acetaminophen / <e1>theophylline</e1> ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

633	 acetaminophen / <e1>theophylline</e1> ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

634	 acetaminophen / <e1>theophylline</e1> ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

635	 acetaminophen / <e1>theophylline</e1> ,  <e0>lidocaine</e0> / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

636	 acetaminophen / theophylline ,  lidocaine / <e0>quinidine</e0> ,  <e1>phenobarbital</e1> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

637	 acetaminophen / theophylline ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / <e1>acetaminophen</e1> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

638	 acetaminophen / theophylline ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  <e1>phenobarbital</e1> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

639	 acetaminophen / theophylline ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

640	 acetaminophen / theophylline ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

641	 acetaminophen / theophylline ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

642	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

643	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

644	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

645	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / <e0>quinidine</e0> ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

646	 acetaminophen / theophylline ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / <e1>acetaminophen</e1> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

647	 acetaminophen / theophylline ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  <e1>phenobarbital</e1> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

648	 acetaminophen / theophylline ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

649	 acetaminophen / theophylline ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

650	 acetaminophen / theophylline ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

651	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

652	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

653	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

654	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  <e0>phenobarbital</e0> / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

655	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  <e1>phenobarbital</e1> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

656	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

657	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

658	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

659	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

660	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

661	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

662	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / <e0>acetaminophen</e0> ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

663	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / <e1>valproic acid</e1> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

664	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / valproic acid ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

665	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / valproic acid ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

666	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

667	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

668	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

669	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  <e0>phenobarbital</e0> / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

670	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e0>valproic acid</e0> ,  <e1>quinidine</e1> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

671	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e0>valproic acid</e0> ,  quinidine / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

672	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e0>valproic acid</e0> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

673	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e0>valproic acid</e0> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

674	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e0>valproic acid</e0> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

675	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / <e0>valproic acid</e0> ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

676	 acetaminophen / theophylline ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e0>quinidine</e0> / <e1>lidocaine</e1> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

677	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e0>quinidine</e0> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

678	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e0>quinidine</e0> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

679	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e0>quinidine</e0> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

680	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  <e0>quinidine</e0> / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

681	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e0>lidocaine</e0> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

682	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e0>lidocaine</e0> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

683	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e0>lidocaine</e0> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

684	 acetaminophen / <e1>theophylline</e1> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / <e0>lidocaine</e0> ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

685	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

686	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

687	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

688	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

689	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

690	 acetaminophen / <e0>theophylline</e0> ,  lidocaine / quinidine ,  phenobarbital / acetaminophen ,  phenobarbital / valproic acid ,  quinidine / lidocaine ,  <ne10>theophylline</ne10> / <ne11>acetaminophen</ne11> , and  <ne12>valproic acid</ne12> / <ne13>phenobarbital</ne13> . "
Other
Comment:

800	Similarly dialyzed were  <e0>phenobarbital</e0> ,  <e1>quinidine</e1> , and  theophylline , both alone at therapeutic concentrations in serum and with  ethanol  at three different concentrations in serum. "
Other
Comment:

801	Similarly dialyzed were  <e0>phenobarbital</e0> ,  quinidine , and  <e1>theophylline</e1> , both alone at therapeutic concentrations in serum and with  ethanol  at three different concentrations in serum. "
Other
Comment:

802	Similarly dialyzed were  <e0>phenobarbital</e0> ,  quinidine , and  theophylline , both alone at therapeutic concentrations in serum and with  <e1>ethanol</e1>  at three different concentrations in serum. "
Other
Comment:

803	Similarly dialyzed were  phenobarbital ,  <e0>quinidine</e0> , and  <e1>theophylline</e1> , both alone at therapeutic concentrations in serum and with  ethanol  at three different concentrations in serum. "
Other
Comment:

804	Similarly dialyzed were  phenobarbital ,  <e0>quinidine</e0> , and  theophylline , both alone at therapeutic concentrations in serum and with  <e1>ethanol</e1>  at three different concentrations in serum. "
Other
Comment:

805	Similarly dialyzed were  phenobarbital ,  quinidine , and  <e0>theophylline</e0> , both alone at therapeutic concentrations in serum and with  <e1>ethanol</e1>  at three different concentrations in serum. "
Other
Comment:

1000	 <e0>Acetaminophen</e0>  diminished the binding of  <e1>theophylline</e1>  to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. "
mechanism(e0,e1)Comment:

1100	 <e0>Theophylline</e0>  decreased the binding of  <e1>acetaminophen</e1>  by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; "
mechanism(e0,e1)Comment:

1300	 <e0>Valproic acid</e0>  diminished binding of  <e1>phenobarbital</e1>  by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. "
mechanism(e0,e1)Comment:

1500	Coingestion of  <e0>acetaminophen</e0>  with  <e1>theophylline</e1> ,  phenobarbital  with  acetaminophen , and  valproic acid  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
effect(e0,e1)Comment:

1501	Coingestion of  <e0>acetaminophen</e0>  with  theophylline ,  <e1>phenobarbital</e1>  with  acetaminophen , and  valproic acid  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1502	Coingestion of  <e0>acetaminophen</e0>  with  theophylline ,  phenobarbital  with  <e1>acetaminophen</e1> , and  valproic acid  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1503	Coingestion of  <e0>acetaminophen</e0>  with  theophylline ,  phenobarbital  with  acetaminophen , and  <e1>valproic acid</e1>  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1504	Coingestion of  <e0>acetaminophen</e0>  with  theophylline ,  phenobarbital  with  acetaminophen , and  valproic acid  with  <e1>phenobarbital</e1>  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1505	Coingestion of  acetaminophen  with  <e0>theophylline</e0> ,  <e1>phenobarbital</e1>  with  acetaminophen , and  valproic acid  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1506	Coingestion of  acetaminophen  with  <e0>theophylline</e0> ,  phenobarbital  with  <e1>acetaminophen</e1> , and  valproic acid  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1507	Coingestion of  acetaminophen  with  <e0>theophylline</e0> ,  phenobarbital  with  acetaminophen , and  <e1>valproic acid</e1>  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1508	Coingestion of  acetaminophen  with  <e0>theophylline</e0> ,  phenobarbital  with  acetaminophen , and  valproic acid  with  <e1>phenobarbital</e1>  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1509	Coingestion of  acetaminophen  with  theophylline ,  <e0>phenobarbital</e0>  with  <e1>acetaminophen</e1> , and  valproic acid  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
effect(e0,e1)Comment:

1510	Coingestion of  acetaminophen  with  theophylline ,  <e0>phenobarbital</e0>  with  acetaminophen , and  <e1>valproic acid</e1>  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1511	Coingestion of  acetaminophen  with  theophylline ,  <e0>phenobarbital</e0>  with  acetaminophen , and  valproic acid  with  <e1>phenobarbital</e1>  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1512	Coingestion of  acetaminophen  with  theophylline ,  phenobarbital  with  <e0>acetaminophen</e0> , and  <e1>valproic acid</e1>  with  phenobarbital  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1513	Coingestion of  acetaminophen  with  theophylline ,  phenobarbital  with  <e0>acetaminophen</e0> , and  valproic acid  with  <e1>phenobarbital</e1>  at high to toxic concentrations decreases the binding of the target drug. "
Other
Comment:

1514	Coingestion of  acetaminophen  with  theophylline ,  phenobarbital  with  acetaminophen , and  <e0>valproic acid</e0>  with  <e1>phenobarbital</e1>  at high to toxic concentrations decreases the binding of the target drug. "
effect(e0,e1)Comment:


300	The serum concentration of  <e0>phenytoin</e0>  increased dramatically from 16.6 to 49.1 microg/mL when  <e1>fluvoxamine</e1>  was coadministered, although the daily dosage of  phenytoin  and other  drugs  had not changed. "
Other
Comment:

301	The serum concentration of  <e0>phenytoin</e0>  increased dramatically from 16.6 to 49.1 microg/mL when  fluvoxamine  was coadministered, although the daily dosage of  <e1>phenytoin</e1>  and other  drugs  had not changed. "
Other
Comment:

302	The serum concentration of  <e0>phenytoin</e0>  increased dramatically from 16.6 to 49.1 microg/mL when  fluvoxamine  was coadministered, although the daily dosage of  phenytoin  and other  <e1>drugs</e1>  had not changed. "
Other
Comment:

303	The serum concentration of  phenytoin  increased dramatically from 16.6 to 49.1 microg/mL when  <e0>fluvoxamine</e0>  was coadministered, although the daily dosage of  <e1>phenytoin</e1>  and other  drugs  had not changed. "
Other
Comment:

304	The serum concentration of  phenytoin  increased dramatically from 16.6 to 49.1 microg/mL when  <e0>fluvoxamine</e0>  was coadministered, although the daily dosage of  phenytoin  and other  <e1>drugs</e1>  had not changed. "
Other
Comment:

305	The serum concentration of  phenytoin  increased dramatically from 16.6 to 49.1 microg/mL when  fluvoxamine  was coadministered, although the daily dosage of  <e0>phenytoin</e0>  and other  <e1>drugs</e1>  had not changed. "
Other
Comment:

400	During  <e0>phenytoin</e0>  and fluvoxamine treatment, ataxia, a typical side effect of  <e1>phenytoin</e1> , was observed. "
Other
Comment:

500	The genotypes of  <e0>CYP2C9</e0>  and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles ( <e1>CYP2C9</e1> *1/*1 and 2C19*1/ *1). "
Other
Comment:

600	The interaction may be a result of inhibition of both  <e0>CYP2C9</e0>  and 2C19 by  <e1>fluvoxamine</e1> ."
Other
Comment:


300	Here we show that a combination of  <e0>galangin</e0>  or 3,7-dihydroxyflavone with  <e1>vancomycin</e1>  may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. "
Other
Comment:


100	 <e0>Glucose</e0>  and  <e1>insulin</e1>  exert additive ocular and renal vasodilator effects on healthy humans.
"
Other
Comment:

200	AIMS/HYPOTHESIS: There is evidence that  <e0>insulin</e0>  and  <e1>glucose</e1>  cause renal and ocular vasodilation. "
Other
Comment:

1000	Haemodynamic effects of  <e0>glucose</e0>  and  <e1>insulin</e1>  were additive when  somatostatin  was co-administered but not under basal conditions. "
Other
Comment:

1001	Haemodynamic effects of  <e0>glucose</e0>  and  insulin  were additive when  <e1>somatostatin</e1>  was co-administered but not under basal conditions. "
Other
Comment:

1002	Haemodynamic effects of  glucose  and  <e0>insulin</e0>  were additive when  <e1>somatostatin</e1>  was co-administered but not under basal conditions. "
Other
Comment:

1100	CONCLUSIONS/INTERPRETATION:  <e0>Glucose</e0>  and  <e1>insulin</e1>  can exert additive vasodilator properties on renal and ocular circulation. "
Other
Comment:


100	Lack of interaction between  <e0>levofloxacin</e0>  and  <e1>oxycodone</e1> : pharmacokinetics and drug disposition.
"
Other
Comment:

200	Previous studies have demonstrated a significant reduction in the oral bioavailability of  <e0>trovafloxacin</e0>  and  <e1>ciprofloxacin</e1>  when administered concomitantly with an intravenous  opiate  such as  morphine . "
Other
Comment:

201	Previous studies have demonstrated a significant reduction in the oral bioavailability of  <e0>trovafloxacin</e0>  and  ciprofloxacin  when administered concomitantly with an intravenous  <e1>opiate</e1>  such as  morphine . "
mechanism(e0,e1)Comment:

202	Previous studies have demonstrated a significant reduction in the oral bioavailability of  <e0>trovafloxacin</e0>  and  ciprofloxacin  when administered concomitantly with an intravenous  opiate  such as  <e1>morphine</e1> . "
mechanism(e0,e1)Comment:

203	Previous studies have demonstrated a significant reduction in the oral bioavailability of  trovafloxacin  and  <e0>ciprofloxacin</e0>  when administered concomitantly with an intravenous  <e1>opiate</e1>  such as  morphine . "
mechanism(e0,e1)Comment:

204	Previous studies have demonstrated a significant reduction in the oral bioavailability of  trovafloxacin  and  <e0>ciprofloxacin</e0>  when administered concomitantly with an intravenous  opiate  such as  <e1>morphine</e1> . "
mechanism(e0,e1)Comment:

205	Previous studies have demonstrated a significant reduction in the oral bioavailability of  trovafloxacin  and  ciprofloxacin  when administered concomitantly with an intravenous  <e0>opiate</e0>  such as  <e1>morphine</e1> . "
Other
Comment:

300	This decrease in absorption results in a 36% and 50% lower AUC for  <e0>trovafloxacin</e0>  and  <e1>ciprofloxacin</e1> , respectively, which could cause clinical failures. "
Other
Comment:

400	The authors investigated the possibility of a similar interaction between  <e0>oxycodone</e0>  and  <e1>levofloxacin</e1> . "
Other
Comment:

700	1 hour after starting the  <e0>oxycodone</e0>  or  <e1>levofloxacin</e1>  500 mg p.o. "
Other
Comment:

1000	There was not a significant difference (p gt; 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for  <e0>levofloxacin</e0>  versus  <e1>levofloxacin</e1> / oxycodone  regimens. "
Other
Comment:

1001	There was not a significant difference (p gt; 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for  <e0>levofloxacin</e0>  versus  levofloxacin / <e1>oxycodone</e1>  regimens. "
Other
Comment:

1002	There was not a significant difference (p gt; 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for  levofloxacin  versus  <e0>levofloxacin</e0> / <e1>oxycodone</e1>  regimens. "
Other
Comment:

1100	It was concluded that oral  <e0>oxycodone</e0>  and  <e1>levofloxacin</e1>  can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax."
Other
Comment:


100	Lack of an effect of  <e0>azithromycin</e0>  on the disposition of  <e1>zidovudine</e1>  and  dideoxyinosine  in HIV-infected patients."
Other
Comment:

101	Lack of an effect of  <e0>azithromycin</e0>  on the disposition of  zidovudine  and  <e1>dideoxyinosine</e1>  in HIV-infected patients."
Other
Comment:

102	Lack of an effect of  azithromycin  on the disposition of  <e0>zidovudine</e0>  and  <e1>dideoxyinosine</e1>  in HIV-infected patients."
Other
Comment:

200	Two studies were conducted in HIV-infected subjects to assess the potential for  <e0>azithromycin</e0>  to interact with  <e1>zidovudine</e1>  and  dideoxyinosine . "
Other
Comment:

201	Two studies were conducted in HIV-infected subjects to assess the potential for  <e0>azithromycin</e0>  to interact with  zidovudine  and  <e1>dideoxyinosine</e1> . "
Other
Comment:

202	Two studies were conducted in HIV-infected subjects to assess the potential for  azithromycin  to interact with  <e0>zidovudine</e0>  and  <e1>dideoxyinosine</e1> . "
Other
Comment:

400	The  <e0>zidovudine</e0>  study dosed subjects with 1200 mg/day of  <e1>azithromycin</e1>  (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of  zidovudine . "
Other
Comment:

401	The  <e0>zidovudine</e0>  study dosed subjects with 1200 mg/day of  azithromycin  (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of  <e1>zidovudine</e1> . "
Other
Comment:

402	The  zidovudine  study dosed subjects with 1200 mg/day of  <e0>azithromycin</e0>  (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of  <e1>zidovudine</e1> . "
Other
Comment:

500	Subjects treated with 200 mg of  <e0>dideoxyinosine</e0>  twice daily for 21 days received 1200 mg of  <e1>azithromycin</e1>  or an equivalent amount of placebo/day for Days 8 to 21. "
Other
Comment:

600	 <e0>Antiretroviral</e0>  plasma and urine sampling were conducted on Days 1, 7, and 21 for  <e1>zidovudine</e1>  and on Days 7 and 21 for  dideoxyinosine . "
Other
Comment:

601	 <e0>Antiretroviral</e0>  plasma and urine sampling were conducted on Days 1, 7, and 21 for  zidovudine  and on Days 7 and 21 for  <e1>dideoxyinosine</e1> . "
Other
Comment:

602	 Antiretroviral  plasma and urine sampling were conducted on Days 1, 7, and 21 for  <e0>zidovudine</e0>  and on Days 7 and 21 for  <e1>dideoxyinosine</e1> . "
Other
Comment:

800	 <e0>Azithromycin</e0>  had no significant impact on the Cmax and AUC of  <e1>zidovudine</e1> , although it significantly decreased the  zidovudine  tmax by 44% and increased the intracellular exposure to phosphorylated  zidovudine  by 110%. "
Other
Comment:

801	 <e0>Azithromycin</e0>  had no significant impact on the Cmax and AUC of  zidovudine , although it significantly decreased the  <e1>zidovudine</e1>  tmax by 44% and increased the intracellular exposure to phosphorylated  zidovudine  by 110%. "
mechanism(e0,e1)Comment:

802	 <e0>Azithromycin</e0>  had no significant impact on the Cmax and AUC of  zidovudine , although it significantly decreased the  zidovudine  tmax by 44% and increased the intracellular exposure to phosphorylated  <e1>zidovudine</e1>  by 110%. "
mechanism(e0,e1)Comment:

803	 Azithromycin  had no significant impact on the Cmax and AUC of  <e0>zidovudine</e0> , although it significantly decreased the  <e1>zidovudine</e1>  tmax by 44% and increased the intracellular exposure to phosphorylated  zidovudine  by 110%. "
Other
Comment:

804	 Azithromycin  had no significant impact on the Cmax and AUC of  <e0>zidovudine</e0> , although it significantly decreased the  zidovudine  tmax by 44% and increased the intracellular exposure to phosphorylated  <e1>zidovudine</e1>  by 110%. "
Other
Comment:

805	 Azithromycin  had no significant impact on the Cmax and AUC of  zidovudine , although it significantly decreased the  <e0>zidovudine</e0>  tmax by 44% and increased the intracellular exposure to phosphorylated  <e1>zidovudine</e1>  by 110%. "
Other
Comment:

900	 <e0>Azithromycin</e0>  had no significant effect on  <e1>dideoxyinosine</e1>  pharmacokinetics. "
Other
Comment:

1000	Based on the results of these studies, it is concluded that  <e0>azithromycin</e0>  may be safely coadministered with both  <e1>zidovudine</e1>  and  dideoxyinosine ."
Other
Comment:

1001	Based on the results of these studies, it is concluded that  <e0>azithromycin</e0>  may be safely coadministered with both  zidovudine  and  <e1>dideoxyinosine</e1> ."
Other
Comment:

1002	Based on the results of these studies, it is concluded that  azithromycin  may be safely coadministered with both  <e0>zidovudine</e0>  and  <e1>dideoxyinosine</e1> ."
Other
Comment:


100	Effect of  <e0>diazepam</e0>  and  <e1>midazolam</e1>  on the antinociceptive effect of  morphine ,  metamizol  and  indomethacin  in mice."
Other
Comment:

101	Effect of  <e0>diazepam</e0>  and  midazolam  on the antinociceptive effect of  <e1>morphine</e1> ,  metamizol  and  indomethacin  in mice."
Other
Comment:

102	Effect of  <e0>diazepam</e0>  and  midazolam  on the antinociceptive effect of  morphine ,  <e1>metamizol</e1>  and  indomethacin  in mice."
Other
Comment:

103	Effect of  <e0>diazepam</e0>  and  midazolam  on the antinociceptive effect of  morphine ,  metamizol  and  <e1>indomethacin</e1>  in mice."
Other
Comment:

104	Effect of  diazepam  and  <e0>midazolam</e0>  on the antinociceptive effect of  <e1>morphine</e1> ,  metamizol  and  indomethacin  in mice."
Other
Comment:

105	Effect of  diazepam  and  <e0>midazolam</e0>  on the antinociceptive effect of  morphine ,  <e1>metamizol</e1>  and  indomethacin  in mice."
Other
Comment:

106	Effect of  diazepam  and  <e0>midazolam</e0>  on the antinociceptive effect of  morphine ,  metamizol  and  <e1>indomethacin</e1>  in mice."
Other
Comment:

107	Effect of  diazepam  and  midazolam  on the antinociceptive effect of  <e0>morphine</e0> ,  <e1>metamizol</e1>  and  indomethacin  in mice."
Other
Comment:

108	Effect of  diazepam  and  midazolam  on the antinociceptive effect of  <e0>morphine</e0> ,  metamizol  and  <e1>indomethacin</e1>  in mice."
Other
Comment:

109	Effect of  diazepam  and  midazolam  on the antinociceptive effect of  morphine ,  <e0>metamizol</e0>  and  <e1>indomethacin</e1>  in mice."
Other
Comment:

200	The influence of  <e0>midazolam</e0>  and  <e1>diazepam</e1>  on antinociceptive effect of  morphine  (10 mg/kg),  metamizol  (500 mg/kg) and  indomethacin  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

201	The influence of  <e0>midazolam</e0>  and  diazepam  on antinociceptive effect of  <e1>morphine</e1>  (10 mg/kg),  metamizol  (500 mg/kg) and  indomethacin  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

202	The influence of  <e0>midazolam</e0>  and  diazepam  on antinociceptive effect of  morphine  (10 mg/kg),  <e1>metamizol</e1>  (500 mg/kg) and  indomethacin  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

203	The influence of  <e0>midazolam</e0>  and  diazepam  on antinociceptive effect of  morphine  (10 mg/kg),  metamizol  (500 mg/kg) and  <e1>indomethacin</e1>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

204	The influence of  midazolam  and  <e0>diazepam</e0>  on antinociceptive effect of  <e1>morphine</e1>  (10 mg/kg),  metamizol  (500 mg/kg) and  indomethacin  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

205	The influence of  midazolam  and  <e0>diazepam</e0>  on antinociceptive effect of  morphine  (10 mg/kg),  <e1>metamizol</e1>  (500 mg/kg) and  indomethacin  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

206	The influence of  midazolam  and  <e0>diazepam</e0>  on antinociceptive effect of  morphine  (10 mg/kg),  metamizol  (500 mg/kg) and  <e1>indomethacin</e1>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

207	The influence of  midazolam  and  diazepam  on antinociceptive effect of  <e0>morphine</e0>  (10 mg/kg),  <e1>metamizol</e1>  (500 mg/kg) and  indomethacin  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

208	The influence of  midazolam  and  diazepam  on antinociceptive effect of  <e0>morphine</e0>  (10 mg/kg),  metamizol  (500 mg/kg) and  <e1>indomethacin</e1>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

209	The influence of  midazolam  and  diazepam  on antinociceptive effect of  morphine  (10 mg/kg),  <e0>metamizol</e0>  (500 mg/kg) and  <e1>indomethacin</e1>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. "
Other
Comment:

400	 <e0>Benzodiazepines</e0>  were administered to mice 30 min before applying the  <e1>analgesic drugs</e1> . "
Other
Comment:

600	 <e0>Diazepam</e0>  at doses of 0.25 mg/kg and 2.5 mg/kg injected with  <e1>morphine</e1>  was found to decrease the antinociceptive effect of  morphine . "
effect(e0,e1)Comment:

601	 <e0>Diazepam</e0>  at doses of 0.25 mg/kg and 2.5 mg/kg injected with  morphine  was found to decrease the antinociceptive effect of  <e1>morphine</e1> . "
Other
Comment:

602	 Diazepam  at doses of 0.25 mg/kg and 2.5 mg/kg injected with  <e0>morphine</e0>  was found to decrease the antinociceptive effect of  <e1>morphine</e1> . "
Other
Comment:

700	Similarly,  <e0>diazepam</e0>  decreased the antinociceptive effect of  <e1>metamizol</e1>  (only in the tail-flick test) and  indomethacin . "
effect(e0,e1)Comment:

701	Similarly,  <e0>diazepam</e0>  decreased the antinociceptive effect of  metamizol  (only in the tail-flick test) and  <e1>indomethacin</e1> . "
effect(e0,e1)Comment:

702	Similarly,  diazepam  decreased the antinociceptive effect of  <e0>metamizol</e0>  (only in the tail-flick test) and  <e1>indomethacin</e1> . "
Other
Comment:

800	 <e0>Midazolam</e0>  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  <e1>morphine</e1> ,  metamizol  (only in the tail-flick test) and  indomethacin ."
effect(e0,e1)Comment:

801	 <e0>Midazolam</e0>  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  morphine ,  <e1>metamizol</e1>  (only in the tail-flick test) and  indomethacin ."
effect(e0,e1)Comment:

802	 <e0>Midazolam</e0>  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  morphine ,  metamizol  (only in the tail-flick test) and  <e1>indomethacin</e1> ."
effect(e0,e1)Comment:

803	 Midazolam  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  <e0>morphine</e0> ,  <e1>metamizol</e1>  (only in the tail-flick test) and  indomethacin ."
Other
Comment:

804	 Midazolam  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  <e0>morphine</e0> ,  metamizol  (only in the tail-flick test) and  <e1>indomethacin</e1> ."
Other
Comment:

805	 Midazolam  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  morphine ,  <e0>metamizol</e0>  (only in the tail-flick test) and  <e1>indomethacin</e1> ."
Other
Comment:



100	Influence of  <e0>estradiol</e0>  and  <e1>progesterone</e1>  on the sensitivity of rat thoracic aorta to  noradrenaline .
"
Other
Comment:

101	Influence of  <e0>estradiol</e0>  and  progesterone  on the sensitivity of rat thoracic aorta to  <e1>noradrenaline</e1> .
"
Other
Comment:

102	Influence of  estradiol  and  <e0>progesterone</e0>  on the sensitivity of rat thoracic aorta to  <e1>noradrenaline</e1> .
"
Other
Comment:

200	The aim of this study was to investigate the effects of low and high doses of  <e0>estradiol</e0> , and of  <e1>progesterone</e1>  on the response to  noradrenaline  in rat thoracic aorta. "
Other
Comment:

201	The aim of this study was to investigate the effects of low and high doses of  <e0>estradiol</e0> , and of  progesterone  on the response to  <e1>noradrenaline</e1>  in rat thoracic aorta. "
Other
Comment:

202	The aim of this study was to investigate the effects of low and high doses of  estradiol , and of  <e0>progesterone</e0>  on the response to  <e1>noradrenaline</e1>  in rat thoracic aorta. "
Other
Comment:

400	injection of vehicle (corn oil, 0.1 mL/day),  <e0>estradiol</e0>  (10 microg/kg/day or 4 mg/kg/day) and/or  <e1>progesterone</e1>  (20 mg/kg/day), for eight days. "
Other
Comment:

600	Aortic rings with intact endothelium from the high-dose (4 mg/kg/day)  <e0>estradiol</e0>  group were supersensitive to  <e1>noradrenaline</e1>  compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). "
effect(e0,e1)Comment:

700	Endothelium-intact aortic rings from high- <e0>estradiol</e0>  rats were supersensitive to  <e1>noradrenaline</e1>  when compared to vehicle-,  progesterone - and  progesterone  + high- estradiol -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
effect(e0,e1)Comment:

701	Endothelium-intact aortic rings from high- <e0>estradiol</e0>  rats were supersensitive to  noradrenaline  when compared to vehicle-,  <e1>progesterone</e1> - and  progesterone  + high- estradiol -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

702	Endothelium-intact aortic rings from high- <e0>estradiol</e0>  rats were supersensitive to  noradrenaline  when compared to vehicle-,  progesterone - and  <e1>progesterone</e1>  + high- estradiol -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

703	Endothelium-intact aortic rings from high- <e0>estradiol</e0>  rats were supersensitive to  noradrenaline  when compared to vehicle-,  progesterone - and  progesterone  + high- <e1>estradiol</e1> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

704	Endothelium-intact aortic rings from high- estradiol  rats were supersensitive to  <e0>noradrenaline</e0>  when compared to vehicle-,  <e1>progesterone</e1> - and  progesterone  + high- estradiol -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

705	Endothelium-intact aortic rings from high- estradiol  rats were supersensitive to  <e0>noradrenaline</e0>  when compared to vehicle-,  progesterone - and  <e1>progesterone</e1>  + high- estradiol -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

706	Endothelium-intact aortic rings from high- estradiol  rats were supersensitive to  <e0>noradrenaline</e0>  when compared to vehicle-,  progesterone - and  progesterone  + high- <e1>estradiol</e1> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

707	Endothelium-intact aortic rings from high- estradiol  rats were supersensitive to  noradrenaline  when compared to vehicle-,  <e0>progesterone</e0> - and  <e1>progesterone</e1>  + high- estradiol -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

708	Endothelium-intact aortic rings from high- estradiol  rats were supersensitive to  noradrenaline  when compared to vehicle-,  <e0>progesterone</e0> - and  progesterone  + high- <e1>estradiol</e1> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:

709	Endothelium-intact aortic rings from high- estradiol  rats were supersensitive to  noradrenaline  when compared to vehicle-,  progesterone - and  <e0>progesterone</e0>  + high- <e1>estradiol</e1> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). "
Other
Comment:


200	Since the arrival of oral  <e0>erection-supporting medication</e0> , patients want to know how safe sexual activity is in cardiovascular disease in general and during use of  <e1>erection-supporting medication</e1>  in particular. "
Other
Comment:

600	 <e0>Sildenafil</e0>  is contraindicated in patients using  <e1>long-acting nitrates</e1>  or who may need to use  short-acting nitrates , because the combination may cause a sharp fall of the blood pressure. "
advise(e0,e1)Comment:

601	 <e0>Sildenafil</e0>  is contraindicated in patients using  long-acting nitrates  or who may need to use  <e1>short-acting nitrates</e1> , because the combination may cause a sharp fall of the blood pressure. "
advise(e0,e1)Comment:

602	 Sildenafil  is contraindicated in patients using  <e0>long-acting nitrates</e0>  or who may need to use  <e1>short-acting nitrates</e1> , because the combination may cause a sharp fall of the blood pressure. "
Other
Comment:

700	No interactions have been observed with  <e0>beta-receptor blockers</e0> ,  <e1>calcium antagonists</e1> ,  thiazide diuretics  and  loop diuretics  and  ACE inhibitors . "
Other
Comment:

701	No interactions have been observed with  <e0>beta-receptor blockers</e0> ,  calcium antagonists ,  <e1>thiazide diuretics</e1>  and  loop diuretics  and  ACE inhibitors . "
Other
Comment:

702	No interactions have been observed with  <e0>beta-receptor blockers</e0> ,  calcium antagonists ,  thiazide diuretics  and  <e1>loop diuretics</e1>  and  ACE inhibitors . "
Other
Comment:

703	No interactions have been observed with  <e0>beta-receptor blockers</e0> ,  calcium antagonists ,  thiazide diuretics  and  loop diuretics  and  <e1>ACE inhibitors</e1> . "
Other
Comment:

704	No interactions have been observed with  beta-receptor blockers ,  <e0>calcium antagonists</e0> ,  <e1>thiazide diuretics</e1>  and  loop diuretics  and  ACE inhibitors . "
Other
Comment:

705	No interactions have been observed with  beta-receptor blockers ,  <e0>calcium antagonists</e0> ,  thiazide diuretics  and  <e1>loop diuretics</e1>  and  ACE inhibitors . "
Other
Comment:

706	No interactions have been observed with  beta-receptor blockers ,  <e0>calcium antagonists</e0> ,  thiazide diuretics  and  loop diuretics  and  <e1>ACE inhibitors</e1> . "
Other
Comment:

707	No interactions have been observed with  beta-receptor blockers ,  calcium antagonists ,  <e0>thiazide diuretics</e0>  and  <e1>loop diuretics</e1>  and  ACE inhibitors . "
Other
Comment:

708	No interactions have been observed with  beta-receptor blockers ,  calcium antagonists ,  <e0>thiazide diuretics</e0>  and  loop diuretics  and  <e1>ACE inhibitors</e1> . "
Other
Comment:

709	No interactions have been observed with  beta-receptor blockers ,  calcium antagonists ,  thiazide diuretics  and  <e0>loop diuretics</e0>  and  <e1>ACE inhibitors</e1> . "
Other
Comment:


100	Influence of coadministration of  <e0>fluoxetine</e0>  on  <e1>cisapride</e1>  pharmacokinetics and QTc intervals in healthy volunteers.
"
Other
Comment:

200	STUDY OBJECTIVE: To evaluate the effect of  <e0>fluoxetine</e0>  on the pharmacokinetics and cardiovascular safety of  <e1>cisapride</e1>  at steady state in healthy men. "
Other
Comment:

1000	and phase 3 (days 45-52):  <e0>cisapride</e0>  10 mg 4 times/day (days 45-51) plus  <e1>fluoxetine</e1>  20 mg/day (days 45-52). "
Other
Comment:

1400	Coadministration of  <e0>fluoxetine</e0>  significantly decreased  <e1>cisapride</e1>  plasma concentrations. "
mechanism(e0,e1)Comment:

1500	There were no clinically significant changes in corrected QT intervals during administration of  <e0>cisapride</e0>  alone or with  <e1>fluoxetine</e1> . "
Other
Comment:

1600	 <e0>Cisapride</e0>  was well tolerated when administered alone or with  <e1>fluoxetine</e1> . "
Other
Comment:

1700	CONCLUSION:  <e0>Cisapride</e0>  can be administered safely to patients receiving low therapeutic dosages of  <e1>fluoxetine</e1> ."
Other
Comment:


200	 <e0>Olanzapine</e0> , a  <e1>thienobenzodiazepine derivative</e1> , is a  second generation (atypical) antipsychotic agent  which has proven efficacy against the positive and negative symptoms of schizophrenia. "
Other
Comment:

201	 <e0>Olanzapine</e0> , a  thienobenzodiazepine derivative , is a  <e1>second generation (atypical) antipsychotic agent</e1>  which has proven efficacy against the positive and negative symptoms of schizophrenia. "
Other
Comment:

202	 Olanzapine , a  <e0>thienobenzodiazepine derivative</e0> , is a  <e1>second generation (atypical) antipsychotic agent</e1>  which has proven efficacy against the positive and negative symptoms of schizophrenia. "
Other
Comment:

400	In large, well controlled trials in patients with schizophrenia or related psychoses,  <e0>olanzapine</e0>  5 to 20 mg/day was significantly superior to  <e1>haloperidol</e1>  5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. "
Other
Comment:

500	The 1-year risk of relapse (rehospitalisation) was significantly lower with  <e0>olanzapine</e0>  than with  <e1>haloperidol</e1>  treatment. "
Other
Comment:

600	In the first double-blind comparative study (28-week) of  <e0>olanzapine</e0>  and  <e1>risperidone</e1> ,  olanzapine  10 to 20 mg/day proved to be significantly more effective than  risperidone  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. "
Other
Comment:

601	In the first double-blind comparative study (28-week) of  <e0>olanzapine</e0>  and  risperidone ,  <e1>olanzapine</e1>  10 to 20 mg/day proved to be significantly more effective than  risperidone  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. "
Other
Comment:

602	In the first double-blind comparative study (28-week) of  <e0>olanzapine</e0>  and  risperidone ,  olanzapine  10 to 20 mg/day proved to be significantly more effective than  <e1>risperidone</e1>  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. "
Other
Comment:

603	In the first double-blind comparative study (28-week) of  olanzapine  and  <e0>risperidone</e0> ,  <e1>olanzapine</e1>  10 to 20 mg/day proved to be significantly more effective than  risperidone  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. "
Other
Comment:

604	In the first double-blind comparative study (28-week) of  olanzapine  and  <e0>risperidone</e0> ,  olanzapine  10 to 20 mg/day proved to be significantly more effective than  <e1>risperidone</e1>  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. "
Other
Comment:

605	In the first double-blind comparative study (28-week) of  olanzapine  and  risperidone ,  <e0>olanzapine</e0>  10 to 20 mg/day proved to be significantly more effective than  <e1>risperidone</e1>  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. "
Other
Comment:

700	In contrast, preliminary results from an 8-week controlled study suggested  <e0>risperidone</e0>  2 to 6 mg/day was superior to  <e1>olanzapine</e1>  5 to 20 mg/day against positive and anxiety/depressive symptoms (p lt; 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. "
Other
Comment:

800	Improvements in general cognitive function seen with  <e0>olanzapine</e0>  treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either  <e1>risperidone</e1>  or  haloperidol . "
Other
Comment:

801	Improvements in general cognitive function seen with  <e0>olanzapine</e0>  treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either  risperidone  or  <e1>haloperidol</e1> . "
Other
Comment:

802	Improvements in general cognitive function seen with  olanzapine  treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either  <e0>risperidone</e0>  or  <e1>haloperidol</e1> . "
Other
Comment:

900	However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of  <e0>olanzapine</e0>  and  <e1>risperidone</e1>  treatment in patients with schizophrenia or schizoaffective disorder. "
Other
Comment:

1000	Several studies indicate that  <e0>olanzapine</e0>  has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of  <e1>olanzapine</e1>  in the treatment of depressive symptomatology. "
Other
Comment:

1100	 <e0>Olanzapine</e0>  is associated with significantly fewer extrapyramidal symptoms than  <e1>haloperidol</e1>  and  risperidone . "
Other
Comment:

1101	 <e0>Olanzapine</e0>  is associated with significantly fewer extrapyramidal symptoms than  haloperidol  and  <e1>risperidone</e1> . "
Other
Comment:

1102	 Olanzapine  is associated with significantly fewer extrapyramidal symptoms than  <e0>haloperidol</e0>  and  <e1>risperidone</e1> . "
Other
Comment:

1200	In addition,  <e0>olanzapine</e0>  is not associated with a risk of agranulocytosis as seen with  <e1>clozapine</e1>  or clinically significant hyperprolactinaemia as seen with  risperidone  or prolongation of the QT interval. "
Other
Comment:

1201	In addition,  <e0>olanzapine</e0>  is not associated with a risk of agranulocytosis as seen with  clozapine  or clinically significant hyperprolactinaemia as seen with  <e1>risperidone</e1>  or prolongation of the QT interval. "
Other
Comment:

1202	In addition,  olanzapine  is not associated with a risk of agranulocytosis as seen with  <e0>clozapine</e0>  or clinically significant hyperprolactinaemia as seen with  <e1>risperidone</e1>  or prolongation of the QT interval. "
Other
Comment:

1400	In comparison with  <e0>haloperidol</e0> , the adverse events reported significantly more frequently with  <e1>olanzapine</e1>  in gt; or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  risperidone , only bodyweight gain occurred significantly more frequently with  olanzapine . "
Other
Comment:

1401	In comparison with  <e0>haloperidol</e0> , the adverse events reported significantly more frequently with  olanzapine  in gt; or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  <e1>risperidone</e1> , only bodyweight gain occurred significantly more frequently with  olanzapine . "
Other
Comment:

1402	In comparison with  <e0>haloperidol</e0> , the adverse events reported significantly more frequently with  olanzapine  in gt; or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  risperidone , only bodyweight gain occurred significantly more frequently with  <e1>olanzapine</e1> . "
Other
Comment:

1403	In comparison with  haloperidol , the adverse events reported significantly more frequently with  <e0>olanzapine</e0>  in gt; or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  <e1>risperidone</e1> , only bodyweight gain occurred significantly more frequently with  olanzapine . "
Other
Comment:

1404	In comparison with  haloperidol , the adverse events reported significantly more frequently with  <e0>olanzapine</e0>  in gt; or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  risperidone , only bodyweight gain occurred significantly more frequently with  <e1>olanzapine</e1> . "
Other
Comment:

1405	In comparison with  haloperidol , the adverse events reported significantly more frequently with  olanzapine  in gt; or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  <e0>risperidone</e0> , only bodyweight gain occurred significantly more frequently with  <e1>olanzapine</e1> . "
Other
Comment:

1600	Pharmacoeconomic analyses indicate that  <e0>olanzapine</e0>  does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with  <e1>haloperidol</e1> . "
Other
Comment:

1700	Compared with  <e0>risperidone</e0> ,  <e1>olanzapine</e1>  has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. "
Other
Comment:

1800	 <e0>Olanzapine</e0>  treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than  <e1>haloperidol</e1> , and to broadly the same extent as  risperidone . "
Other
Comment:

1801	 <e0>Olanzapine</e0>  treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than  haloperidol , and to broadly the same extent as  <e1>risperidone</e1> . "
Other
Comment:

1802	 Olanzapine  treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than  <e0>haloperidol</e0> , and to broadly the same extent as  <e1>risperidone</e1> . "
Other
Comment:

1900	CONCLUSIONS:  <e0>Olanzapine</e0>  demonstrated superior antipsychotic efficacy compared with  <e1>haloperidol</e1>  in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. "
Other
Comment:

2000	The reduced risk of adverse events and therapeutic superiority compared with  <e0>haloperidol</e0>  and  <e1>risperidone</e1>  in the treatment of negative and depressive symptoms support the choice of  olanzapine  as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response."
Other
Comment:

2001	The reduced risk of adverse events and therapeutic superiority compared with  <e0>haloperidol</e0>  and  risperidone  in the treatment of negative and depressive symptoms support the choice of  <e1>olanzapine</e1>  as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response."
Other
Comment:

2002	The reduced risk of adverse events and therapeutic superiority compared with  haloperidol  and  <e0>risperidone</e0>  in the treatment of negative and depressive symptoms support the choice of  <e1>olanzapine</e1>  as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response."
Other
Comment:


100	The emerging roles of  <e0>non-nucleoside reverse transcriptase inhibitors</e0>  in  <e1>antiretroviral</e1>  therapy."
Other
Comment:

200	The availability of potent  <e0>non-nucleoside reverse transcriptase inhibitor</e0>  ( <e1>NNRTI</e1> )-based regimens for  antiretroviral  therapy and concerns regarding  protease inhibitor  ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

201	The availability of potent  <e0>non-nucleoside reverse transcriptase inhibitor</e0>  ( NNRTI )-based regimens for  <e1>antiretroviral</e1>  therapy and concerns regarding  protease inhibitor  ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

202	The availability of potent  <e0>non-nucleoside reverse transcriptase inhibitor</e0>  ( NNRTI )-based regimens for  antiretroviral  therapy and concerns regarding  <e1>protease inhibitor</e1>  ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

203	The availability of potent  <e0>non-nucleoside reverse transcriptase inhibitor</e0>  ( NNRTI )-based regimens for  antiretroviral  therapy and concerns regarding  protease inhibitor  ( <e1>PI</e1> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

204	The availability of potent  non-nucleoside reverse transcriptase inhibitor  ( <e0>NNRTI</e0> )-based regimens for  <e1>antiretroviral</e1>  therapy and concerns regarding  protease inhibitor  ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

205	The availability of potent  non-nucleoside reverse transcriptase inhibitor  ( <e0>NNRTI</e0> )-based regimens for  antiretroviral  therapy and concerns regarding  <e1>protease inhibitor</e1>  ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

206	The availability of potent  non-nucleoside reverse transcriptase inhibitor  ( <e0>NNRTI</e0> )-based regimens for  antiretroviral  therapy and concerns regarding  protease inhibitor  ( <e1>PI</e1> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

207	The availability of potent  non-nucleoside reverse transcriptase inhibitor  ( NNRTI )-based regimens for  <e0>antiretroviral</e0>  therapy and concerns regarding  <e1>protease inhibitor</e1>  ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

208	The availability of potent  non-nucleoside reverse transcriptase inhibitor  ( NNRTI )-based regimens for  <e0>antiretroviral</e0>  therapy and concerns regarding  protease inhibitor  ( <e1>PI</e1> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

209	The availability of potent  non-nucleoside reverse transcriptase inhibitor  ( NNRTI )-based regimens for  antiretroviral  therapy and concerns regarding  <e0>protease inhibitor</e0>  ( <e1>PI</e1> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. "
Other
Comment:

300	 <e0>NNRTI</e0> -based regimens may have several advantages over  <e1>PI</e1> -based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration. "
Other
Comment:

400	No data from prospective clinical trials currently exist comparing the 3 approved agents ( <e0>efavirenz</e0> ,  <e1>nevirapine</e1>  or  delavirdine ). "
Other
Comment:

401	No data from prospective clinical trials currently exist comparing the 3 approved agents ( <e0>efavirenz</e0> ,  nevirapine  or  <e1>delavirdine</e1> ). "
Other
Comment:

402	No data from prospective clinical trials currently exist comparing the 3 approved agents ( efavirenz ,  <e0>nevirapine</e0>  or  <e1>delavirdine</e1> ). "
Other
Comment:

500	Both  <e0>efavirenz</e0>  and  <e1>nevirapine</e1>  have been compared to triple therapy with the  PI   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  efavirenz . "
Other
Comment:

501	Both  <e0>efavirenz</e0>  and  nevirapine  have been compared to triple therapy with the  <e1>PI</e1>   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  efavirenz . "
Other
Comment:

502	Both  <e0>efavirenz</e0>  and  nevirapine  have been compared to triple therapy with the  PI   <e1>indinavir</e1>  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  efavirenz . "
Other
Comment:

503	Both  <e0>efavirenz</e0>  and  nevirapine  have been compared to triple therapy with the  PI   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  <e1>nevirapine</e1>  regimens and superiority observed with  efavirenz . "
Other
Comment:

504	Both  <e0>efavirenz</e0>  and  nevirapine  have been compared to triple therapy with the  PI   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  <e1>efavirenz</e1> . "
Other
Comment:

505	Both  efavirenz  and  <e0>nevirapine</e0>  have been compared to triple therapy with the  <e1>PI</e1>   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  efavirenz . "
Other
Comment:

506	Both  efavirenz  and  <e0>nevirapine</e0>  have been compared to triple therapy with the  PI   <e1>indinavir</e1>  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  efavirenz . "
Other
Comment:

507	Both  efavirenz  and  <e0>nevirapine</e0>  have been compared to triple therapy with the  PI   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  <e1>nevirapine</e1>  regimens and superiority observed with  efavirenz . "
Other
Comment:

508	Both  efavirenz  and  <e0>nevirapine</e0>  have been compared to triple therapy with the  PI   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  <e1>efavirenz</e1> . "
Other
Comment:

509	Both  efavirenz  and  nevirapine  have been compared to triple therapy with the  <e0>PI</e0>   <e1>indinavir</e1>  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  efavirenz . "
Other
Comment:

510	Both  efavirenz  and  nevirapine  have been compared to triple therapy with the  <e0>PI</e0>   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  <e1>nevirapine</e1>  regimens and superiority observed with  efavirenz . "
Other
Comment:

511	Both  efavirenz  and  nevirapine  have been compared to triple therapy with the  <e0>PI</e0>   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  <e1>efavirenz</e1> . "
Other
Comment:

512	Both  efavirenz  and  nevirapine  have been compared to triple therapy with the  PI   <e0>indinavir</e0>  over 48 weeks as initial therapy, with similar responses being observed with  <e1>nevirapine</e1>  regimens and superiority observed with  efavirenz . "
Other
Comment:

513	Both  efavirenz  and  nevirapine  have been compared to triple therapy with the  PI   <e0>indinavir</e0>  over 48 weeks as initial therapy, with similar responses being observed with  nevirapine  regimens and superiority observed with  <e1>efavirenz</e1> . "
Other
Comment:

514	Both  efavirenz  and  nevirapine  have been compared to triple therapy with the  PI   indinavir  over 48 weeks as initial therapy, with similar responses being observed with  <e0>nevirapine</e0>  regimens and superiority observed with  <e1>efavirenz</e1> . "
Other
Comment:

600	A smaller 24-week study has suggested  <e0>nevirapine</e0>  may be superior to the  <e1>PI</e1>   nelfinavir . "
Other
Comment:

601	A smaller 24-week study has suggested  <e0>nevirapine</e0>  may be superior to the  PI   <e1>nelfinavir</e1> . "
Other
Comment:

602	A smaller 24-week study has suggested  nevirapine  may be superior to the  <e0>PI</e0>   <e1>nelfinavir</e1> . "
Other
Comment:

700	Limited comparative data in patients with high viral loads treated with  <e0>nevirapine</e0> - or  <e1>delavirdine</e1> -based regimens currently exist. "
Other
Comment:

900	The superiority of  <e0>efavirenz</e0>  over  <e1>indinavir</e1> -based regimens has been observed in comparative data in a subset of patients with high viral loads. "
Other
Comment:

1100	 <e0>Efavirenz</e0>  has demonstrated superiority over  <e1>nelfinavir</e1>  in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances. "
Other
Comment:




500	METHODS: Clinical studies, case reports, and commentaries and editorials concerning  <e0>sildenafil</e0>  published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms  <e1>sildenafil</e1> ,  Viagra , and erectile dysfunction. "
Other
Comment:

501	METHODS: Clinical studies, case reports, and commentaries and editorials concerning  <e0>sildenafil</e0>  published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms  sildenafil ,  <e1>Viagra</e1> , and erectile dysfunction. "
Other
Comment:

502	METHODS: Clinical studies, case reports, and commentaries and editorials concerning  sildenafil  published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms  <e0>sildenafil</e0> ,  <e1>Viagra</e1> , and erectile dysfunction. "
Other
Comment:

600	RESULTS:  <e0>Sildenafil</e0>  has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg,  <e1>selective serotonin reuptake inhibitors</e1>  [ SSRIs ]). "
Other
Comment:

601	RESULTS:  <e0>Sildenafil</e0>  has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg,  selective serotonin reuptake inhibitors  [ <e1>SSRIs</e1> ]). "
Other
Comment:

602	RESULTS:  Sildenafil  has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg,  <e0>selective serotonin reuptake inhibitors</e0>  [ <e1>SSRIs</e1> ]). "
Other
Comment:

1000	however, patients with moderate to severe cardiovascular disease or those taking  <e0>nitrate</e0>  therapy are at increased risk for potentially serious cardiovascular adverse effects with  <e1>sildenafil</e1>  therapy. "
effect(e0,e1)Comment:

1100	In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes  <e0>sildenafil</e0> , may experience increased drug concentrations and possible toxicity from normal doses of  <e1>sildenafil</e1> . "
Other
Comment:


100	Acute  <e0>hydrocortisone</e0>  administration does not affect subjective responses to  <e1>d-amphetamine</e1>  in humans.
"
Other
Comment:

300	However, the effects of stress and  <e0>glucocorticoids</e0>  on the subjective and behavioral effects of  <e1>psychostimulants</e1>  have not been well studied in humans. "
Other
Comment:

400	OBJECTIVES: To examine the effects of acute  <e0>hydrocortisone</e0>  pretreatment on the subjective and behavioral effects of  <e1>d-amphetamine</e1> . "
Other
Comment:

500	METHODS:  <e0>Hydrocortisone</e0>  (100 mg) and  <e1>d-amphetamine</e1>  (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. "
Other
Comment:

900	However,  <e0>hydrocortisone</e0>  pretreatment did not affect any of the physiological, behavioral, or subjective effects of  <e1>d-amphetamine</e1> . "
Other
Comment:

1000	CONCLUSIONS: In contrast to the effects of  <e0>glucocorticoids</e0>  in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of  <e1>d-amphetamine</e1>  in humans."
Other
Comment:


100	The effects of  <e0>ketamine</e0>  and of  <e1>Innovar</e1>  anesthesia on  digitalis  tolerance in dogs.
"
Other
Comment:

101	The effects of  <e0>ketamine</e0>  and of  Innovar  anesthesia on  <e1>digitalis</e1>  tolerance in dogs.
"
Other
Comment:

102	The effects of  ketamine  and of  <e0>Innovar</e0>  anesthesia on  <e1>digitalis</e1>  tolerance in dogs.
"
Other
Comment:

200	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  <e1>ketamine</e1> ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

201	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  <e1>Innovar Vet</e1> , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

202	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  <e1>pentobarbital</e1> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

203	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  <e1>ouabain</e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

204	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1>ouabain</e1> , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

205	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e1>ketamine</e1>  or  Innovar  than with  pentobarbital . "
Other
Comment:

206	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

207	In a comparison of  <e0>digitalis</e0>  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

208	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  <e1>Innovar Vet</e1> , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

209	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  Innovar Vet , or  <e1>pentobarbital</e1> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

210	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  Innovar Vet , or  pentobarbital , the dosage of  <e1>ouabain</e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
effect(e0,e1)Comment:

211	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1>ouabain</e1> , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

212	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e1>ketamine</e1>  or  Innovar  than with  pentobarbital . "
Other
Comment:

213	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

214	In a comparison of  digitalis  tolerance in dogs anesthetized with  <e0>ketamine</e0> ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

215	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  <e0>Innovar Vet</e0> , or  <e1>pentobarbital</e1> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

216	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  <e0>Innovar Vet</e0> , or  pentobarbital , the dosage of  <e1>ouabain</e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
effect(e0,e1)Comment:

217	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  <e0>Innovar Vet</e0> , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1>ouabain</e1> , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

218	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  <e0>Innovar Vet</e0> , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e1>ketamine</e1>  or  Innovar  than with  pentobarbital . "
Other
Comment:

219	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  <e0>Innovar Vet</e0> , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

220	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  <e0>Innovar Vet</e0> , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

221	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  <e0>pentobarbital</e0> , the dosage of  <e1>ouabain</e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  pentobarbital . "
effect(e0,e1)Comment:

222	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  <e0>pentobarbital</e0> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1>ouabain</e1> , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

223	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  <e0>pentobarbital</e0> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e1>ketamine</e1>  or  Innovar  than with  pentobarbital . "
Other
Comment:

224	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  <e0>pentobarbital</e0> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

225	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  <e0>pentobarbital</e0> , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

226	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  <e0>ouabain</e0>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1>ouabain</e1> , with  ketamine  or  Innovar  than with  pentobarbital . "
Other
Comment:

227	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  <e0>ouabain</e0>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e1>ketamine</e1>  or  Innovar  than with  pentobarbital . "
Other
Comment:

228	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  <e0>ouabain</e0>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

229	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  <e0>ouabain</e0>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

230	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e0>ouabain</e0> , with  <e1>ketamine</e1>  or  Innovar  than with  pentobarbital . "
Other
Comment:

231	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e0>ouabain</e0> , with  ketamine  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

232	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e0>ouabain</e0> , with  ketamine  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

233	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e0>ketamine</e0>  or  <e1>Innovar</e1>  than with  pentobarbital . "
Other
Comment:

234	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  <e0>ketamine</e0>  or  Innovar  than with  <e1>pentobarbital</e1> . "
Other
Comment:

235	In a comparison of  digitalis  tolerance in dogs anesthetized with  ketamine ,  Innovar Vet , or  pentobarbital , the dosage of  ouabain  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  ouabain , with  ketamine  or  <e0>Innovar</e0>  than with  <e1>pentobarbital</e1> . "
Other
Comment:

300	Ventricular tachycardia induced by  <e0>ouabain</e0>  was generally converted to sinus rhythm following administration of  <e1>Innovar</e1> ,  ketamine , or  droperidol  but not after administration of  fentayl  alone or after  pentobarbital ."
effect(e0,e1)Comment:

301	Ventricular tachycardia induced by  <e0>ouabain</e0>  was generally converted to sinus rhythm following administration of  Innovar ,  <e1>ketamine</e1> , or  droperidol  but not after administration of  fentayl  alone or after  pentobarbital ."
effect(e0,e1)Comment:

302	Ventricular tachycardia induced by  <e0>ouabain</e0>  was generally converted to sinus rhythm following administration of  Innovar ,  ketamine , or  <e1>droperidol</e1>  but not after administration of  fentayl  alone or after  pentobarbital ."
effect(e0,e1)Comment:

303	Ventricular tachycardia induced by  <e0>ouabain</e0>  was generally converted to sinus rhythm following administration of  Innovar ,  ketamine , or  droperidol  but not after administration of  <e1>fentayl</e1>  alone or after  pentobarbital ."
Other
Comment:

304	Ventricular tachycardia induced by  <e0>ouabain</e0>  was generally converted to sinus rhythm following administration of  Innovar ,  ketamine , or  droperidol  but not after administration of  fentayl  alone or after  <e1>pentobarbital</e1> ."
Other
Comment:

305	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  <e0>Innovar</e0> ,  <e1>ketamine</e1> , or  droperidol  but not after administration of  fentayl  alone or after  pentobarbital ."
Other
Comment:

306	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  <e0>Innovar</e0> ,  ketamine , or  <e1>droperidol</e1>  but not after administration of  fentayl  alone or after  pentobarbital ."
Other
Comment:

307	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  <e0>Innovar</e0> ,  ketamine , or  droperidol  but not after administration of  <e1>fentayl</e1>  alone or after  pentobarbital ."
Other
Comment:

308	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  <e0>Innovar</e0> ,  ketamine , or  droperidol  but not after administration of  fentayl  alone or after  <e1>pentobarbital</e1> ."
Other
Comment:

309	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  Innovar ,  <e0>ketamine</e0> , or  <e1>droperidol</e1>  but not after administration of  fentayl  alone or after  pentobarbital ."
Other
Comment:

310	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  Innovar ,  <e0>ketamine</e0> , or  droperidol  but not after administration of  <e1>fentayl</e1>  alone or after  pentobarbital ."
Other
Comment:

311	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  Innovar ,  <e0>ketamine</e0> , or  droperidol  but not after administration of  fentayl  alone or after  <e1>pentobarbital</e1> ."
Other
Comment:

312	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  Innovar ,  ketamine , or  <e0>droperidol</e0>  but not after administration of  <e1>fentayl</e1>  alone or after  pentobarbital ."
Other
Comment:

313	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  Innovar ,  ketamine , or  <e0>droperidol</e0>  but not after administration of  fentayl  alone or after  <e1>pentobarbital</e1> ."
Other
Comment:

314	Ventricular tachycardia induced by  ouabain  was generally converted to sinus rhythm following administration of  Innovar ,  ketamine , or  droperidol  but not after administration of  <e0>fentayl</e0>  alone or after  <e1>pentobarbital</e1> ."
Other
Comment:



100	Interaction of  <e0>clindamycin</e0>  and  <e1>gentamicin</e1>  in vitro.
"
int(e0,e1)Comment:

200	The minimal inhibitory concentrations of  <e0>clindamycin</e0>  and  <e1>gentamicin</e1>  alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. "
Other
Comment:

400	 <e0>Gentamicin</e0>  did not interfere with the activity of  <e1>clindamycin</e1>  within the range of concentrations tested (0.1 to 100 mug/ml); "
Other
Comment:

700	Combinations of  <e0>clindamycin</e0>  and  <e1>gentamicin</e1>  were indifferent for 29 strains and synergistic for 33 strains. "
effect(e0,e1)Comment:

800	All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both  <e0>clindamycin</e0>  (minimal inhibitory concentration greater than 3.1 mug/ml) and  <e1>gentamicin</e1>  (minimal inhibitory concentration greater than 6.2 mug/ml). "
Other
Comment:

900	Combinations of  <e0>clindamycin</e0>  and  <e1>gentamicin</e1>  were indifferent for 16 and synergistic for 11 of the resistant strains. "
effect(e0,e1)Comment:


100	Molecular basis for the selective toxicity of  <e0>amphotericin B</e0>  for yeast and  <e1>filipin</e1>  for animal cells."
Other
Comment:

200	Among the  <e0>polyene antibiotics</e0> , many, like  <e1>filipin</e1> , cannot be used clinically because they are toxic; "
Other
Comment:

400	Both the toxicity of  <e0>filipin</e0>  and the therapeutic value of  <e1>amphotericin B</e1>  can be rationalized at the cellular and molecular level by the following observations: (i) these  polyene antibiotics  showed differential effects on cells; "
Other
Comment:

401	Both the toxicity of  <e0>filipin</e0>  and the therapeutic value of  amphotericin B  can be rationalized at the cellular and molecular level by the following observations: (i) these  <e1>polyene antibiotics</e1>  showed differential effects on cells; "
Other
Comment:

402	Both the toxicity of  filipin  and the therapeutic value of  <e0>amphotericin B</e0>  can be rationalized at the cellular and molecular level by the following observations: (i) these  <e1>polyene antibiotics</e1>  showed differential effects on cells; "
Other
Comment:

500	 <e0>filipin</e0>  was more potent in lysing human red blood cells, whereas  <e1>amphotericin B</e1>  was more potent in inhibiting yeast cell growth; "
Other
Comment:

600	and (ii) the effects of  <e0>filipin</e0>  were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of  <e1>amphotericin B</e1>  were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. "
Other
Comment:


100	Studies on the mechanism of action of  <e0>miconazole</e0> : effect of  <e1>miconazole</e1>  on respiration and cell permeability of Candida albicans.
"
Other
Comment:

200	The  <e0>antifungal drug</e0> ,  <e1>miconazole nitrate</e1> , inhibits the growth of several species of Candida. "
Other
Comment:


100	Effect of  <e0>probenecid</e0>  on the apparent volume of distribution and elimination of  <e1>cloxacillin</e1> .
"
Other
Comment:

300	(1968, 1970), the higher serum concentrations of  <e0>penicillins</e0>  and  <e1>cephaloridine</e1>  reached after administration of  probenecid  are due not only to slower renal elimination but also to an altered distribution in the body. "
Other
Comment:

301	(1968, 1970), the higher serum concentrations of  <e0>penicillins</e0>  and  cephaloridine  reached after administration of  <e1>probenecid</e1>  are due not only to slower renal elimination but also to an altered distribution in the body. "
mechanism(e0,e1)Comment:

302	(1968, 1970), the higher serum concentrations of  penicillins  and  <e0>cephaloridine</e0>  reached after administration of  <e1>probenecid</e1>  are due not only to slower renal elimination but also to an altered distribution in the body. "
mechanism(e0,e1)Comment:

400	To determine whether  <e0>probenecid</e0>  has a direct effect on the distribution of  <e1>cloxacillin</e1> , the elimination and distribution of  cloxacillin  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  probenecid . "
Other
Comment:

401	To determine whether  <e0>probenecid</e0>  has a direct effect on the distribution of  cloxacillin , the elimination and distribution of  <e1>cloxacillin</e1>  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  probenecid . "
Other
Comment:

402	To determine whether  <e0>probenecid</e0>  has a direct effect on the distribution of  cloxacillin , the elimination and distribution of  cloxacillin  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  <e1>probenecid</e1> . "
Other
Comment:

403	To determine whether  probenecid  has a direct effect on the distribution of  <e0>cloxacillin</e0> , the elimination and distribution of  <e1>cloxacillin</e1>  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  probenecid . "
Other
Comment:

404	To determine whether  probenecid  has a direct effect on the distribution of  <e0>cloxacillin</e0> , the elimination and distribution of  cloxacillin  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  <e1>probenecid</e1> . "
Other
Comment:

405	To determine whether  probenecid  has a direct effect on the distribution of  cloxacillin , the elimination and distribution of  <e0>cloxacillin</e0>  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  <e1>probenecid</e1> . "
Other
Comment:

500	No significant difference was found between the mean values of the volume of distribution of  <e0>cloxacillin</e0>  with and without  <e1>probenecid</e1>  (13.0 and 12.6 liters, respectively). "
Other
Comment:

900	This might be explained by a blockade by  <e0>probenecid</e0>  of the elimination of  <e1>cloxacillin</e1>  by the liver."
mechanism(e0,e1)Comment:


200	Many people use both  <e0>alcohol</e0>  and  <e1>nicotine</e1>  (i.e., cigarettes and other tobacco products). "
Other
Comment:

400	The initiation of  <e0>alcohol</e0>  or  <e1>nicotine</e1>  use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. "
Other
Comment:

500	Moreover, the mechanisms underlying the development of dependence may be similar for  <e0>alcohol</e0>  and  <e1>nicotine</e1> . "
Other
Comment:


100	[Dose-time effects of competitive displacement of  <e0>radiopertechnetate</e0>  by  <e1>sodium perchlorate</e1>  following oral and intravenous administration]
The effect of various doses of  sodium perchlorate  in several dose fractions on the extent and the time scale of displacement of  radiopertechnetate , in dependence on application mode, was studied. "
Other
Comment:

101	[Dose-time effects of competitive displacement of  <e0>radiopertechnetate</e0>  by  sodium perchlorate  following oral and intravenous administration]
The effect of various doses of  <e1>sodium perchlorate</e1>  in several dose fractions on the extent and the time scale of displacement of  radiopertechnetate , in dependence on application mode, was studied. "
Other
Comment:

102	[Dose-time effects of competitive displacement of  <e0>radiopertechnetate</e0>  by  sodium perchlorate  following oral and intravenous administration]
The effect of various doses of  sodium perchlorate  in several dose fractions on the extent and the time scale of displacement of  <e1>radiopertechnetate</e1> , in dependence on application mode, was studied. "
Other
Comment:

103	[Dose-time effects of competitive displacement of  radiopertechnetate  by  <e0>sodium perchlorate</e0>  following oral and intravenous administration]
The effect of various doses of  <e1>sodium perchlorate</e1>  in several dose fractions on the extent and the time scale of displacement of  radiopertechnetate , in dependence on application mode, was studied. "
Other
Comment:

104	[Dose-time effects of competitive displacement of  radiopertechnetate  by  <e0>sodium perchlorate</e0>  following oral and intravenous administration]
The effect of various doses of  sodium perchlorate  in several dose fractions on the extent and the time scale of displacement of  <e1>radiopertechnetate</e1> , in dependence on application mode, was studied. "
Other
Comment:

105	[Dose-time effects of competitive displacement of  radiopertechnetate  by  sodium perchlorate  following oral and intravenous administration]
The effect of various doses of  <e0>sodium perchlorate</e0>  in several dose fractions on the extent and the time scale of displacement of  <e1>radiopertechnetate</e1> , in dependence on application mode, was studied. "
Other
Comment:

200	An intravenous dose of 50 mg  <e0>perchlorate</e0>  was in respect of competitive suppression of organs actively concentrating  <e1>pertechnetate</e1>  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  radiopertechnetate . "
Other
Comment:

201	An intravenous dose of 50 mg  <e0>perchlorate</e0>  was in respect of competitive suppression of organs actively concentrating  pertechnetate  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  <e1>radiopertechnetate</e1> . "
Other
Comment:

202	An intravenous dose of 50 mg  perchlorate  was in respect of competitive suppression of organs actively concentrating  <e0>pertechnetate</e0>  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  <e1>radiopertechnetate</e1> . "
Other
Comment:

300	An intravenous injection of  <e0>perchlorate</e0>  given later also produces a complete and immediately beginning depletion of  <e1>pertechnetate</e1>  already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. "
mechanism(e0,e1)Comment:



100	 <e0>Sirolimus</e0> : mammalian target of  <e1>rapamycin</e1>  inhibitor to prevent kidney rejection.
"
Other
Comment:

300	 <e0>Sirolimus</e0>  works differently from the  <e1>immunosuppressants</e1>  currently available, and except for increased lipid levels, the adverse reaction profile of  sirolimus  does not appear to overlap to any great extent with that associated with  cyclosporine  or  tacrolimus . "
Other
Comment:

301	 <e0>Sirolimus</e0>  works differently from the  immunosuppressants  currently available, and except for increased lipid levels, the adverse reaction profile of  <e1>sirolimus</e1>  does not appear to overlap to any great extent with that associated with  cyclosporine  or  tacrolimus . "
Other
Comment:

302	 <e0>Sirolimus</e0>  works differently from the  immunosuppressants  currently available, and except for increased lipid levels, the adverse reaction profile of  sirolimus  does not appear to overlap to any great extent with that associated with  <e1>cyclosporine</e1>  or  tacrolimus . "
Other
Comment:

303	 <e0>Sirolimus</e0>  works differently from the  immunosuppressants  currently available, and except for increased lipid levels, the adverse reaction profile of  sirolimus  does not appear to overlap to any great extent with that associated with  cyclosporine  or  <e1>tacrolimus</e1> . "
Other
Comment:

304	 Sirolimus  works differently from the  <e0>immunosuppressants</e0>  currently available, and except for increased lipid levels, the adverse reaction profile of  <e1>sirolimus</e1>  does not appear to overlap to any great extent with that associated with  cyclosporine  or  tacrolimus . "
Other
Comment:

305	 Sirolimus  works differently from the  <e0>immunosuppressants</e0>  currently available, and except for increased lipid levels, the adverse reaction profile of  sirolimus  does not appear to overlap to any great extent with that associated with  <e1>cyclosporine</e1>  or  tacrolimus . "
Other
Comment:

306	 Sirolimus  works differently from the  <e0>immunosuppressants</e0>  currently available, and except for increased lipid levels, the adverse reaction profile of  sirolimus  does not appear to overlap to any great extent with that associated with  cyclosporine  or  <e1>tacrolimus</e1> . "
Other
Comment:

307	 Sirolimus  works differently from the  immunosuppressants  currently available, and except for increased lipid levels, the adverse reaction profile of  <e0>sirolimus</e0>  does not appear to overlap to any great extent with that associated with  <e1>cyclosporine</e1>  or  tacrolimus . "
Other
Comment:

308	 Sirolimus  works differently from the  immunosuppressants  currently available, and except for increased lipid levels, the adverse reaction profile of  <e0>sirolimus</e0>  does not appear to overlap to any great extent with that associated with  cyclosporine  or  <e1>tacrolimus</e1> . "
Other
Comment:

309	 Sirolimus  works differently from the  immunosuppressants  currently available, and except for increased lipid levels, the adverse reaction profile of  sirolimus  does not appear to overlap to any great extent with that associated with  <e0>cyclosporine</e0>  or  <e1>tacrolimus</e1> . "
Other
Comment:

400	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e0>sirolimus</e0> , in combination with  <e1>cyclosporine</e1>  or  tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in  cyclosporine  or  tacrolimus  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

401	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e0>sirolimus</e0> , in combination with  cyclosporine  or  <e1>tacrolimus</e1> , might have the potential to reduce the frequency of rejection episodes, permit reductions in  cyclosporine  or  tacrolimus  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

402	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e0>sirolimus</e0> , in combination with  cyclosporine  or  tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e1>cyclosporine</e1>  or  tacrolimus  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

403	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e0>sirolimus</e0> , in combination with  cyclosporine  or  tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in  cyclosporine  or  <e1>tacrolimus</e1>  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

404	While additional research is needed, the initial clinical data in kidney recipients suggest that  sirolimus , in combination with  <e0>cyclosporine</e0>  or  <e1>tacrolimus</e1> , might have the potential to reduce the frequency of rejection episodes, permit reductions in  cyclosporine  or  tacrolimus  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

405	While additional research is needed, the initial clinical data in kidney recipients suggest that  sirolimus , in combination with  <e0>cyclosporine</e0>  or  tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e1>cyclosporine</e1>  or  tacrolimus  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

406	While additional research is needed, the initial clinical data in kidney recipients suggest that  sirolimus , in combination with  <e0>cyclosporine</e0>  or  tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in  cyclosporine  or  <e1>tacrolimus</e1>  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

407	While additional research is needed, the initial clinical data in kidney recipients suggest that  sirolimus , in combination with  cyclosporine  or  <e0>tacrolimus</e0> , might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e1>cyclosporine</e1>  or  tacrolimus  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

408	While additional research is needed, the initial clinical data in kidney recipients suggest that  sirolimus , in combination with  cyclosporine  or  <e0>tacrolimus</e0> , might have the potential to reduce the frequency of rejection episodes, permit reductions in  cyclosporine  or  <e1>tacrolimus</e1>  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:

409	While additional research is needed, the initial clinical data in kidney recipients suggest that  sirolimus , in combination with  cyclosporine  or  tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e0>cyclosporine</e0>  or  <e1>tacrolimus</e1>  dosage, and permit steroid withdrawal (Kelly, 1999)."
Other
Comment:


100	The effects of  <e0>chlordiazepoxide</e0> ,  <e1>amphetamine</e1>  and  cocaine  on bar-press behavior in normal and genetically nervous dogs.
"
Other
Comment:

101	The effects of  <e0>chlordiazepoxide</e0> ,  amphetamine  and  <e1>cocaine</e1>  on bar-press behavior in normal and genetically nervous dogs.
"
Other
Comment:

102	The effects of  chlordiazepoxide ,  <e0>amphetamine</e0>  and  <e1>cocaine</e1>  on bar-press behavior in normal and genetically nervous dogs.
"
Other
Comment:

200	Studies on two strains of pointer dogs have demonstrated that administration of a  <e0>benzodiazepine</e0>  ( <e1>chlordiazepoxide</e1> ) facilitates acquisition of goal-directed behavior in "genetically nervous""
Other
Comment:

500	The concomitant administration of either  <e0>cocaine</e0>  or  <e1>amphetamine</e1> , compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects. "
Other
Comment:


200	 <e0>Fluvastatin</e0>  is the first  <e1>synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor</e1>  to be approved for clinical use, and has been studied extensively in humans since 1986. "
Other
Comment:

300	It is structurally distinct from the other currently available  <e0>HMGCoA reductase inhibitors</e0>  ( <e1>lovastatin</e1> ,  simvastatin , and  pravastatin ), leading to unique biopharmaceutical properties relative to the other agents of this class. "
Other
Comment:

301	It is structurally distinct from the other currently available  <e0>HMGCoA reductase inhibitors</e0>  ( lovastatin ,  <e1>simvastatin</e1> , and  pravastatin ), leading to unique biopharmaceutical properties relative to the other agents of this class. "
Other
Comment:

302	It is structurally distinct from the other currently available  <e0>HMGCoA reductase inhibitors</e0>  ( lovastatin ,  simvastatin , and  <e1>pravastatin</e1> ), leading to unique biopharmaceutical properties relative to the other agents of this class. "
Other
Comment:

303	It is structurally distinct from the other currently available  HMGCoA reductase inhibitors  ( <e0>lovastatin</e0> ,  <e1>simvastatin</e1> , and  pravastatin ), leading to unique biopharmaceutical properties relative to the other agents of this class. "
Other
Comment:

304	It is structurally distinct from the other currently available  HMGCoA reductase inhibitors  ( <e0>lovastatin</e0> ,  simvastatin , and  <e1>pravastatin</e1> ), leading to unique biopharmaceutical properties relative to the other agents of this class. "
Other
Comment:

305	It is structurally distinct from the other currently available  HMGCoA reductase inhibitors  ( lovastatin ,  <e0>simvastatin</e0> , and  <e1>pravastatin</e1> ), leading to unique biopharmaceutical properties relative to the other agents of this class. "
Other
Comment:

1600	 <e0>Cholestyramine</e0> , an anionic-binding resin, has a considerable effect in lowering the rate and extent of  <e1>fluvastatin</e1>  bioavailability. "
mechanism(e0,e1)Comment:

1700	Although this effect was noted even when  <e0>cholestyramine</e0>  was given 4 hours prior to  <e1>fluvastatin</e1> , this regimen did not result in diminished efficacy. "
effect(e0,e1)Comment:

1800	Further, no effects on either  <e0>warfarin</e0>  levels or prothrombin times were observed in a study involving concomitant administration of  <e1>warfarin</e1>  and  fluvastatin . "
Other
Comment:

1801	Further, no effects on either  <e0>warfarin</e0>  levels or prothrombin times were observed in a study involving concomitant administration of  warfarin  and  <e1>fluvastatin</e1> . "
Other
Comment:

1802	Further, no effects on either  warfarin  levels or prothrombin times were observed in a study involving concomitant administration of  <e0>warfarin</e0>  and  <e1>fluvastatin</e1> . "
Other
Comment:

1900	Moreover, additional interaction studies with  <e0>niacin</e0>  and  <e1>propranolol</e1>  have not demonstrated any effect on  fluvastatin  plasma levels, and administration to a patient population chronically receiving  digoxin  resulted in no difference in the extent of bioavailability of  digoxin  relative to control data. "
Other
Comment:

1901	Moreover, additional interaction studies with  <e0>niacin</e0>  and  propranolol  have not demonstrated any effect on  <e1>fluvastatin</e1>  plasma levels, and administration to a patient population chronically receiving  digoxin  resulted in no difference in the extent of bioavailability of  digoxin  relative to control data. "
Other
Comment:

1902	Moreover, additional interaction studies with  <e0>niacin</e0>  and  propranolol  have not demonstrated any effect on  fluvastatin  plasma levels, and administration to a patient population chronically receiving  <e1>digoxin</e1>  resulted in no difference in the extent of bioavailability of  digoxin  relative to control data. "
Other
Comment:

1903	Moreover, additional interaction studies with  <e0>niacin</e0>  and  propranolol  have not demonstrated any effect on  fluvastatin  plasma levels, and administration to a patient population chronically receiving  digoxin  resulted in no difference in the extent of bioavailability of  <e1>digoxin</e1>  relative to control data. "
Other
Comment:

1904	Moreover, additional interaction studies with  niacin  and  <e0>propranolol</e0>  have not demonstrated any effect on  <e1>fluvastatin</e1>  plasma levels, and administration to a patient population chronically receiving  digoxin  resulted in no difference in the extent of bioavailability of  digoxin  relative to control data. "
Other
Comment:

1905	Moreover, additional interaction studies with  niacin  and  <e0>propranolol</e0>  have not demonstrated any effect on  fluvastatin  plasma levels, and administration to a patient population chronically receiving  <e1>digoxin</e1>  resulted in no difference in the extent of bioavailability of  digoxin  relative to control data. "
Other
Comment:

1906	Moreover, additional interaction studies with  niacin  and  <e0>propranolol</e0>  have not demonstrated any effect on  fluvastatin  plasma levels, and administration to a patient population chronically receiving  digoxin  resulted in no difference in the extent of bioavailability of  <e1>digoxin</e1>  relative to control data. "
Other
Comment:

1907	Moreover, additional interaction studies with  niacin  and  propranolol  have not demonstrated any effect on  <e0>fluvastatin</e0>  plasma levels, and administration to a patient population chronically receiving  <e1>digoxin</e1>  resulted in no difference in the extent of bioavailability of  digoxin  relative to control data. "
Other
Comment:

1908	Moreover, additional interaction studies with  niacin  and  propranolol  have not demonstrated any effect on  <e0>fluvastatin</e0>  plasma levels, and administration to a patient population chronically receiving  digoxin  resulted in no difference in the extent of bioavailability of  <e1>digoxin</e1>  relative to control data. "
Other
Comment:

1909	Moreover, additional interaction studies with  niacin  and  propranolol  have not demonstrated any effect on  fluvastatin  plasma levels, and administration to a patient population chronically receiving  <e0>digoxin</e0>  resulted in no difference in the extent of bioavailability of  <e1>digoxin</e1>  relative to control data. "
Other
Comment:



200	The literature provides considerable evidence indicating that several, but not all  <e0>antihistaminics</e0> , are indeed  <e1>analgesic agents</e1>  and some are  analgesic adjuvants  as well."
Other
Comment:

201	The literature provides considerable evidence indicating that several, but not all  <e0>antihistaminics</e0> , are indeed  analgesic agents  and some are  <e1>analgesic adjuvants</e1>  as well."
Other
Comment:

202	The literature provides considerable evidence indicating that several, but not all  antihistaminics , are indeed  <e0>analgesic agents</e0>  and some are  <e1>analgesic adjuvants</e1>  as well."
Other
Comment:

300	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  <e1>hydroxyzine</e1> ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

301	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  hydroxyzine ,  <e1>orphenadrine</e1> ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

302	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  hydroxyzine ,  orphenadrine ,  <e1>pyrilamine</e1> ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

303	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  <e1>phenyltoloxamine</e1> ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

304	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  <e1>promethazine</e1> ,  methdilazine , and  tripelennamine . "
Other
Comment:

305	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  <e1>methdilazine</e1> , and  tripelennamine . "
Other
Comment:

306	Those for which effectiveness is reported includes  <e0>diphenhydramine</e0> ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  <e1>tripelennamine</e1> . "
Other
Comment:

307	Those for which effectiveness is reported includes  diphenhydramine ,  <e0>hydroxyzine</e0> ,  <e1>orphenadrine</e1> ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

308	Those for which effectiveness is reported includes  diphenhydramine ,  <e0>hydroxyzine</e0> ,  orphenadrine ,  <e1>pyrilamine</e1> ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

309	Those for which effectiveness is reported includes  diphenhydramine ,  <e0>hydroxyzine</e0> ,  orphenadrine ,  pyrilamine ,  <e1>phenyltoloxamine</e1> ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

310	Those for which effectiveness is reported includes  diphenhydramine ,  <e0>hydroxyzine</e0> ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  <e1>promethazine</e1> ,  methdilazine , and  tripelennamine . "
Other
Comment:

311	Those for which effectiveness is reported includes  diphenhydramine ,  <e0>hydroxyzine</e0> ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  <e1>methdilazine</e1> , and  tripelennamine . "
Other
Comment:

312	Those for which effectiveness is reported includes  diphenhydramine ,  <e0>hydroxyzine</e0> ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  <e1>tripelennamine</e1> . "
Other
Comment:

313	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  <e0>orphenadrine</e0> ,  <e1>pyrilamine</e1> ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

314	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  <e0>orphenadrine</e0> ,  pyrilamine ,  <e1>phenyltoloxamine</e1> ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

315	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  <e0>orphenadrine</e0> ,  pyrilamine ,  phenyltoloxamine ,  <e1>promethazine</e1> ,  methdilazine , and  tripelennamine . "
Other
Comment:

316	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  <e0>orphenadrine</e0> ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  <e1>methdilazine</e1> , and  tripelennamine . "
Other
Comment:

317	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  <e0>orphenadrine</e0> ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  <e1>tripelennamine</e1> . "
Other
Comment:

318	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  <e0>pyrilamine</e0> ,  <e1>phenyltoloxamine</e1> ,  promethazine ,  methdilazine , and  tripelennamine . "
Other
Comment:

319	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  <e0>pyrilamine</e0> ,  phenyltoloxamine ,  <e1>promethazine</e1> ,  methdilazine , and  tripelennamine . "
Other
Comment:

320	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  <e0>pyrilamine</e0> ,  phenyltoloxamine ,  promethazine ,  <e1>methdilazine</e1> , and  tripelennamine . "
Other
Comment:

321	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  <e0>pyrilamine</e0> ,  phenyltoloxamine ,  promethazine ,  methdilazine , and  <e1>tripelennamine</e1> . "
Other
Comment:

322	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  <e0>phenyltoloxamine</e0> ,  <e1>promethazine</e1> ,  methdilazine , and  tripelennamine . "
Other
Comment:

323	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  <e0>phenyltoloxamine</e0> ,  promethazine ,  <e1>methdilazine</e1> , and  tripelennamine . "
Other
Comment:

324	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  <e0>phenyltoloxamine</e0> ,  promethazine ,  methdilazine , and  <e1>tripelennamine</e1> . "
Other
Comment:

325	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  <e0>promethazine</e0> ,  <e1>methdilazine</e1> , and  tripelennamine . "
Other
Comment:

326	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  <e0>promethazine</e0> ,  methdilazine , and  <e1>tripelennamine</e1> . "
Other
Comment:

327	Those for which effectiveness is reported includes  diphenhydramine ,  hydroxyzine ,  orphenadrine ,  pyrilamine ,  phenyltoloxamine ,  promethazine ,  <e0>methdilazine</e0> , and  <e1>tripelennamine</e1> . "
Other
Comment:


100	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  <e0>picrotoxin</e0>  (1 mg/kg) removes the antiedematous action of  <e1>diazepam</e1> ,  phenazepam ,  phenibut  and  amizyl  and reduces the action of  phentolamine . "
effect(e0,e1)Comment:

101	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  <e0>picrotoxin</e0>  (1 mg/kg) removes the antiedematous action of  diazepam ,  <e1>phenazepam</e1> ,  phenibut  and  amizyl  and reduces the action of  phentolamine . "
effect(e0,e1)Comment:

102	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  <e0>picrotoxin</e0>  (1 mg/kg) removes the antiedematous action of  diazepam ,  phenazepam ,  <e1>phenibut</e1>  and  amizyl  and reduces the action of  phentolamine . "
effect(e0,e1)Comment:

103	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  <e0>picrotoxin</e0>  (1 mg/kg) removes the antiedematous action of  diazepam ,  phenazepam ,  phenibut  and  <e1>amizyl</e1>  and reduces the action of  phentolamine . "
effect(e0,e1)Comment:

104	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  <e0>picrotoxin</e0>  (1 mg/kg) removes the antiedematous action of  diazepam ,  phenazepam ,  phenibut  and  amizyl  and reduces the action of  <e1>phentolamine</e1> . "
effect(e0,e1)Comment:

105	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  <e0>diazepam</e0> ,  <e1>phenazepam</e1> ,  phenibut  and  amizyl  and reduces the action of  phentolamine . "
Other
Comment:

106	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  <e0>diazepam</e0> ,  phenazepam ,  <e1>phenibut</e1>  and  amizyl  and reduces the action of  phentolamine . "
Other
Comment:

107	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  <e0>diazepam</e0> ,  phenazepam ,  phenibut  and  <e1>amizyl</e1>  and reduces the action of  phentolamine . "
Other
Comment:

108	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  <e0>diazepam</e0> ,  phenazepam ,  phenibut  and  amizyl  and reduces the action of  <e1>phentolamine</e1> . "
Other
Comment:

109	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  diazepam ,  <e0>phenazepam</e0> ,  <e1>phenibut</e1>  and  amizyl  and reduces the action of  phentolamine . "
Other
Comment:

110	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  diazepam ,  <e0>phenazepam</e0> ,  phenibut  and  <e1>amizyl</e1>  and reduces the action of  phentolamine . "
Other
Comment:

111	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  diazepam ,  <e0>phenazepam</e0> ,  phenibut  and  amizyl  and reduces the action of  <e1>phentolamine</e1> . "
Other
Comment:

112	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  diazepam ,  phenazepam ,  <e0>phenibut</e0>  and  <e1>amizyl</e1>  and reduces the action of  phentolamine . "
Other
Comment:

113	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  diazepam ,  phenazepam ,  <e0>phenibut</e0>  and  amizyl  and reduces the action of  <e1>phentolamine</e1> . "
Other
Comment:

114	[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that  picrotoxin  (1 mg/kg) removes the antiedematous action of  diazepam ,  phenazepam ,  phenibut  and  <e0>amizyl</e0>  and reduces the action of  <e1>phentolamine</e1> . "
Other
Comment:


100	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  <e1>3H-spiroperidol</e1>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

101	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e1>neuroleptics</e1> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

102	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e1>haloperidol</e1>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

103	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e1>pyreneperone</e1>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

104	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e1>3H-spiroperidol</e1>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

105	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e1>apomorphine</e1>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

106	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

107	[Stimulation by  <e0>cerulein</e0> --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

108	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  <e1>neuroleptics</e1> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

109	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e1>haloperidol</e1>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

110	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e1>pyreneperone</e1>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

111	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e1>3H-spiroperidol</e1>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

112	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e1>apomorphine</e1>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

113	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

114	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  <e0>3H-spiroperidol</e0>  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

115	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e0>neuroleptics</e0> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e1>haloperidol</e1>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

116	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e0>neuroleptics</e0> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e1>pyreneperone</e1>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

117	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e0>neuroleptics</e0> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e1>3H-spiroperidol</e1>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

118	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e0>neuroleptics</e0> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e1>apomorphine</e1>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

119	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e0>neuroleptics</e0> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

120	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  <e0>neuroleptics</e0> ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

121	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e0>haloperidol</e0>  (0.25 mg/kg) and  <e1>pyreneperone</e1>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

122	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e0>haloperidol</e0>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e1>3H-spiroperidol</e1>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

123	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e0>haloperidol</e0>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e1>apomorphine</e1>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

124	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e0>haloperidol</e0>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

125	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  <e0>haloperidol</e0>  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

126	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e0>pyreneperone</e0>  (0.25 mg/kg) resulted in the reduced interaction between  <e1>3H-spiroperidol</e1>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

127	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e0>pyreneperone</e0>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e1>apomorphine</e1>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

128	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e0>pyreneperone</e0>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

129	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  <e0>pyreneperone</e0>  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

130	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e0>3H-spiroperidol</e0>  and low affinity binding sites for  <e1>apomorphine</e1>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

131	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e0>3H-spiroperidol</e0>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

132	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  <e0>3H-spiroperidol</e0>  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

133	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e0>apomorphine</e0>  in subcortical structures, whereas  <e1>3H-spiroperidol</e1>  binding with high affinity binding sites for  apomorphine  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

134	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  <e0>apomorphine</e0>  in subcortical structures, whereas  3H-spiroperidol  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

135	[Stimulation by  cerulein --an analog of the octapeptide cholecystokinin--of  3H-spiroperidol  binding after the long-term administration of  neuroleptics ]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of  haloperidol  (0.25 mg/kg) and  pyreneperone  (0.25 mg/kg) resulted in the reduced interaction between  3H-spiroperidol  and low affinity binding sites for  apomorphine  in subcortical structures, whereas  <e0>3H-spiroperidol</e0>  binding with high affinity binding sites for  <e1>apomorphine</e1>  increased both in the frontal cortex and subcortical structures of the forebrain. "
Other
Comment:

200	After prolonged administration of  <e0>neuroleptics</e0>  the displacing effect of  <e1>cerulein</e1> , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  3H-spiroperidol  binding. "
Other
Comment:

201	After prolonged administration of  <e0>neuroleptics</e0>  the displacing effect of  cerulein , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  <e1>3H-spiroperidol</e1>  binding. "
Other
Comment:

202	After prolonged administration of  neuroleptics  the displacing effect of  <e0>cerulein</e0> , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  <e1>3H-spiroperidol</e1>  binding. "
Other
Comment:

300	It is assumed that increased interaction between  <e0>3H-spiroperidol</e0>  and high affinity binding sites for  <e1>apomorphine</e1>  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  neuroleptics  after their prolonged administration. "
Other
Comment:

301	It is assumed that increased interaction between  <e0>3H-spiroperidol</e0>  and high affinity binding sites for  apomorphine  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  <e1>neuroleptics</e1>  after their prolonged administration. "
Other
Comment:

302	It is assumed that increased interaction between  3H-spiroperidol  and high affinity binding sites for  <e0>apomorphine</e0>  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  <e1>neuroleptics</e1>  after their prolonged administration. "
Other
Comment:


100	Dual effect of  <e0>ouabain</e0>  on the  <e1>palytoxin</e1> -induced contraction and norepinephrine release in the guinea-pig vas deferens."
Other
Comment:

200	 <e0>Palytoxin</e0>  ( <e1>PTX</e1> ), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. "
Other
Comment:

300	In the presence of  <e0>ouabain</e0>  (10(-5) M),  <e1>PTX</e1>  (10(-8) M) failed to cause the first contraction; "
effect(e0,e1)Comment:

600	When  <e0>ouabain</e0>  was applied to the muscle in the presence of  <e1>phentolamine</e1> , both first and second contractile responses to  PTX  were abolished. "
effect(e0,e1)Comment:

601	When  <e0>ouabain</e0>  was applied to the muscle in the presence of  phentolamine , both first and second contractile responses to  <e1>PTX</e1>  were abolished. "
Other
Comment:

602	When  ouabain  was applied to the muscle in the presence of  <e0>phentolamine</e0> , both first and second contractile responses to  <e1>PTX</e1>  were abolished. "
Other
Comment:

900	Exposure of the muscle to  <e0>ouabain</e0>  (10(-5) M) markedly increased the  <e1>PTX</e1> -induced release. "
effect(e0,e1)Comment:

1100	The second response is due to a release of norepinephrine from nerves and was potentiated by  <e0>ouabain</e0>  through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by  <e1>ouabain</e1> . "
Other
Comment:


100	[Quantitative approach to treatment with incisive  <e0>neuroleptics</e0>  by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with  <e1>neuroleptics</e1>  are illustrated by six typical case reports. "
Other
Comment:


200	The intestinal absorption of  <e0>arsenate</e0> ( <e1>As(V)</e1> ) has been investigated in the chick by means of the in situ ligated duodenal loop technique. "
Other
Comment:

300	By this procedure, it was observed that  <e0>arsenate</e0>  is rapidly and essentially completely absorbed (80-95%) from the lumen at  <e1>As(V)</e1>  concentrations up to 5 mM, declining to about 50% absorption at 50 mM. "
Other
Comment:

500	At stable  <e0>As(V)</e0>  concentrations greater than 1 mM, fractional mucosal cell accumulation of  <e1>As(V)</e1>  remains constant, while fractional transfer to the body declines. "
Other
Comment:

600	However, total mucosal accumulation of  <e0>As(V)</e0>  and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm  <e1>As(V)</e1> . "
Other
Comment:

800	Furthermore,  <e0>arsenate</e0>  and  <e1>phosphate</e1>  do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. "
Other
Comment:

900	 <e0>Vitamin D3</e0>  administration to rachitic chicks was effective in significantly elevating duodenal  <e1>arsenate</e1>  absorption, acting primarily to enhance serosal transport."
mechanism(e0,e1)Comment:


300	By contrast,  <e0>spermidine</e0>  (1 mM) and  <e1>putrescine</e1>  (1 mM) had no significant effect on the translocation when added alone. "
Other
Comment:

400	 <e0>Spermine</e0> , and to a lesser extent,  <e1>spermidine</e1> , enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction. "
Other
Comment:


600	 <e0>Slow-channel calcium blockers</e0> , such as  <e1>verapamil</e1> ,  diltiazem  and  nifedipine , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. "
Other
Comment:

601	 <e0>Slow-channel calcium blockers</e0> , such as  verapamil ,  <e1>diltiazem</e1>  and  nifedipine , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. "
Other
Comment:

602	 <e0>Slow-channel calcium blockers</e0> , such as  verapamil ,  diltiazem  and  <e1>nifedipine</e1> , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. "
Other
Comment:

603	 Slow-channel calcium blockers , such as  <e0>verapamil</e0> ,  <e1>diltiazem</e1>  and  nifedipine , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. "
Other
Comment:

604	 Slow-channel calcium blockers , such as  <e0>verapamil</e0> ,  diltiazem  and  <e1>nifedipine</e1> , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. "
Other
Comment:

605	 Slow-channel calcium blockers , such as  verapamil ,  <e0>diltiazem</e0>  and  <e1>nifedipine</e1> , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. "
Other
Comment:


100	Differential actions of intrathecal  <e0>naloxone</e0>  on blocking the tail-flick inhibition induced by intraventricular  <e1>beta-endorphin</e1>  and  morphine  in rats.
"
Other
Comment:

101	Differential actions of intrathecal  <e0>naloxone</e0>  on blocking the tail-flick inhibition induced by intraventricular  beta-endorphin  and  <e1>morphine</e1>  in rats.
"
Other
Comment:

102	Differential actions of intrathecal  naloxone  on blocking the tail-flick inhibition induced by intraventricular  <e0>beta-endorphin</e0>  and  <e1>morphine</e1>  in rats.
"
Other
Comment:

300	The blockade of the spinal endorphinergic system by intrathecal  <e0>naloxone</e0>  on the production of tail-flick inhibition induced by intraventricular  <e1>beta-endorphin</e1>  and  morphine  was then studied. "
Other
Comment:

301	The blockade of the spinal endorphinergic system by intrathecal  <e0>naloxone</e0>  on the production of tail-flick inhibition induced by intraventricular  beta-endorphin  and  <e1>morphine</e1>  was then studied. "
Other
Comment:

302	The blockade of the spinal endorphinergic system by intrathecal  naloxone  on the production of tail-flick inhibition induced by intraventricular  <e0>beta-endorphin</e0>  and  <e1>morphine</e1>  was then studied. "
Other
Comment:

400	Intraventricular injection of  <e0>beta-endorphin</e0>  and  <e1>morphine</e1>  produced an inhibition of the tail-flick response to the heat stimulus in rats. "
Other
Comment:

500	Intrathecal injection of  <e0>naloxone</e0>  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  <e1>beta-endorphin</e1> , and a high dose of  naloxone  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  beta-endorphin  (16 micrograms). "
effect(e0,e1)Comment:

501	Intrathecal injection of  <e0>naloxone</e0>  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  beta-endorphin , and a high dose of  <e1>naloxone</e1>  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  beta-endorphin  (16 micrograms). "
Other
Comment:

502	Intrathecal injection of  <e0>naloxone</e0>  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  beta-endorphin , and a high dose of  naloxone  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  <e1>beta-endorphin</e1>  (16 micrograms). "
Other
Comment:

503	Intrathecal injection of  naloxone  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  <e0>beta-endorphin</e0> , and a high dose of  <e1>naloxone</e1>  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  beta-endorphin  (16 micrograms). "
Other
Comment:

504	Intrathecal injection of  naloxone  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  <e0>beta-endorphin</e0> , and a high dose of  naloxone  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  <e1>beta-endorphin</e1>  (16 micrograms). "
Other
Comment:

505	Intrathecal injection of  naloxone  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  beta-endorphin , and a high dose of  <e0>naloxone</e0>  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  <e1>beta-endorphin</e1>  (16 micrograms). "
effect(e0,e1)Comment:

600	On the other hand, intrathecal  <e0>naloxone</e0>  (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular  <e1>morphine</e1>  (40 micrograms). "
effect(e0,e1)Comment:

700	Intraventricular injection of  <e0>naloxone</e0>  at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular  <e1>beta-endorphin</e1>  and  morphine . "
effect(e0,e1)Comment:

701	Intraventricular injection of  <e0>naloxone</e0>  at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular  beta-endorphin  and  <e1>morphine</e1> . "
effect(e0,e1)Comment:

702	Intraventricular injection of  naloxone  at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular  <e0>beta-endorphin</e0>  and  <e1>morphine</e1> . "
Other
Comment:

800	The results indicate that a spinal  <e0>naloxone</e0> -sensitive endorphinergic system is involved in the production of  <e1>beta-endorphin</e1>  but not  morphine -induced tail-flick inhibition, and suggest that intraventricular  beta-endorphin  and  morphine  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

801	The results indicate that a spinal  <e0>naloxone</e0> -sensitive endorphinergic system is involved in the production of  beta-endorphin  but not  <e1>morphine</e1> -induced tail-flick inhibition, and suggest that intraventricular  beta-endorphin  and  morphine  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

802	The results indicate that a spinal  <e0>naloxone</e0> -sensitive endorphinergic system is involved in the production of  beta-endorphin  but not  morphine -induced tail-flick inhibition, and suggest that intraventricular  <e1>beta-endorphin</e1>  and  morphine  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

803	The results indicate that a spinal  <e0>naloxone</e0> -sensitive endorphinergic system is involved in the production of  beta-endorphin  but not  morphine -induced tail-flick inhibition, and suggest that intraventricular  beta-endorphin  and  <e1>morphine</e1>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

804	The results indicate that a spinal  naloxone -sensitive endorphinergic system is involved in the production of  <e0>beta-endorphin</e0>  but not  <e1>morphine</e1> -induced tail-flick inhibition, and suggest that intraventricular  beta-endorphin  and  morphine  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

805	The results indicate that a spinal  naloxone -sensitive endorphinergic system is involved in the production of  <e0>beta-endorphin</e0>  but not  morphine -induced tail-flick inhibition, and suggest that intraventricular  <e1>beta-endorphin</e1>  and  morphine  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

806	The results indicate that a spinal  naloxone -sensitive endorphinergic system is involved in the production of  <e0>beta-endorphin</e0>  but not  morphine -induced tail-flick inhibition, and suggest that intraventricular  beta-endorphin  and  <e1>morphine</e1>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

807	The results indicate that a spinal  naloxone -sensitive endorphinergic system is involved in the production of  beta-endorphin  but not  <e0>morphine</e0> -induced tail-flick inhibition, and suggest that intraventricular  <e1>beta-endorphin</e1>  and  morphine  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

808	The results indicate that a spinal  naloxone -sensitive endorphinergic system is involved in the production of  beta-endorphin  but not  <e0>morphine</e0> -induced tail-flick inhibition, and suggest that intraventricular  beta-endorphin  and  <e1>morphine</e1>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

809	The results indicate that a spinal  naloxone -sensitive endorphinergic system is involved in the production of  beta-endorphin  but not  morphine -induced tail-flick inhibition, and suggest that intraventricular  <e0>beta-endorphin</e0>  and  <e1>morphine</e1>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; "
Other
Comment:

900	descending epsilon and mu systems for  <e0>beta-endorphin</e0>  and  <e1>morphine</e1> , respectively, are proposed."
Other
Comment:


100	Neurochemical and functional consequences following  <e0>1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine</e0>  ( <e1>MPTP</e1> ) and  methamphetamine .
"
Other
Comment:

101	Neurochemical and functional consequences following  <e0>1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine</e0>  ( MPTP ) and  <e1>methamphetamine</e1> .
"
Other
Comment:

102	Neurochemical and functional consequences following  1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine  ( <e0>MPTP</e0> ) and  <e1>methamphetamine</e1> .
"
Other
Comment:

200	The neurochemical and functional consequences following  <e0>MPTP</e0>  administration to the rat were evaluated and compared to similar effects following  <e1>methamphetamine</e1>  administration. "
Other
Comment:

300	It was observed that  <e0>MPTP</e0>  induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by  <e1>pargyline</e1>  pretreatment. "
effect(e0,e1)Comment:

400	The  <e0>MPTP</e0> -induced neuronal damage produced a tolerance to the disruptive effects of  <e1>amphetamine</e1>  and a supersensitivity to the disruptive effects of  apomorphine  in rats responding in a schedule controlled paradigm. "
effect(e0,e1)Comment:

401	The  <e0>MPTP</e0> -induced neuronal damage produced a tolerance to the disruptive effects of  amphetamine  and a supersensitivity to the disruptive effects of  <e1>apomorphine</e1>  in rats responding in a schedule controlled paradigm. "
effect(e0,e1)Comment:

402	The  MPTP -induced neuronal damage produced a tolerance to the disruptive effects of  <e0>amphetamine</e0>  and a supersensitivity to the disruptive effects of  <e1>apomorphine</e1>  in rats responding in a schedule controlled paradigm. "
Other
Comment:

500	 <e0>Methamphetamine</e0> , like  <e1>MPTP</e1> , produced depletions of striatal dopamine but these actions were potentiated by  pargyline  pretreatment. "
Other
Comment:

501	 <e0>Methamphetamine</e0> , like  MPTP , produced depletions of striatal dopamine but these actions were potentiated by  <e1>pargyline</e1>  pretreatment. "
effect(e0,e1)Comment:

502	 Methamphetamine , like  <e0>MPTP</e0> , produced depletions of striatal dopamine but these actions were potentiated by  <e1>pargyline</e1>  pretreatment. "
Other
Comment:




100	 <e0>Dexamethasone</e0>  and  <e1>retinyl acetate</e1>  similarly inhibit and stimulate  EGF - or  insulin -induced proliferation of prostatic epithelium."
Other
Comment:

101	 <e0>Dexamethasone</e0>  and  retinyl acetate  similarly inhibit and stimulate  <e1>EGF</e1> - or  insulin -induced proliferation of prostatic epithelium."
effect(e0,e1)Comment:

102	 <e0>Dexamethasone</e0>  and  retinyl acetate  similarly inhibit and stimulate  EGF - or  <e1>insulin</e1> -induced proliferation of prostatic epithelium."
effect(e0,e1)Comment:

103	 Dexamethasone  and  <e0>retinyl acetate</e0>  similarly inhibit and stimulate  <e1>EGF</e1> - or  insulin -induced proliferation of prostatic epithelium."
effect(e0,e1)Comment:

104	 Dexamethasone  and  <e0>retinyl acetate</e0>  similarly inhibit and stimulate  EGF - or  <e1>insulin</e1> -induced proliferation of prostatic epithelium."
effect(e0,e1)Comment:

105	 Dexamethasone  and  retinyl acetate  similarly inhibit and stimulate  <e0>EGF</e0> - or  <e1>insulin</e1> -induced proliferation of prostatic epithelium."
Other
Comment:

200	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing  <e0>transferrin</e0>  (1 microgram/ml),  <e1>EGF</e1>  (10 ng/ml), and  insulin  (3.7 micrograms/ml or 0.1 IU/ml). "
Other
Comment:

201	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing  <e0>transferrin</e0>  (1 microgram/ml),  EGF  (10 ng/ml), and  <e1>insulin</e1>  (3.7 micrograms/ml or 0.1 IU/ml). "
Other
Comment:

202	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing  transferrin  (1 microgram/ml),  <e0>EGF</e0>  (10 ng/ml), and  <e1>insulin</e1>  (3.7 micrograms/ml or 0.1 IU/ml). "
Other
Comment:

300	Although neither  <e0>dexamethasone</e0>  nor  <e1>retinyl acetate</e1>  affected the proliferation of prostatic epithelium in RPMI1640 containing  transferrin  alone, they modify the mitogenic effect of  EGF  and  insulin . "
Other
Comment:

301	Although neither  <e0>dexamethasone</e0>  nor  retinyl acetate  affected the proliferation of prostatic epithelium in RPMI1640 containing  <e1>transferrin</e1>  alone, they modify the mitogenic effect of  EGF  and  insulin . "
Other
Comment:

302	Although neither  <e0>dexamethasone</e0>  nor  retinyl acetate  affected the proliferation of prostatic epithelium in RPMI1640 containing  transferrin  alone, they modify the mitogenic effect of  <e1>EGF</e1>  and  insulin . "
effect(e0,e1)Comment:

303	Although neither  <e0>dexamethasone</e0>  nor  retinyl acetate  affected the proliferation of prostatic epithelium in RPMI1640 containing  transferrin  alone, they modify the mitogenic effect of  EGF  and  <e1>insulin</e1> . "
effect(e0,e1)Comment:

304	Although neither  dexamethasone  nor  <e0>retinyl acetate</e0>  affected the proliferation of prostatic epithelium in RPMI1640 containing  <e1>transferrin</e1>  alone, they modify the mitogenic effect of  EGF  and  insulin . "
Other
Comment:

305	Although neither  dexamethasone  nor  <e0>retinyl acetate</e0>  affected the proliferation of prostatic epithelium in RPMI1640 containing  transferrin  alone, they modify the mitogenic effect of  <e1>EGF</e1>  and  insulin . "
effect(e0,e1)Comment:

306	Although neither  dexamethasone  nor  <e0>retinyl acetate</e0>  affected the proliferation of prostatic epithelium in RPMI1640 containing  transferrin  alone, they modify the mitogenic effect of  EGF  and  <e1>insulin</e1> . "
effect(e0,e1)Comment:

307	Although neither  dexamethasone  nor  retinyl acetate  affected the proliferation of prostatic epithelium in RPMI1640 containing  <e0>transferrin</e0>  alone, they modify the mitogenic effect of  <e1>EGF</e1>  and  insulin . "
Other
Comment:

308	Although neither  dexamethasone  nor  retinyl acetate  affected the proliferation of prostatic epithelium in RPMI1640 containing  <e0>transferrin</e0>  alone, they modify the mitogenic effect of  EGF  and  <e1>insulin</e1> . "
Other
Comment:

309	Although neither  dexamethasone  nor  retinyl acetate  affected the proliferation of prostatic epithelium in RPMI1640 containing  transferrin  alone, they modify the mitogenic effect of  <e0>EGF</e0>  and  <e1>insulin</e1> . "
Other
Comment:

400	 <e0>Dexamethasone</e0>  at 10(-10) M or  <e1>retinyl acetate</e1>  at about 3 X 10(-9) M inhibits proliferation stimulated by  EGF . "
Other
Comment:

401	 <e0>Dexamethasone</e0>  at 10(-10) M or  retinyl acetate  at about 3 X 10(-9) M inhibits proliferation stimulated by  <e1>EGF</e1> . "
effect(e0,e1)Comment:

402	 Dexamethasone  at 10(-10) M or  <e0>retinyl acetate</e0>  at about 3 X 10(-9) M inhibits proliferation stimulated by  <e1>EGF</e1> . "
effect(e0,e1)Comment:

500	Higher concentrations of  <e0>dexamethasone</e0>  (10(-8) - 10(-6) M) or  <e1>retinyl acetate</e1>  (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of  EGF . "
Other
Comment:

501	Higher concentrations of  <e0>dexamethasone</e0>  (10(-8) - 10(-6) M) or  retinyl acetate  (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of  <e1>EGF</e1> . "
effect(e0,e1)Comment:

502	Higher concentrations of  dexamethasone  (10(-8) - 10(-6) M) or  <e0>retinyl acetate</e0>  (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of  <e1>EGF</e1> . "
effect(e0,e1)Comment:

600	 <e0>Dexamethasone</e0>  had a similar effect in the presence of  <e1>insulin</e1> . "
Other
Comment:

700	However,  <e0>retinyl acetate</e0>  stimulated, but did not significantly inhibit, proliferation in the presence of  <e1>insulin</e1> . "
effect(e0,e1)Comment:

800	These results suggest that both  <e0>dexamethasone</e0>  and  <e1>retinyl acetate</e1> , and possibly other  glucocorticoids  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  EGF ."
Other
Comment:

801	These results suggest that both  <e0>dexamethasone</e0>  and  retinyl acetate , and possibly other  <e1>glucocorticoids</e1>  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  EGF ."
Other
Comment:

802	These results suggest that both  <e0>dexamethasone</e0>  and  retinyl acetate , and possibly other  glucocorticoids  and  <e1>retinoids</e1> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  EGF ."
Other
Comment:

803	These results suggest that both  <e0>dexamethasone</e0>  and  retinyl acetate , and possibly other  glucocorticoids  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e1>insulin</e1>  and  EGF ."
effect(e0,e1)Comment:

804	These results suggest that both  <e0>dexamethasone</e0>  and  retinyl acetate , and possibly other  glucocorticoids  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  <e1>EGF</e1> ."
effect(e0,e1)Comment:

805	These results suggest that both  dexamethasone  and  <e0>retinyl acetate</e0> , and possibly other  <e1>glucocorticoids</e1>  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  EGF ."
Other
Comment:

806	These results suggest that both  dexamethasone  and  <e0>retinyl acetate</e0> , and possibly other  glucocorticoids  and  <e1>retinoids</e1> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  EGF ."
Other
Comment:

807	These results suggest that both  dexamethasone  and  <e0>retinyl acetate</e0> , and possibly other  glucocorticoids  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e1>insulin</e1>  and  EGF ."
effect(e0,e1)Comment:

808	These results suggest that both  dexamethasone  and  <e0>retinyl acetate</e0> , and possibly other  glucocorticoids  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  <e1>EGF</e1> ."
effect(e0,e1)Comment:

809	These results suggest that both  dexamethasone  and  retinyl acetate , and possibly other  <e0>glucocorticoids</e0>  and  <e1>retinoids</e1> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  EGF ."
Other
Comment:

810	These results suggest that both  dexamethasone  and  retinyl acetate , and possibly other  <e0>glucocorticoids</e0>  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e1>insulin</e1>  and  EGF ."
effect(e0,e1)Comment:

811	These results suggest that both  dexamethasone  and  retinyl acetate , and possibly other  <e0>glucocorticoids</e0>  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  <e1>EGF</e1> ."
effect(e0,e1)Comment:

812	These results suggest that both  dexamethasone  and  retinyl acetate , and possibly other  glucocorticoids  and  <e0>retinoids</e0> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e1>insulin</e1>  and  EGF ."
effect(e0,e1)Comment:

813	These results suggest that both  dexamethasone  and  retinyl acetate , and possibly other  glucocorticoids  and  <e0>retinoids</e0> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  insulin  and  <e1>EGF</e1> ."
effect(e0,e1)Comment:

814	These results suggest that both  dexamethasone  and  retinyl acetate , and possibly other  glucocorticoids  and  retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e0>insulin</e0>  and  <e1>EGF</e1> ."
Other
Comment:


400	For the  <e0>calcium-entry blocking agents</e0>  now available in the United States ( <e1>verapamil</e1> ,  nifedipine  and  diltiazem ), these data appeared well after clinical patterns of use evolved. "
Other
Comment:

401	For the  <e0>calcium-entry blocking agents</e0>  now available in the United States ( verapamil ,  <e1>nifedipine</e1>  and  diltiazem ), these data appeared well after clinical patterns of use evolved. "
Other
Comment:

402	For the  <e0>calcium-entry blocking agents</e0>  now available in the United States ( verapamil ,  nifedipine  and  <e1>diltiazem</e1> ), these data appeared well after clinical patterns of use evolved. "
Other
Comment:

403	For the  calcium-entry blocking agents  now available in the United States ( <e0>verapamil</e0> ,  <e1>nifedipine</e1>  and  diltiazem ), these data appeared well after clinical patterns of use evolved. "
Other
Comment:

404	For the  calcium-entry blocking agents  now available in the United States ( <e0>verapamil</e0> ,  nifedipine  and  <e1>diltiazem</e1> ), these data appeared well after clinical patterns of use evolved. "
Other
Comment:

405	For the  calcium-entry blocking agents  now available in the United States ( verapamil ,  <e0>nifedipine</e0>  and  <e1>diltiazem</e1> ), these data appeared well after clinical patterns of use evolved. "
Other
Comment:

600	by the nonlinear kinetic characteristics for  <e0>verapamil</e0>  and  <e1>diltiazem</e1>  (and probably for  nifedipine , as well) and the derivative implications for decreased dosing frequency requirements; "
Other
Comment:

601	by the nonlinear kinetic characteristics for  <e0>verapamil</e0>  and  diltiazem  (and probably for  <e1>nifedipine</e1> , as well) and the derivative implications for decreased dosing frequency requirements; "
Other
Comment:

602	by the nonlinear kinetic characteristics for  verapamil  and  <e0>diltiazem</e0>  (and probably for  <e1>nifedipine</e1> , as well) and the derivative implications for decreased dosing frequency requirements; "
Other
Comment:


100	Selective survival in  <e0>pentazocine</e0>  and  <e1>tripelennamine</e1>  of Pseudomonas aeruginosa serotype O11 from drug addicts.
"
Other
Comment:

200	The growth of Pseudomonas aeruginosa, particularly serotype O11, in  <e0>pentazocine</e0>  and  <e1>tripelennamine</e1>  "
Other
Comment:

600	Twelve strains of Staphylococcus aureus (a frequent cause of infection in  <e0>heroin</e0> , but not in  <e1>pentazocine</e1>  and  tripelennamine , addicts) were completely inhibited by the drug combination. "
Other
Comment:

601	Twelve strains of Staphylococcus aureus (a frequent cause of infection in  <e0>heroin</e0> , but not in  pentazocine  and  <e1>tripelennamine</e1> , addicts) were completely inhibited by the drug combination. "
Other
Comment:

602	Twelve strains of Staphylococcus aureus (a frequent cause of infection in  heroin , but not in  <e0>pentazocine</e0>  and  <e1>tripelennamine</e1> , addicts) were completely inhibited by the drug combination. "
effect(e0,e1)Comment:

700	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that  <e0>tripelennamine</e0>  was responsible for the inhibitory activity, which was partially antagonized by  <e1>pentazocine</e1> . "
effect(e0,e1)Comment:

1000	aureus, to survive in  <e0>pentazocine</e0>  and  <e1>tripelennamine</e1>  may explain in part a shift from S. "
Other
Comment:


100	Pharmacokinetic evaluation of the  <e0>digoxin</e0> - <e1>amiodarone</e1>  interaction.
"
Other
Comment:

200	 <e0>Amiodarone</e0>  is known to raise serum  <e1>digoxin</e1>  levels. "
mechanism(e0,e1)Comment:

400	The pharmacokinetic variables for  <e0>digoxin</e0>  were determined after a 1.0 mg intravenous dose of  <e1>digoxin</e1>  in each subject, before and after oral  amiodarone , 400 mg daily for 3 weeks. "
Other
Comment:

401	The pharmacokinetic variables for  <e0>digoxin</e0>  were determined after a 1.0 mg intravenous dose of  digoxin  in each subject, before and after oral  <e1>amiodarone</e1> , 400 mg daily for 3 weeks. "
Other
Comment:

402	The pharmacokinetic variables for  digoxin  were determined after a 1.0 mg intravenous dose of  <e0>digoxin</e0>  in each subject, before and after oral  <e1>amiodarone</e1> , 400 mg daily for 3 weeks. "
Other
Comment:

500	During  <e0>amiodarone</e0>  administration, systemic clearance of  <e1>digoxin</e1>  was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). "
mechanism(e0,e1)Comment:

900	 <e0>Amiodarone</e0>  caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in  <e1>digoxin</e1>  pharmacokinetics. "
Other
Comment:

1000	These alterations in  <e0>digoxin</e0>  pharmacokinetics produced by  <e1>amiodarone</e1>  explain the increase in serum  digoxin  level that has been observed when this drug combination has been used clinically."
mechanism(e0,e1)Comment:

1001	These alterations in  <e0>digoxin</e0>  pharmacokinetics produced by  amiodarone  explain the increase in serum  <e1>digoxin</e1>  level that has been observed when this drug combination has been used clinically."
Other
Comment:

1002	These alterations in  digoxin  pharmacokinetics produced by  <e0>amiodarone</e0>  explain the increase in serum  <e1>digoxin</e1>  level that has been observed when this drug combination has been used clinically."
Other
Comment:


100	 <e0>Misonidazole</e0>  protects mouse tumour and normal tissues from the toxicity of oral  <e1>CCNU</e1> .
"
effect(e0,e1)Comment:

200	Because the  <e0>nitrosourea</e0>   <e1>CCNU</e1>  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  CCNU , either alone or in combination with the chemosensitizer  misonidazole . "
Other
Comment:

201	Because the  <e0>nitrosourea</e0>   CCNU  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  <e1>CCNU</e1> , either alone or in combination with the chemosensitizer  misonidazole . "
Other
Comment:

202	Because the  <e0>nitrosourea</e0>   CCNU  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  CCNU , either alone or in combination with the chemosensitizer  <e1>misonidazole</e1> . "
Other
Comment:

203	Because the  nitrosourea   <e0>CCNU</e0>  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  <e1>CCNU</e1> , either alone or in combination with the chemosensitizer  misonidazole . "
Other
Comment:

204	Because the  nitrosourea   <e0>CCNU</e0>  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  CCNU , either alone or in combination with the chemosensitizer  <e1>misonidazole</e1> . "
Other
Comment:

205	Because the  nitrosourea   CCNU  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  <e0>CCNU</e0> , either alone or in combination with the chemosensitizer  <e1>misonidazole</e1> . "
Other
Comment:

800	 <e0>Misonidazole</e0>  reduced the antitumour activity of oral  <e1>CCNU</e1>  by dose modifying factors (DMF) of 0.58-0.71. "
effect(e0,e1)Comment:

1000	 <e0>Misonidazole</e0>  has a complex effect on oral  <e1>CCNU</e1>  pharmacokinetics. "
mechanism(e0,e1)Comment:

1500	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral  <e0>CCNU</e0>  cytotoxicity by  <e1>misonidazole</e1> . "
mechanism(e0,e1)Comment:


100	Enhanced  <e0>theophylline</e0>  clearance secondary to  <e1>phenytoin</e1>  therapy.
"
mechanism(e0,e1)Comment:

200	This report describes two cases in which  <e0>theophylline</e0>  clearance accelerated markedly with concomitant  <e1>phenytoin</e1>  administration. "
mechanism(e0,e1)Comment:

500	With combined use, clinicians should be aware, when  <e0>phenytoin</e0>  is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum  <e1>theophylline</e1>  concentrations."
effect(e0,e1)Comment:


200	The behavioral effects of the stereoisomers of  <e0>N-allylnormetazocine</e0>  ( <e1>NANM</e1> ) were compared with those of  phencyclidine  ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. "
Other
Comment:

201	The behavioral effects of the stereoisomers of  <e0>N-allylnormetazocine</e0>  ( NANM ) were compared with those of  <e1>phencyclidine</e1>  ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. "
Other
Comment:

202	The behavioral effects of the stereoisomers of  <e0>N-allylnormetazocine</e0>  ( NANM ) were compared with those of  phencyclidine  ( <e1>PCP</e1> ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. "
Other
Comment:

203	The behavioral effects of the stereoisomers of  N-allylnormetazocine  ( <e0>NANM</e0> ) were compared with those of  <e1>phencyclidine</e1>  ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. "
Other
Comment:

204	The behavioral effects of the stereoisomers of  N-allylnormetazocine  ( <e0>NANM</e0> ) were compared with those of  phencyclidine  ( <e1>PCP</e1> ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. "
Other
Comment:

205	The behavioral effects of the stereoisomers of  N-allylnormetazocine  ( NANM ) were compared with those of  <e0>phencyclidine</e0>  ( <e1>PCP</e1> ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. "
Other
Comment:

300	Intermediate doses of  <e0>(+)-NANM</e0>  or  <e1>PCP</e1>  produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; "
Other
Comment:

700	In monkeys,  <e0>(-)-NANM</e0>  was about 10 times more potent than  <e1>(+)-NANM</e1>  in decreasing responding, whereas in pigeons  (-)-NANM  was about equipotent with  (+)-NANM . "
Other
Comment:

701	In monkeys,  <e0>(-)-NANM</e0>  was about 10 times more potent than  (+)-NANM  in decreasing responding, whereas in pigeons  <e1>(-)-NANM</e1>  was about equipotent with  (+)-NANM . "
Other
Comment:

702	In monkeys,  <e0>(-)-NANM</e0>  was about 10 times more potent than  (+)-NANM  in decreasing responding, whereas in pigeons  (-)-NANM  was about equipotent with  <e1>(+)-NANM</e1> . "
Other
Comment:

703	In monkeys,  (-)-NANM  was about 10 times more potent than  <e0>(+)-NANM</e0>  in decreasing responding, whereas in pigeons  <e1>(-)-NANM</e1>  was about equipotent with  (+)-NANM . "
Other
Comment:

704	In monkeys,  (-)-NANM  was about 10 times more potent than  <e0>(+)-NANM</e0>  in decreasing responding, whereas in pigeons  (-)-NANM  was about equipotent with  <e1>(+)-NANM</e1> . "
Other
Comment:

705	In monkeys,  (-)-NANM  was about 10 times more potent than  (+)-NANM  in decreasing responding, whereas in pigeons  <e0>(-)-NANM</e0>  was about equipotent with  <e1>(+)-NANM</e1> . "
Other
Comment:

800	In both species,  <e0>(-)-NANM</e0> , but not  <e1>(+)-NANM</e1> , antagonized the rate-decreasing effects of  morphine  on FI and FR responding. "
Other
Comment:

801	In both species,  <e0>(-)-NANM</e0> , but not  (+)-NANM , antagonized the rate-decreasing effects of  <e1>morphine</e1>  on FI and FR responding. "
effect(e0,e1)Comment:

802	In both species,  (-)-NANM , but not  <e0>(+)-NANM</e0> , antagonized the rate-decreasing effects of  <e1>morphine</e1>  on FI and FR responding. "
Other
Comment:

900	In monkeys, the effects of  <e0>(-)-NANM</e0> , but not  <e1>(+)-NANM</e1>  or  PCP , were antagonized by  naloxone ; "
Other
Comment:

901	In monkeys, the effects of  <e0>(-)-NANM</e0> , but not  (+)-NANM  or  <e1>PCP</e1> , were antagonized by  naloxone ; "
Other
Comment:

902	In monkeys, the effects of  <e0>(-)-NANM</e0> , but not  (+)-NANM  or  PCP , were antagonized by  <e1>naloxone</e1> ; "
effect(e0,e1)Comment:

903	In monkeys, the effects of  (-)-NANM , but not  <e0>(+)-NANM</e0>  or  <e1>PCP</e1> , were antagonized by  naloxone ; "
Other
Comment:

904	In monkeys, the effects of  (-)-NANM , but not  <e0>(+)-NANM</e0>  or  PCP , were antagonized by  <e1>naloxone</e1> ; "
Other
Comment:

905	In monkeys, the effects of  (-)-NANM , but not  (+)-NANM  or  <e0>PCP</e0> , were antagonized by  <e1>naloxone</e1> ; "
Other
Comment:

1000	the doses of  <e0>naloxone</e0>  required to antagonize the effects of  <e1>(-)-NANM</e1>  were more than 100 times higher than those required to antagonize the effects of  morphine . "
effect(e0,e1)Comment:

1001	the doses of  <e0>naloxone</e0>  required to antagonize the effects of  (-)-NANM  were more than 100 times higher than those required to antagonize the effects of  <e1>morphine</e1> . "
effect(e0,e1)Comment:

1002	the doses of  naloxone  required to antagonize the effects of  <e0>(-)-NANM</e0>  were more than 100 times higher than those required to antagonize the effects of  <e1>morphine</e1> . "
Other
Comment:

1100	In pigeons,  <e0>naloxone</e0>  did not systematically alter the effects of  <e1>(-)-NANM</e1> ,  (+)-NANM  or  PCP . "
Other
Comment:

1101	In pigeons,  <e0>naloxone</e0>  did not systematically alter the effects of  (-)-NANM ,  <e1>(+)-NANM</e1>  or  PCP . "
Other
Comment:

1102	In pigeons,  <e0>naloxone</e0>  did not systematically alter the effects of  (-)-NANM ,  (+)-NANM  or  <e1>PCP</e1> . "
Other
Comment:

1103	In pigeons,  naloxone  did not systematically alter the effects of  <e0>(-)-NANM</e0> ,  <e1>(+)-NANM</e1>  or  PCP . "
Other
Comment:

1104	In pigeons,  naloxone  did not systematically alter the effects of  <e0>(-)-NANM</e0> ,  (+)-NANM  or  <e1>PCP</e1> . "
Other
Comment:

1105	In pigeons,  naloxone  did not systematically alter the effects of  (-)-NANM ,  <e0>(+)-NANM</e0>  or  <e1>PCP</e1> . "
Other
Comment:

1200	 <e0>Haloperidol</e0>  reduced or eliminated the increases in FI responding produced by intermediate doses of either  <e1>(+)-NANM</e1>  or  PCP  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  NANM . "
effect(e0,e1)Comment:

1201	 <e0>Haloperidol</e0>  reduced or eliminated the increases in FI responding produced by intermediate doses of either  (+)-NANM  or  <e1>PCP</e1>  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  NANM . "
effect(e0,e1)Comment:

1202	 <e0>Haloperidol</e0>  reduced or eliminated the increases in FI responding produced by intermediate doses of either  (+)-NANM  or  PCP  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  <e1>NANM</e1> . "
Other
Comment:

1203	 Haloperidol  reduced or eliminated the increases in FI responding produced by intermediate doses of either  <e0>(+)-NANM</e0>  or  <e1>PCP</e1>  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  NANM . "
Other
Comment:

1204	 Haloperidol  reduced or eliminated the increases in FI responding produced by intermediate doses of either  <e0>(+)-NANM</e0>  or  PCP  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  <e1>NANM</e1> . "
Other
Comment:

1205	 Haloperidol  reduced or eliminated the increases in FI responding produced by intermediate doses of either  (+)-NANM  or  <e0>PCP</e0>  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  <e1>NANM</e1> . "
Other
Comment:


100	Increased hepatotoxicity of  <e0>acetaminophen</e0>  by concomitant administration of  <e1>caffeine</e1>  in the rat."
effect(e0,e1)Comment:

200	Since  <e0>caffeine</e0>  is frequently co-administered with  <e1>acetaminophen</e1> , it is of clinical interest to study the effect of  caffeine  on the hepatotoxicity of  acetaminophen . "
Other
Comment:

201	Since  <e0>caffeine</e0>  is frequently co-administered with  acetaminophen , it is of clinical interest to study the effect of  <e1>caffeine</e1>  on the hepatotoxicity of  acetaminophen . "
Other
Comment:

202	Since  <e0>caffeine</e0>  is frequently co-administered with  acetaminophen , it is of clinical interest to study the effect of  caffeine  on the hepatotoxicity of  <e1>acetaminophen</e1> . "
Other
Comment:

203	Since  caffeine  is frequently co-administered with  <e0>acetaminophen</e0> , it is of clinical interest to study the effect of  <e1>caffeine</e1>  on the hepatotoxicity of  acetaminophen . "
Other
Comment:

204	Since  caffeine  is frequently co-administered with  <e0>acetaminophen</e0> , it is of clinical interest to study the effect of  caffeine  on the hepatotoxicity of  <e1>acetaminophen</e1> . "
Other
Comment:

205	Since  caffeine  is frequently co-administered with  acetaminophen , it is of clinical interest to study the effect of  <e0>caffeine</e0>  on the hepatotoxicity of  <e1>acetaminophen</e1> . "
Other
Comment:

500	Careful observations on hepatotoxicity are suggested when  <e0>acetaminophen</e0>  is prescribed with  <e1>caffeine</e1> ."
effect(e0,e1)Comment:


100	High-dose  <e0>cisplatin</e0>  with  <e1>sodium thiosulfate</e1>  protection.
"
effect(e0,e1)Comment:

300	 <e0>Sodium thiosulfate</e0>  is a neutralizing agent for  <e1>cisplatin</e1>  that protects against renal damage. "
effect(e0,e1)Comment:

400	To determine whether injection of  <e0>thiosulfate</e0>  would permit larger doses of  <e1>cisplatin</e1>  to be administered, a fixed 9.9-g/m2 dose of  thiosulfate  was given intravenously over three hours concurrently with escalating doses of  cisplatin . "
Other
Comment:

401	To determine whether injection of  <e0>thiosulfate</e0>  would permit larger doses of  cisplatin  to be administered, a fixed 9.9-g/m2 dose of  <e1>thiosulfate</e1>  was given intravenously over three hours concurrently with escalating doses of  cisplatin . "
Other
Comment:

402	To determine whether injection of  <e0>thiosulfate</e0>  would permit larger doses of  cisplatin  to be administered, a fixed 9.9-g/m2 dose of  thiosulfate  was given intravenously over three hours concurrently with escalating doses of  <e1>cisplatin</e1> . "
Other
Comment:

403	To determine whether injection of  thiosulfate  would permit larger doses of  <e0>cisplatin</e0>  to be administered, a fixed 9.9-g/m2 dose of  <e1>thiosulfate</e1>  was given intravenously over three hours concurrently with escalating doses of  cisplatin . "
Other
Comment:

404	To determine whether injection of  thiosulfate  would permit larger doses of  <e0>cisplatin</e0>  to be administered, a fixed 9.9-g/m2 dose of  thiosulfate  was given intravenously over three hours concurrently with escalating doses of  <e1>cisplatin</e1> . "
Other
Comment:

405	To determine whether injection of  thiosulfate  would permit larger doses of  cisplatin  to be administered, a fixed 9.9-g/m2 dose of  <e0>thiosulfate</e0>  was given intravenously over three hours concurrently with escalating doses of  <e1>cisplatin</e1> . "
Other
Comment:

500	 <e0>Cisplatin</e0>  was administered over the last two hours of the  <e1>thiosulfate</e1>  infusion. "
Other
Comment:

700	Comparison of  <e0>cisplatin</e0>  pharmacokinetics in patients treated with 202.5 mg/m2 plus  <e1>thiosulfate</e1>  to those in patients treated with 100 mg/m2 without  thiosulfate  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  cisplatin . "
Other
Comment:

701	Comparison of  <e0>cisplatin</e0>  pharmacokinetics in patients treated with 202.5 mg/m2 plus  thiosulfate  to those in patients treated with 100 mg/m2 without  <e1>thiosulfate</e1>  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  cisplatin . "
Other
Comment:

702	Comparison of  <e0>cisplatin</e0>  pharmacokinetics in patients treated with 202.5 mg/m2 plus  thiosulfate  to those in patients treated with 100 mg/m2 without  thiosulfate  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  <e1>cisplatin</e1> . "
Other
Comment:

703	Comparison of  cisplatin  pharmacokinetics in patients treated with 202.5 mg/m2 plus  <e0>thiosulfate</e0>  to those in patients treated with 100 mg/m2 without  <e1>thiosulfate</e1>  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  cisplatin . "
Other
Comment:

704	Comparison of  cisplatin  pharmacokinetics in patients treated with 202.5 mg/m2 plus  <e0>thiosulfate</e0>  to those in patients treated with 100 mg/m2 without  thiosulfate  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  <e1>cisplatin</e1> . "
Other
Comment:

705	Comparison of  cisplatin  pharmacokinetics in patients treated with 202.5 mg/m2 plus  thiosulfate  to those in patients treated with 100 mg/m2 without  <e0>thiosulfate</e0>  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  <e1>cisplatin</e1> . "
Other
Comment:

900	This study demonstrates that concurrent administration of  <e0>thiosulfate</e0>  permits at least a twofold increase in dose and total exposure to  <e1>cisplatin</e1> ."
mechanism(e0,e1)Comment:



100	Repeated oral administration of  <e0>coumaphos</e0>  in sheep: interactions of  <e1>coumaphos</e1>  with  bishydroxycoumarin ,  trichlorfon , and  phenobarbital sodium .
"
Other
Comment:

101	Repeated oral administration of  <e0>coumaphos</e0>  in sheep: interactions of  coumaphos  with  <e1>bishydroxycoumarin</e1> ,  trichlorfon , and  phenobarbital sodium .
"
Other
Comment:

102	Repeated oral administration of  <e0>coumaphos</e0>  in sheep: interactions of  coumaphos  with  bishydroxycoumarin ,  <e1>trichlorfon</e1> , and  phenobarbital sodium .
"
Other
Comment:

103	Repeated oral administration of  <e0>coumaphos</e0>  in sheep: interactions of  coumaphos  with  bishydroxycoumarin ,  trichlorfon , and  <e1>phenobarbital sodium</e1> .
"
Other
Comment:

104	Repeated oral administration of  coumaphos  in sheep: interactions of  <e0>coumaphos</e0>  with  <e1>bishydroxycoumarin</e1> ,  trichlorfon , and  phenobarbital sodium .
"
Other
Comment:

105	Repeated oral administration of  coumaphos  in sheep: interactions of  <e0>coumaphos</e0>  with  bishydroxycoumarin ,  <e1>trichlorfon</e1> , and  phenobarbital sodium .
"
Other
Comment:

106	Repeated oral administration of  coumaphos  in sheep: interactions of  <e0>coumaphos</e0>  with  bishydroxycoumarin ,  trichlorfon , and  <e1>phenobarbital sodium</e1> .
"
Other
Comment:

107	Repeated oral administration of  coumaphos  in sheep: interactions of  coumaphos  with  <e0>bishydroxycoumarin</e0> ,  <e1>trichlorfon</e1> , and  phenobarbital sodium .
"
Other
Comment:

108	Repeated oral administration of  coumaphos  in sheep: interactions of  coumaphos  with  <e0>bishydroxycoumarin</e0> ,  trichlorfon , and  <e1>phenobarbital sodium</e1> .
"
Other
Comment:

109	Repeated oral administration of  coumaphos  in sheep: interactions of  coumaphos  with  bishydroxycoumarin ,  <e0>trichlorfon</e0> , and  <e1>phenobarbital sodium</e1> .
"
Other
Comment:

200	Interactions between treatments with  <e0>coumaphos</e0> ,  <e1>bishydroxycoumarin</e1>  (an  anticoagulant ),  trichlorfon  (an  organophosphorous compound ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

201	Interactions between treatments with  <e0>coumaphos</e0> ,  bishydroxycoumarin  (an  <e1>anticoagulant</e1> ),  trichlorfon  (an  organophosphorous compound ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

202	Interactions between treatments with  <e0>coumaphos</e0> ,  bishydroxycoumarin  (an  anticoagulant ),  <e1>trichlorfon</e1>  (an  organophosphorous compound ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

203	Interactions between treatments with  <e0>coumaphos</e0> ,  bishydroxycoumarin  (an  anticoagulant ),  trichlorfon  (an  <e1>organophosphorous compound</e1> ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

204	Interactions between treatments with  <e0>coumaphos</e0> ,  bishydroxycoumarin  (an  anticoagulant ),  trichlorfon  (an  organophosphorous compound ), and  <e1>phenobarbital sodium</e1>  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

205	Interactions between treatments with  coumaphos ,  <e0>bishydroxycoumarin</e0>  (an  <e1>anticoagulant</e1> ),  trichlorfon  (an  organophosphorous compound ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

206	Interactions between treatments with  coumaphos ,  <e0>bishydroxycoumarin</e0>  (an  anticoagulant ),  <e1>trichlorfon</e1>  (an  organophosphorous compound ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

207	Interactions between treatments with  coumaphos ,  <e0>bishydroxycoumarin</e0>  (an  anticoagulant ),  trichlorfon  (an  <e1>organophosphorous compound</e1> ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

208	Interactions between treatments with  coumaphos ,  <e0>bishydroxycoumarin</e0>  (an  anticoagulant ),  trichlorfon  (an  organophosphorous compound ), and  <e1>phenobarbital sodium</e1>  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

209	Interactions between treatments with  coumaphos ,  bishydroxycoumarin  (an  <e0>anticoagulant</e0> ),  <e1>trichlorfon</e1>  (an  organophosphorous compound ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

210	Interactions between treatments with  coumaphos ,  bishydroxycoumarin  (an  <e0>anticoagulant</e0> ),  trichlorfon  (an  <e1>organophosphorous compound</e1> ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

211	Interactions between treatments with  coumaphos ,  bishydroxycoumarin  (an  <e0>anticoagulant</e0> ),  trichlorfon  (an  organophosphorous compound ), and  <e1>phenobarbital sodium</e1>  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

212	Interactions between treatments with  coumaphos ,  bishydroxycoumarin  (an  anticoagulant ),  <e0>trichlorfon</e0>  (an  <e1>organophosphorous compound</e1> ), and  phenobarbital sodium  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

213	Interactions between treatments with  coumaphos ,  bishydroxycoumarin  (an  anticoagulant ),  <e0>trichlorfon</e0>  (an  organophosphorous compound ), and  <e1>phenobarbital sodium</e1>  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

214	Interactions between treatments with  coumaphos ,  bishydroxycoumarin  (an  anticoagulant ),  trichlorfon  (an  <e0>organophosphorous compound</e0> ), and  <e1>phenobarbital sodium</e1>  (an inducer of microsomal enzymes) were investigated in sheep. "
Other
Comment:

300	A daily dose of 2 mg of  <e0>coumaphos</e0> /kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of  <e1>bishydroxy-coumarin</e1>  in wethers. "
Other
Comment:

400	The treatment of ewes with an intravenous (IV) injection of  <e0>trichlorfon</e0> , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of  <e1>coumaphos</e1> /kg/day. "
effect(e0,e1)Comment:

500	In ewes given 40 mg of  <e0>phenobarbital sodium</e0> /kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of  <e1>coumaphos</e1> /kg was significantly reduced and signs of toxicity were not present. "
effect(e0,e1)Comment:



100	Failure of  <e0>neomycin</e0>  to modify  <e1>ACTH</e1>  induced hypertension in sheep."
Other
Comment:

200	Studies in rats have shown that  <e0>neomycin</e0>  administration attenuates certain types of  <e1>adrenocortical steroid</e1>  dependent hypertension, including  ACTH  hypertension. "
Other
Comment:

201	Studies in rats have shown that  <e0>neomycin</e0>  administration attenuates certain types of  adrenocortical steroid  dependent hypertension, including  <e1>ACTH</e1>  hypertension. "
effect(e0,e1)Comment:

202	Studies in rats have shown that  neomycin  administration attenuates certain types of  <e0>adrenocortical steroid</e0>  dependent hypertension, including  <e1>ACTH</e1>  hypertension. "
Other
Comment:

300	The effects of oral  <e0>neomycin</e0>  on  <e1>ACTH</e1>  induced hypertension were examined in conscious sheep. "
Other
Comment:

400	 <e0>Neomycin</e0>  has no effect on the blood pressure or metabolic responses to  <e1>ACTH</e1>  in sheep."
Other
Comment:


100	Changes in urinary homocysteine following  <e0>synthetic steroidal estrogen</e0>  and progest <e1>synthetic steroidal progestogen</e1>  estrogen and progestogen administration to rats."
Other
Comment:

200	The present work involved the administration of both  <e0>ethynyl estradiol</e0>  and  <e1>levonorgestrel</e1>  to groups of rats, followed by determination of the homocysteine excretion rate in urine. "
Other
Comment:

300	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and  <e0>levonorgestrel</e0> -treated rats and the levels shown by rats treated with  <e1>ethynyl estradiol</e1> . "
Other
Comment:


500	Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of  <e0>trimethyl lead</e0>  ( <e1>TML</e1> ) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle. "
Other
Comment:

700	The 20% v/v solution of  <e0>alcohol</e0>  was prepared in water from a stock solution of 95%  <e1>ethanol</e1> . "
Other
Comment:

1000	These results suggest that exposure to environmental  <e0>lead</e0>  may alter the biological and behavioral responsiveness of an animal to  <e1>alcohol</e1> ."
effect(e0,e1)Comment:


300	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of  <e0>alcohol</e0>  on these components may help to trace pathways which are affected by  <e1>alcohol</e1> . "
Other
Comment:

400	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline,  <e0>ethanol</e0>  (2.0 g/kg),  <e1>physostigmine</e1>  (0.6 mg/kg) or  atropine  (15.0 mg/kg) on separate days. "
Other
Comment:

401	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline,  <e0>ethanol</e0>  (2.0 g/kg),  physostigmine  (0.6 mg/kg) or  <e1>atropine</e1>  (15.0 mg/kg) on separate days. "
Other
Comment:

402	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline,  ethanol  (2.0 g/kg),  <e0>physostigmine</e0>  (0.6 mg/kg) or  <e1>atropine</e1>  (15.0 mg/kg) on separate days. "
Other
Comment:

900	 <e0>Physostigmine</e0>  pretreatment augmented the depressant effect of  <e1>alcohol</e1>  on the early components P1 and N1, while attenuating  alcohol 's influence on components P2 and P3. "
effect(e0,e1)Comment:

901	 <e0>Physostigmine</e0>  pretreatment augmented the depressant effect of  alcohol  on the early components P1 and N1, while attenuating  <e1>alcohol</e1> 's influence on components P2 and P3. "
effect(e0,e1)Comment:

902	 Physostigmine  pretreatment augmented the depressant effect of  <e0>alcohol</e0>  on the early components P1 and N1, while attenuating  <e1>alcohol</e1> 's influence on components P2 and P3. "
Other
Comment:

1100	 <e0>Atropine</e0> , either alone or in combination with  <e1>alcohol</e1> , produced approximately the same degree of enhancement of component P2. "
Other
Comment:


100	Hypothermia as an index of the  <e0>disulfiram</e0> - <e1>ethanol</e1>  reaction in the rat.
"
Other
Comment:

200	Decreased core temperature in female rats was investigated as one possible index of the  <e0>disulfiram</e0> - <e1>ethanol</e1>  reaction (DER). "
Other
Comment:

300	Core temperature was decreased in rats in a dose-dependent manner when  <e0>ethanol</e0>  was administered to rats treated with  <e1>disulfiram</e1>  8 hours before the  ethanol  challenge. "
effect(e0,e1)Comment:

301	Core temperature was decreased in rats in a dose-dependent manner when  <e0>ethanol</e0>  was administered to rats treated with  disulfiram  8 hours before the  <e1>ethanol</e1>  challenge. "
Other
Comment:

302	Core temperature was decreased in rats in a dose-dependent manner when  ethanol  was administered to rats treated with  <e0>disulfiram</e0>  8 hours before the  <e1>ethanol</e1>  challenge. "
Other
Comment:

400	The decrease in temperature began within 20 minutes after  <e0>ethanol</e0>  administration, reaching a maximal decrease between 60 and 120 minutes post  <e1>ethanol</e1> . "
Other
Comment:

700	Maximal hypotension was found 120 minutes post  <e0>ethanol</e0> , and returned to normal 300 minutes after  <e1>ethanol</e1> . "
Other
Comment:



100	Interaction on the antinociceptive effect between  <e0>neurotensin</e0>  and  <e1>enkephalins</e1>  or  tuftsin .
"
effect(e0,e1)Comment:

101	Interaction on the antinociceptive effect between  <e0>neurotensin</e0>  and  enkephalins  or  <e1>tuftsin</e1> .
"
effect(e0,e1)Comment:

102	Interaction on the antinociceptive effect between  neurotensin  and  <e0>enkephalins</e0>  or  <e1>tuftsin</e1> .
"
Other
Comment:

200	The aim of this paper was to study the interaction between  <e0>neurotensin</e0>  and both  <e1>enkephalins</e1>  or its synthetic analogue  D-Ala2-metenkephalinamide , or  tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection. "
Other
Comment:

201	The aim of this paper was to study the interaction between  <e0>neurotensin</e0>  and both  enkephalins  or its synthetic analogue  <e1>D-Ala2-metenkephalinamide</e1> , or  tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection. "
Other
Comment:

202	The aim of this paper was to study the interaction between  <e0>neurotensin</e0>  and both  enkephalins  or its synthetic analogue  D-Ala2-metenkephalinamide , or  <e1>tuftsin</e1> , on the antinonciceptive effect of these peptides in mice after intracisternal injection. "
Other
Comment:

203	The aim of this paper was to study the interaction between  neurotensin  and both  <e0>enkephalins</e0>  or its synthetic analogue  <e1>D-Ala2-metenkephalinamide</e1> , or  tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection. "
Other
Comment:

204	The aim of this paper was to study the interaction between  neurotensin  and both  <e0>enkephalins</e0>  or its synthetic analogue  D-Ala2-metenkephalinamide , or  <e1>tuftsin</e1> , on the antinonciceptive effect of these peptides in mice after intracisternal injection. "
Other
Comment:

205	The aim of this paper was to study the interaction between  neurotensin  and both  enkephalins  or its synthetic analogue  <e0>D-Ala2-metenkephalinamide</e0> , or  <e1>tuftsin</e1> , on the antinonciceptive effect of these peptides in mice after intracisternal injection. "
Other
Comment:

400	It was shown that  <e0>neurotensin</e0>  antagonized evidently the antinociceptive effect of  <e1>enkephalins</e1>  and their analogue. "
effect(e0,e1)Comment:

500	On the contrary,  <e0>neurotensin</e0>  and  <e1>tuftsin</e1>  were agonists in induction of analgesia. "
effect(e0,e1)Comment:

600	It is concluded that  <e0>neurotensin</e0>  modulates in an opposite way the function of the enkephalinergic neurons and the central action of  <e1>tuftsin</e1> ."
effect(e0,e1)Comment:



900	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of  <e0>thiabendazole</e0>  to treat strongyloidiasis during the  <e1>melarsoprol</e1>  cure and the bad general clinical conditions of patients. "
effect(e0,e1)Comment:

1100	Recommendations were to avoid administration of diffusible  <e0>anti-helminthic</e0>  treatment during the cure, and to improve the general conditions of patients before the cure of  <e1>melarsoprol</e1> ."
Other
Comment:


100	Interactions of  <e0>cobalt</e0>  and  <e1>iron</e1>  in absorption and retention.
"
mechanism(e0,e1)Comment:

200	The effects of supplementary oral  <e0>cobalt</e0>  and  <e1>iron</e1> , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  Co  and 48 or 446 mg/kg of  Fe  over a period of 19 days in a total of 24 rats. "
Other
Comment:

201	The effects of supplementary oral  <e0>cobalt</e0>  and  iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  <e1>Co</e1>  and 48 or 446 mg/kg of  Fe  over a period of 19 days in a total of 24 rats. "
Other
Comment:

202	The effects of supplementary oral  <e0>cobalt</e0>  and  iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  Co  and 48 or 446 mg/kg of  <e1>Fe</e1>  over a period of 19 days in a total of 24 rats. "
Other
Comment:

203	The effects of supplementary oral  cobalt  and  <e0>iron</e0> , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  <e1>Co</e1>  and 48 or 446 mg/kg of  Fe  over a period of 19 days in a total of 24 rats. "
Other
Comment:

204	The effects of supplementary oral  cobalt  and  <e0>iron</e0> , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  Co  and 48 or 446 mg/kg of  <e1>Fe</e1>  over a period of 19 days in a total of 24 rats. "
Other
Comment:

205	The effects of supplementary oral  cobalt  and  iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  <e0>Co</e0>  and 48 or 446 mg/kg of  <e1>Fe</e1>  over a period of 19 days in a total of 24 rats. "
Other
Comment:

500	 <e0>Cobalt</e0>  excretion was enhanced by supplementary  <e1>cobalt</e1> ; "
Other
Comment:

800	Additional  <e0>iron</e0>  significantly inhibited the absorption of  <e1>cobalt</e1>  in both dietary  cobalt  treatments. "
mechanism(e0,e1)Comment:

801	Additional  <e0>iron</e0>  significantly inhibited the absorption of  cobalt  in both dietary  <e1>cobalt</e1>  treatments. "
mechanism(e0,e1)Comment:

802	Additional  iron  significantly inhibited the absorption of  <e0>cobalt</e0>  in both dietary  <e1>cobalt</e1>  treatments. "
Other
Comment:

900	The lower rate of absorption in the groups receiving 446 mg  <e0>Fe</e0>  instead of 48 mg of  <e1>Fe</e1>  per kg diet resulted in a decreased renal excretion of  cobalt . "
Other
Comment:

901	The lower rate of absorption in the groups receiving 446 mg  <e0>Fe</e0>  instead of 48 mg of  Fe  per kg diet resulted in a decreased renal excretion of  <e1>cobalt</e1> . "
mechanism(e0,e1)Comment:

902	The lower rate of absorption in the groups receiving 446 mg  Fe  instead of 48 mg of  <e0>Fe</e0>  per kg diet resulted in a decreased renal excretion of  <e1>cobalt</e1> . "
Other
Comment:

1000	Consequently, the effect of  <e0>iron</e0>  on the retention of  <e1>cobalt</e1>  was lower than on absorption. "
mechanism(e0,e1)Comment:

1200	Because of the low dietary  <e0>cobalt</e0>  concentration as compared to the  <e1>iron</e1>  contents of the diets, no effect of  cobalt  on  iron  absorption and excretion occurred. "
Other
Comment:

1201	Because of the low dietary  <e0>cobalt</e0>  concentration as compared to the  iron  contents of the diets, no effect of  <e1>cobalt</e1>  on  iron  absorption and excretion occurred. "
Other
Comment:

1202	Because of the low dietary  <e0>cobalt</e0>  concentration as compared to the  iron  contents of the diets, no effect of  cobalt  on  <e1>iron</e1>  absorption and excretion occurred. "
Other
Comment:

1203	Because of the low dietary  cobalt  concentration as compared to the  <e0>iron</e0>  contents of the diets, no effect of  <e1>cobalt</e1>  on  iron  absorption and excretion occurred. "
Other
Comment:

1204	Because of the low dietary  cobalt  concentration as compared to the  <e0>iron</e0>  contents of the diets, no effect of  cobalt  on  <e1>iron</e1>  absorption and excretion occurred. "
Other
Comment:

1205	Because of the low dietary  cobalt  concentration as compared to the  iron  contents of the diets, no effect of  <e0>cobalt</e0>  on  <e1>iron</e1>  absorption and excretion occurred. "
Other
Comment:

1300	Differences in  <e0>iron</e0>  balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further  <e1>Fe</e1> .(ABSTRACT TRUNCATED AT 250 WORDS)"
Other
Comment:


100	Effect of  <e0>estradiol</e0>  on  <e1>endotoxin</e1> -induced changes in steroid hormone levels and lethality in male rats."
Other
Comment:

200	We examined the effect of exogenous  <e0>estradiol</e0>  on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli  <e1>endotoxin</e1>  in male rats and the deaths due to nonlethal and lethal doses of  endotoxin . "
Other
Comment:

201	We examined the effect of exogenous  <e0>estradiol</e0>  on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli  endotoxin  in male rats and the deaths due to nonlethal and lethal doses of  <e1>endotoxin</e1> . "
Other
Comment:

202	We examined the effect of exogenous  estradiol  on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli  <e0>endotoxin</e0>  in male rats and the deaths due to nonlethal and lethal doses of  <e1>endotoxin</e1> . "
Other
Comment:

300	Injection of  <e0>estradiol</e0>  5 min before a nonlethal dose of  <e1>endotoxin</e1>  changed the serum sex steroid hormone response of male rats to  endotoxin . "
effect(e0,e1)Comment:

301	Injection of  <e0>estradiol</e0>  5 min before a nonlethal dose of  endotoxin  changed the serum sex steroid hormone response of male rats to  <e1>endotoxin</e1> . "
Other
Comment:

302	Injection of  estradiol  5 min before a nonlethal dose of  <e0>endotoxin</e0>  changed the serum sex steroid hormone response of male rats to  <e1>endotoxin</e1> . "
Other
Comment:

400	The serum estrogen concentrations of  <e0>estradiol</e0>  +  <e1>endotoxin</e1> -treated rats decreased by 50%, while those of the  endotoxin -treated rats increased (2- to 5-fold). "
mechanism(e0,e1)Comment:

401	The serum estrogen concentrations of  <e0>estradiol</e0>  +  endotoxin -treated rats decreased by 50%, while those of the  <e1>endotoxin</e1> -treated rats increased (2- to 5-fold). "
Other
Comment:

402	The serum estrogen concentrations of  estradiol  +  <e0>endotoxin</e0> -treated rats decreased by 50%, while those of the  <e1>endotoxin</e1> -treated rats increased (2- to 5-fold). "
Other
Comment:

500	The serum androgen concentrations of  <e0>estradiol</e0>  +  <e1>endotoxin</e1> -treated rats did not change significantly, while those of  endotoxin -treated rats dropped to 30-40%"
Other
Comment:

501	The serum androgen concentrations of  <e0>estradiol</e0>  +  endotoxin -treated rats did not change significantly, while those of  <e1>endotoxin</e1> -treated rats dropped to 30-40%"
Other
Comment:

502	The serum androgen concentrations of  estradiol  +  <e0>endotoxin</e0> -treated rats did not change significantly, while those of  <e1>endotoxin</e1> -treated rats dropped to 30-40%"
Other
Comment:

700	Exogenous  <e0>estradiol</e0>  also appeared to influence the percentage of  <e1>endotoxin</e1> -induced deaths in a dose-dependent manner. "
effect(e0,e1)Comment:

900	These results, together with the known relationships between  <e0>estrogen</e0>  and the immune response, suggest that  <e1>estrogens</e1>  affect the course of septic shock in a complex fashion and may have either protective or deleterious effect."
Other
Comment:


200	The  <e0>16,16-dimethylprostaglandin E2</e0>  ( <e1>dmPGE2</e1> )-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. "
Other
Comment:

1100	On the other hand, the enhanced secretion of colonic fluid by  <e0>dmPGE2</e0> , given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of  <e1>dmPGE2</e1>  in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. "
Other
Comment:

1300	 <e0>Loperamide</e0>  and  <e1>morphine</e1>  (0.1 and 1.0 mg/kg, s.c.) "
Other
Comment:

1400	 <e0>Loperamide</e0>  and  <e1>morphine</e1>  (0.1 and 1.0 mg/kg, s.c.) inhibited the  dmPGE2  (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. "
Other
Comment:

1401	 <e0>Loperamide</e0>  and  morphine  (0.1 and 1.0 mg/kg, s.c.) inhibited the  <e1>dmPGE2</e1>  (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. "
effect(e0,e1)Comment:

1402	 Loperamide  and  <e0>morphine</e0>  (0.1 and 1.0 mg/kg, s.c.) inhibited the  <e1>dmPGE2</e1>  (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. "
effect(e0,e1)Comment:

1600	 <e0>N-methyllevallorphan</e0>  (5 mg/kg, s.c.) completely antagonized the inhibitory effect of  <e1>loperamide</e1>  and partly antagonized the effect of  morphine . "
effect(e0,e1)Comment:

1601	 <e0>N-methyllevallorphan</e0>  (5 mg/kg, s.c.) completely antagonized the inhibitory effect of  loperamide  and partly antagonized the effect of  <e1>morphine</e1> . "
effect(e0,e1)Comment:

1602	 N-methyllevallorphan  (5 mg/kg, s.c.) completely antagonized the inhibitory effect of  <e0>loperamide</e0>  and partly antagonized the effect of  <e1>morphine</e1> . "
Other
Comment:


100	Therapeutic drug monitoring can avoid iatrogenic alterations caused by  <e0>99mTc-methylene diphosphonate</e0>  (MDP)- <e1>gentamicin</e1>  interaction.
"
effect(e0,e1)Comment:

200	 <e0>Gentamicin</e0>  is an  <e1>aminoglycoside antibiotic</e1>  used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. "
Other
Comment:

300	Due to its nephrotoxicity,  <e0>gentamicin</e0>  may cause abnormal renal uptake to be seen on  <e1>99mTc-MDP</e1>  bone scintigraphy. "
mechanism(e0,e1)Comment:

800	Therapeutic drug monitoring (TDM) of  <e0>gentamicin</e0>  therapy, and bone scintigraphy employing  <e1>99mTc-MDP</e1>  as the  radiopharmaceutical  was carried out in 22 patients. "
Other
Comment:

801	Therapeutic drug monitoring (TDM) of  <e0>gentamicin</e0>  therapy, and bone scintigraphy employing  99mTc-MDP  as the  <e1>radiopharmaceutical</e1>  was carried out in 22 patients. "
Other
Comment:

802	Therapeutic drug monitoring (TDM) of  gentamicin  therapy, and bone scintigraphy employing  <e0>99mTc-MDP</e0>  as the  <e1>radiopharmaceutical</e1>  was carried out in 22 patients. "
Other
Comment:

900	The data presented here demonstrate that with serial pharmacokinetic dosing of  <e0>gentamicin</e0> , the iatrogenic alteration caused by  <e1>gentamicin</e1>  therapy can be avoided."
Other
Comment:


500	This article looks at five commonly used  <e0>immunosuppressive drugs</e0>  in turn ( <e1>corticosteroids</e1> ,  cyclosporin ,  azathioprine ,  methotrexate ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

501	This article looks at five commonly used  <e0>immunosuppressive drugs</e0>  in turn ( corticosteroids ,  <e1>cyclosporin</e1> ,  azathioprine ,  methotrexate ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

502	This article looks at five commonly used  <e0>immunosuppressive drugs</e0>  in turn ( corticosteroids ,  cyclosporin ,  <e1>azathioprine</e1> ,  methotrexate ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

503	This article looks at five commonly used  <e0>immunosuppressive drugs</e0>  in turn ( corticosteroids ,  cyclosporin ,  azathioprine ,  <e1>methotrexate</e1> ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

504	This article looks at five commonly used  <e0>immunosuppressive drugs</e0>  in turn ( corticosteroids ,  cyclosporin ,  azathioprine ,  methotrexate ,  <e1>cyclophosphamide</e1> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

505	This article looks at five commonly used  immunosuppressive drugs  in turn ( <e0>corticosteroids</e0> ,  <e1>cyclosporin</e1> ,  azathioprine ,  methotrexate ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

506	This article looks at five commonly used  immunosuppressive drugs  in turn ( <e0>corticosteroids</e0> ,  cyclosporin ,  <e1>azathioprine</e1> ,  methotrexate ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

507	This article looks at five commonly used  immunosuppressive drugs  in turn ( <e0>corticosteroids</e0> ,  cyclosporin ,  azathioprine ,  <e1>methotrexate</e1> ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

508	This article looks at five commonly used  immunosuppressive drugs  in turn ( <e0>corticosteroids</e0> ,  cyclosporin ,  azathioprine ,  methotrexate ,  <e1>cyclophosphamide</e1> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

509	This article looks at five commonly used  immunosuppressive drugs  in turn ( corticosteroids ,  <e0>cyclosporin</e0> ,  <e1>azathioprine</e1> ,  methotrexate ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

510	This article looks at five commonly used  immunosuppressive drugs  in turn ( corticosteroids ,  <e0>cyclosporin</e0> ,  azathioprine ,  <e1>methotrexate</e1> ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

511	This article looks at five commonly used  immunosuppressive drugs  in turn ( corticosteroids ,  <e0>cyclosporin</e0> ,  azathioprine ,  methotrexate ,  <e1>cyclophosphamide</e1> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

512	This article looks at five commonly used  immunosuppressive drugs  in turn ( corticosteroids ,  cyclosporin ,  <e0>azathioprine</e0> ,  <e1>methotrexate</e1> ,  cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

513	This article looks at five commonly used  immunosuppressive drugs  in turn ( corticosteroids ,  cyclosporin ,  <e0>azathioprine</e0> ,  methotrexate ,  <e1>cyclophosphamide</e1> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:

514	This article looks at five commonly used  immunosuppressive drugs  in turn ( corticosteroids ,  cyclosporin ,  azathioprine ,  <e0>methotrexate</e0> ,  <e1>cyclophosphamide</e1> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. "
Other
Comment:


200	Little has been studied of the adverse effects of the exposure of the liver to the interaction of  <e0>ethanol</e0>  with its congeners and  <e1>acetaldehyde</e1> , coexisting in the contents of alcoholic beverages. "
Other
Comment:

400	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  <e0>ethanol</e0> ,  <e1>methanol</e1> , higher  alcohols  and  acetaldehyde  in the same proportions as those found in most common distilled and fermented alcoholic beverages; "
Other
Comment:

401	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  <e0>ethanol</e0> ,  methanol , higher  <e1>alcohols</e1>  and  acetaldehyde  in the same proportions as those found in most common distilled and fermented alcoholic beverages; "
Other
Comment:

402	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  <e0>ethanol</e0> ,  methanol , higher  alcohols  and  <e1>acetaldehyde</e1>  in the same proportions as those found in most common distilled and fermented alcoholic beverages; "
Other
Comment:

403	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  ethanol ,  <e0>methanol</e0> , higher  <e1>alcohols</e1>  and  acetaldehyde  in the same proportions as those found in most common distilled and fermented alcoholic beverages; "
Other
Comment:

404	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  ethanol ,  <e0>methanol</e0> , higher  alcohols  and  <e1>acetaldehyde</e1>  in the same proportions as those found in most common distilled and fermented alcoholic beverages; "
Other
Comment:

405	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  ethanol ,  methanol , higher  <e0>alcohols</e0>  and  <e1>acetaldehyde</e1>  in the same proportions as those found in most common distilled and fermented alcoholic beverages; "
Other
Comment:

1000	These results suggest that the hepatoxicity of  <e0>ethanol</e0>  in alcoholic beverages is enhanced by interaction with its congeners and  <e1>acetaldehyde</e1> ; "
effect(e0,e1)Comment:


100	Induction of apoptosis in breast cancer cells in response to  <e0>vitamin D</e0>  and  <e1>antiestrogens</e1> .
"
Other
Comment:

200	1, <e0>25-Dihydroxycholecalciferol D3</e0>  ( <e1>1,25(OH)2D3</e1> ), the active metabolite of  vitamin D , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. "
Other
Comment:

201	1, <e0>25-Dihydroxycholecalciferol D3</e0>  ( 1,25(OH)2D3 ), the active metabolite of  <e1>vitamin D</e1> , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. "
Other
Comment:

202	1, 25-Dihydroxycholecalciferol D3  ( <e0>1,25(OH)2D3</e0> ), the active metabolite of  <e1>vitamin D</e1> , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. "
Other
Comment:

400	In the experiments reported here, we examined the interactions between  <e0>1,25(OH)2D3</e0>  and the  <e1>antiestrogen</e1>   4-hydroxytamoxifen  ( TAM ), which also induces apoptosis in MCF-7 cells. "
Other
Comment:

401	In the experiments reported here, we examined the interactions between  <e0>1,25(OH)2D3</e0>  and the  antiestrogen   <e1>4-hydroxytamoxifen</e1>  ( TAM ), which also induces apoptosis in MCF-7 cells. "
Other
Comment:

402	In the experiments reported here, we examined the interactions between  <e0>1,25(OH)2D3</e0>  and the  antiestrogen   4-hydroxytamoxifen  ( <e1>TAM</e1> ), which also induces apoptosis in MCF-7 cells. "
Other
Comment:

403	In the experiments reported here, we examined the interactions between  1,25(OH)2D3  and the  <e0>antiestrogen</e0>   <e1>4-hydroxytamoxifen</e1>  ( TAM ), which also induces apoptosis in MCF-7 cells. "
Other
Comment:

404	In the experiments reported here, we examined the interactions between  1,25(OH)2D3  and the  <e0>antiestrogen</e0>   4-hydroxytamoxifen  ( <e1>TAM</e1> ), which also induces apoptosis in MCF-7 cells. "
Other
Comment:

405	In the experiments reported here, we examined the interactions between  1,25(OH)2D3  and the  antiestrogen   <e0>4-hydroxytamoxifen</e0>  ( <e1>TAM</e1> ), which also induces apoptosis in MCF-7 cells. "
Other
Comment:

500	Our data suggest that  <e0>TAM</e0>  significantly potentiates the reduction in cell number induced by  <e1>1,25(OH)2D3</e1>  alone. "
effect(e0,e1)Comment:

600	Combined treatment with  <e0>1,25(OH)2D3</e0>  and  <e1>TAM</e1>  enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. "
effect(e0,e1)Comment:

1000	These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of  <e0>vitamin-D</e0> -mediated signalling or disruption of  <e1>estrogen</e1> -dependent signalling."
Other
Comment:



200	We investigated the effects of adenosine receptor antagonists,  <e0>caffeine</e0> ,  <e1>theophylline</e1> ,  8-phenyltheophylline , and  8-cyclopentyl-1,3-dipropylxanthine  ( DPCPX ), in a light/dark test in mice. "
Other
Comment:

201	We investigated the effects of adenosine receptor antagonists,  <e0>caffeine</e0> ,  theophylline ,  <e1>8-phenyltheophylline</e1> , and  8-cyclopentyl-1,3-dipropylxanthine  ( DPCPX ), in a light/dark test in mice. "
Other
Comment:

202	We investigated the effects of adenosine receptor antagonists,  <e0>caffeine</e0> ,  theophylline ,  8-phenyltheophylline , and  <e1>8-cyclopentyl-1,3-dipropylxanthine</e1>  ( DPCPX ), in a light/dark test in mice. "
Other
Comment:

203	We investigated the effects of adenosine receptor antagonists,  <e0>caffeine</e0> ,  theophylline ,  8-phenyltheophylline , and  8-cyclopentyl-1,3-dipropylxanthine  ( <e1>DPCPX</e1> ), in a light/dark test in mice. "
Other
Comment:

204	We investigated the effects of adenosine receptor antagonists,  caffeine ,  <e0>theophylline</e0> ,  <e1>8-phenyltheophylline</e1> , and  8-cyclopentyl-1,3-dipropylxanthine  ( DPCPX ), in a light/dark test in mice. "
Other
Comment:

205	We investigated the effects of adenosine receptor antagonists,  caffeine ,  <e0>theophylline</e0> ,  8-phenyltheophylline , and  <e1>8-cyclopentyl-1,3-dipropylxanthine</e1>  ( DPCPX ), in a light/dark test in mice. "
Other
Comment:

206	We investigated the effects of adenosine receptor antagonists,  caffeine ,  <e0>theophylline</e0> ,  8-phenyltheophylline , and  8-cyclopentyl-1,3-dipropylxanthine  ( <e1>DPCPX</e1> ), in a light/dark test in mice. "
Other
Comment:

207	We investigated the effects of adenosine receptor antagonists,  caffeine ,  theophylline ,  <e0>8-phenyltheophylline</e0> , and  <e1>8-cyclopentyl-1,3-dipropylxanthine</e1>  ( DPCPX ), in a light/dark test in mice. "
Other
Comment:

208	We investigated the effects of adenosine receptor antagonists,  caffeine ,  theophylline ,  <e0>8-phenyltheophylline</e0> , and  8-cyclopentyl-1,3-dipropylxanthine  ( <e1>DPCPX</e1> ), in a light/dark test in mice. "
Other
Comment:

209	We investigated the effects of adenosine receptor antagonists,  caffeine ,  theophylline ,  8-phenyltheophylline , and  <e0>8-cyclopentyl-1,3-dipropylxanthine</e0>  ( <e1>DPCPX</e1> ), in a light/dark test in mice. "
Other
Comment:

400	The anxiogenic effects of  <e0>theophylline</e0>  were reduced by pretreatment with  <e1>CGS 21680</e1> , an A2-selective agonist, but not by  N6-cyclopentyladenosine  ( CPA ), an A1-selective agonist. "
effect(e0,e1)Comment:

401	The anxiogenic effects of  <e0>theophylline</e0>  were reduced by pretreatment with  CGS 21680 , an A2-selective agonist, but not by  <e1>N6-cyclopentyladenosine</e1>  ( CPA ), an A1-selective agonist. "
Other
Comment:

402	The anxiogenic effects of  <e0>theophylline</e0>  were reduced by pretreatment with  CGS 21680 , an A2-selective agonist, but not by  N6-cyclopentyladenosine  ( <e1>CPA</e1> ), an A1-selective agonist. "
Other
Comment:

403	The anxiogenic effects of  theophylline  were reduced by pretreatment with  <e0>CGS 21680</e0> , an A2-selective agonist, but not by  <e1>N6-cyclopentyladenosine</e1>  ( CPA ), an A1-selective agonist. "
Other
Comment:

404	The anxiogenic effects of  theophylline  were reduced by pretreatment with  <e0>CGS 21680</e0> , an A2-selective agonist, but not by  N6-cyclopentyladenosine  ( <e1>CPA</e1> ), an A1-selective agonist. "
Other
Comment:

405	The anxiogenic effects of  theophylline  were reduced by pretreatment with  CGS 21680 , an A2-selective agonist, but not by  <e0>N6-cyclopentyladenosine</e0>  ( <e1>CPA</e1> ), an A1-selective agonist. "
Other
Comment:

500	However, the antagonism of the  <e0>theophylline</e0> -induced anxiogenic effects by  <e1>CGS21680</e1>  was only observed in the time spent in the light zone, and  DPCPX -induced anxiogenic effects were neither reversed by  CGS 21680  nor by  CPA . "
effect(e0,e1)Comment:

501	However, the antagonism of the  <e0>theophylline</e0> -induced anxiogenic effects by  CGS21680  was only observed in the time spent in the light zone, and  <e1>DPCPX</e1> -induced anxiogenic effects were neither reversed by  CGS 21680  nor by  CPA . "
Other
Comment:

502	However, the antagonism of the  <e0>theophylline</e0> -induced anxiogenic effects by  CGS21680  was only observed in the time spent in the light zone, and  DPCPX -induced anxiogenic effects were neither reversed by  <e1>CGS 21680</e1>  nor by  CPA . "
Other
Comment:

503	However, the antagonism of the  <e0>theophylline</e0> -induced anxiogenic effects by  CGS21680  was only observed in the time spent in the light zone, and  DPCPX -induced anxiogenic effects were neither reversed by  CGS 21680  nor by  <e1>CPA</e1> . "
Other
Comment:

504	However, the antagonism of the  theophylline -induced anxiogenic effects by  <e0>CGS21680</e0>  was only observed in the time spent in the light zone, and  <e1>DPCPX</e1> -induced anxiogenic effects were neither reversed by  CGS 21680  nor by  CPA . "
Other
Comment:

505	However, the antagonism of the  theophylline -induced anxiogenic effects by  <e0>CGS21680</e0>  was only observed in the time spent in the light zone, and  DPCPX -induced anxiogenic effects were neither reversed by  <e1>CGS 21680</e1>  nor by  CPA . "
Other
Comment:

506	However, the antagonism of the  theophylline -induced anxiogenic effects by  <e0>CGS21680</e0>  was only observed in the time spent in the light zone, and  DPCPX -induced anxiogenic effects were neither reversed by  CGS 21680  nor by  <e1>CPA</e1> . "
Other
Comment:

507	However, the antagonism of the  theophylline -induced anxiogenic effects by  CGS21680  was only observed in the time spent in the light zone, and  <e0>DPCPX</e0> -induced anxiogenic effects were neither reversed by  <e1>CGS 21680</e1>  nor by  CPA . "
Other
Comment:

508	However, the antagonism of the  theophylline -induced anxiogenic effects by  CGS21680  was only observed in the time spent in the light zone, and  <e0>DPCPX</e0> -induced anxiogenic effects were neither reversed by  CGS 21680  nor by  <e1>CPA</e1> . "
Other
Comment:

509	However, the antagonism of the  theophylline -induced anxiogenic effects by  CGS21680  was only observed in the time spent in the light zone, and  DPCPX -induced anxiogenic effects were neither reversed by  <e0>CGS 21680</e0>  nor by  <e1>CPA</e1> . "
Other
Comment:


100	[The effect of  <e0>sandimmune</e0>  on the activity of mixed-function mono-oxidases in the liver microsomes]
The effects of the  <e1>immunodepressant</e1> --the drug  sandimmune --on hepatic microsomal monooxygenase activities were studied. "
Other
Comment:

101	[The effect of  <e0>sandimmune</e0>  on the activity of mixed-function mono-oxidases in the liver microsomes]
The effects of the  immunodepressant --the drug  <e1>sandimmune</e1> --on hepatic microsomal monooxygenase activities were studied. "
Other
Comment:

102	[The effect of  sandimmune  on the activity of mixed-function mono-oxidases in the liver microsomes]
The effects of the  <e0>immunodepressant</e0> --the drug  <e1>sandimmune</e1> --on hepatic microsomal monooxygenase activities were studied. "
Other
Comment:


100	[The effect of  <e0>cimetidine</e0>  on the renal excretion of  <e1>verografin</e1>  and  iodamide  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  verografine  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

101	[The effect of  <e0>cimetidine</e0>  on the renal excretion of  verografin  and  <e1>iodamide</e1>  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  verografine  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

102	[The effect of  <e0>cimetidine</e0>  on the renal excretion of  verografin  and  iodamide  in dogs]
The intravenous injection of  <e1>cimetidine</e1>  in a dose of 20 mg/kg enhanced  verografine  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

103	[The effect of  <e0>cimetidine</e0>  on the renal excretion of  verografin  and  iodamide  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  <e1>verografine</e1>  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

104	[The effect of  <e0>cimetidine</e0>  on the renal excretion of  verografin  and  iodamide  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  verografine  and  <e1>iodamide</e1>  excretion in chronic canine experiments. "
Other
Comment:

105	[The effect of  cimetidine  on the renal excretion of  <e0>verografin</e0>  and  <e1>iodamide</e1>  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  verografine  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

106	[The effect of  cimetidine  on the renal excretion of  <e0>verografin</e0>  and  iodamide  in dogs]
The intravenous injection of  <e1>cimetidine</e1>  in a dose of 20 mg/kg enhanced  verografine  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

107	[The effect of  cimetidine  on the renal excretion of  <e0>verografin</e0>  and  iodamide  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  <e1>verografine</e1>  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

108	[The effect of  cimetidine  on the renal excretion of  <e0>verografin</e0>  and  iodamide  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  verografine  and  <e1>iodamide</e1>  excretion in chronic canine experiments. "
Other
Comment:

109	[The effect of  cimetidine  on the renal excretion of  verografin  and  <e0>iodamide</e0>  in dogs]
The intravenous injection of  <e1>cimetidine</e1>  in a dose of 20 mg/kg enhanced  verografine  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

110	[The effect of  cimetidine  on the renal excretion of  verografin  and  <e0>iodamide</e0>  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  <e1>verografine</e1>  and  iodamide  excretion in chronic canine experiments. "
Other
Comment:

111	[The effect of  cimetidine  on the renal excretion of  verografin  and  <e0>iodamide</e0>  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  verografine  and  <e1>iodamide</e1>  excretion in chronic canine experiments. "
Other
Comment:

112	[The effect of  cimetidine  on the renal excretion of  verografin  and  iodamide  in dogs]
The intravenous injection of  <e0>cimetidine</e0>  in a dose of 20 mg/kg enhanced  <e1>verografine</e1>  and  iodamide  excretion in chronic canine experiments. "
mechanism(e0,e1)Comment:

113	[The effect of  cimetidine  on the renal excretion of  verografin  and  iodamide  in dogs]
The intravenous injection of  <e0>cimetidine</e0>  in a dose of 20 mg/kg enhanced  verografine  and  <e1>iodamide</e1>  excretion in chronic canine experiments. "
mechanism(e0,e1)Comment:

114	[The effect of  cimetidine  on the renal excretion of  verografin  and  iodamide  in dogs]
The intravenous injection of  cimetidine  in a dose of 20 mg/kg enhanced  <e0>verografine</e0>  and  <e1>iodamide</e1>  excretion in chronic canine experiments. "
Other
Comment:

200	The higher  <e0>verografine</e0>  and  <e1>iodamide</e1>  excretion was due to their increased renal tubular secretion. "
Other
Comment:

300	In dogs,  <e0>cimetidine</e0>  unchanged the secretion of  <e1>cardiotrast</e1> , a test agent for anionic transport. "
Other
Comment:

400	Possible extrarenal mechanisms of action of  <e0>cimetidine</e0>  on  <e1>verografine</e1>  and  iodamide  transport were also examined."
Other
Comment:

401	Possible extrarenal mechanisms of action of  <e0>cimetidine</e0>  on  verografine  and  <e1>iodamide</e1>  transport were also examined."
Other
Comment:

402	Possible extrarenal mechanisms of action of  cimetidine  on  <e0>verografine</e0>  and  <e1>iodamide</e1>  transport were also examined."
Other
Comment:



200	Two different types of therapy with  <e0>magnesium</e0>  are used: physiological oral  <e1>magnesium</e1>  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  magnesium  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

201	Two different types of therapy with  <e0>magnesium</e0>  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  <e1>magnesium</e1>  deficiencies by simply normalizing the  magnesium  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

202	Two different types of therapy with  <e0>magnesium</e0>  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  <e1>magnesium</e1>  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

203	Two different types of therapy with  <e0>magnesium</e0>  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  magnesium  intake and pharmacological  <e1>magnesium</e1>  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

204	Two different types of therapy with  <e0>magnesium</e0>  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  magnesium  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  <e1>magnesium</e1>  overload. "
Other
Comment:

205	Two different types of therapy with  magnesium  are used: physiological oral  <e0>magnesium</e0>  supplementation which is totally atoxic since it palliates  <e1>magnesium</e1>  deficiencies by simply normalizing the  magnesium  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

206	Two different types of therapy with  magnesium  are used: physiological oral  <e0>magnesium</e0>  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  <e1>magnesium</e1>  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

207	Two different types of therapy with  magnesium  are used: physiological oral  <e0>magnesium</e0>  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  magnesium  intake and pharmacological  <e1>magnesium</e1>  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

208	Two different types of therapy with  magnesium  are used: physiological oral  <e0>magnesium</e0>  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  magnesium  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  <e1>magnesium</e1>  overload. "
Other
Comment:

209	Two different types of therapy with  magnesium  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  <e0>magnesium</e0>  deficiencies by simply normalizing the  <e1>magnesium</e1>  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

210	Two different types of therapy with  magnesium  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  <e0>magnesium</e0>  deficiencies by simply normalizing the  magnesium  intake and pharmacological  <e1>magnesium</e1>  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

211	Two different types of therapy with  magnesium  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  <e0>magnesium</e0>  deficiencies by simply normalizing the  magnesium  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  <e1>magnesium</e1>  overload. "
Other
Comment:

212	Two different types of therapy with  magnesium  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  <e0>magnesium</e0>  intake and pharmacological  <e1>magnesium</e1>  therapy which may induce toxicity since it creates iatrogenic  magnesium  overload. "
Other
Comment:

213	Two different types of therapy with  magnesium  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  <e0>magnesium</e0>  intake and pharmacological  magnesium  therapy which may induce toxicity since it creates iatrogenic  <e1>magnesium</e1>  overload. "
Other
Comment:

214	Two different types of therapy with  magnesium  are used: physiological oral  magnesium  supplementation which is totally atoxic since it palliates  magnesium  deficiencies by simply normalizing the  magnesium  intake and pharmacological  <e0>magnesium</e0>  therapy which may induce toxicity since it creates iatrogenic  <e1>magnesium</e1>  overload. "
Other
Comment:

300	Primary and secondary  <e0>magnesium</e0>  deficiencies constitute the sole indication of physiological oral  <e1>magnesium</e1>  therapy. "
Other
Comment:

400	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e0>magnesium</e0>  deficit and to discriminate between  <e1>magnesium</e1>  deficiency due to an insufficient  magnesium  intake which only requires oral physiological supplementation and  magnesium  depletion related to a dysregulation of the control mechanisms of  magnesium  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

401	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e0>magnesium</e0>  deficit and to discriminate between  magnesium  deficiency due to an insufficient  <e1>magnesium</e1>  intake which only requires oral physiological supplementation and  magnesium  depletion related to a dysregulation of the control mechanisms of  magnesium  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

402	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e0>magnesium</e0>  deficit and to discriminate between  magnesium  deficiency due to an insufficient  magnesium  intake which only requires oral physiological supplementation and  <e1>magnesium</e1>  depletion related to a dysregulation of the control mechanisms of  magnesium  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

403	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e0>magnesium</e0>  deficit and to discriminate between  magnesium  deficiency due to an insufficient  magnesium  intake which only requires oral physiological supplementation and  magnesium  depletion related to a dysregulation of the control mechanisms of  <e1>magnesium</e1>  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

404	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  magnesium  deficit and to discriminate between  <e0>magnesium</e0>  deficiency due to an insufficient  <e1>magnesium</e1>  intake which only requires oral physiological supplementation and  magnesium  depletion related to a dysregulation of the control mechanisms of  magnesium  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

405	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  magnesium  deficit and to discriminate between  <e0>magnesium</e0>  deficiency due to an insufficient  magnesium  intake which only requires oral physiological supplementation and  <e1>magnesium</e1>  depletion related to a dysregulation of the control mechanisms of  magnesium  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

406	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  magnesium  deficit and to discriminate between  <e0>magnesium</e0>  deficiency due to an insufficient  magnesium  intake which only requires oral physiological supplementation and  magnesium  depletion related to a dysregulation of the control mechanisms of  <e1>magnesium</e1>  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

407	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  magnesium  deficit and to discriminate between  magnesium  deficiency due to an insufficient  <e0>magnesium</e0>  intake which only requires oral physiological supplementation and  <e1>magnesium</e1>  depletion related to a dysregulation of the control mechanisms of  magnesium  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

408	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  magnesium  deficit and to discriminate between  magnesium  deficiency due to an insufficient  <e0>magnesium</e0>  intake which only requires oral physiological supplementation and  magnesium  depletion related to a dysregulation of the control mechanisms of  <e1>magnesium</e1>  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

409	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  magnesium  deficit and to discriminate between  magnesium  deficiency due to an insufficient  magnesium  intake which only requires oral physiological supplementation and  <e0>magnesium</e0>  depletion related to a dysregulation of the control mechanisms of  <e1>magnesium</e1>  status which requires more or less specific regulation of its causal dysregulation. "
Other
Comment:

500	Physiological oral  <e0>magnesium</e0>  load constitutes the best tool for diagnosis of  <e1>magnesium</e1>  deficiency and the first step of its treatment. "
Other
Comment:

600	Physiological oral  <e0>magnesium</e0>  supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with  <e1>magnesium salt</e1> s, with practically only one contra-indication: overt renal failure. "
Other
Comment:

700	Specific and aspecific treatments of  <e0>magnesium</e0>  depletion are tricky using for example  <e1>magnesium sparing diuretics</e1> , pharmacological doses of  vitamin B6 , physiological doses of  vitamin D  and of  selenium . "
Other
Comment:

701	Specific and aspecific treatments of  <e0>magnesium</e0>  depletion are tricky using for example  magnesium sparing diuretics , pharmacological doses of  <e1>vitamin B6</e1> , physiological doses of  vitamin D  and of  selenium . "
Other
Comment:

702	Specific and aspecific treatments of  <e0>magnesium</e0>  depletion are tricky using for example  magnesium sparing diuretics , pharmacological doses of  vitamin B6 , physiological doses of  <e1>vitamin D</e1>  and of  selenium . "
Other
Comment:

703	Specific and aspecific treatments of  <e0>magnesium</e0>  depletion are tricky using for example  magnesium sparing diuretics , pharmacological doses of  vitamin B6 , physiological doses of  vitamin D  and of  <e1>selenium</e1> . "
Other
Comment:

704	Specific and aspecific treatments of  magnesium  depletion are tricky using for example  <e0>magnesium sparing diuretics</e0> , pharmacological doses of  <e1>vitamin B6</e1> , physiological doses of  vitamin D  and of  selenium . "
Other
Comment:

705	Specific and aspecific treatments of  magnesium  depletion are tricky using for example  <e0>magnesium sparing diuretics</e0> , pharmacological doses of  vitamin B6 , physiological doses of  <e1>vitamin D</e1>  and of  selenium . "
Other
Comment:

706	Specific and aspecific treatments of  magnesium  depletion are tricky using for example  <e0>magnesium sparing diuretics</e0> , pharmacological doses of  vitamin B6 , physiological doses of  vitamin D  and of  <e1>selenium</e1> . "
Other
Comment:

707	Specific and aspecific treatments of  magnesium  depletion are tricky using for example  magnesium sparing diuretics , pharmacological doses of  <e0>vitamin B6</e0> , physiological doses of  <e1>vitamin D</e1>  and of  selenium . "
Other
Comment:

708	Specific and aspecific treatments of  magnesium  depletion are tricky using for example  magnesium sparing diuretics , pharmacological doses of  <e0>vitamin B6</e0> , physiological doses of  vitamin D  and of  <e1>selenium</e1> . "
Other
Comment:

709	Specific and aspecific treatments of  magnesium  depletion are tricky using for example  magnesium sparing diuretics , pharmacological doses of  vitamin B6 , physiological doses of  <e0>vitamin D</e0>  and of  <e1>selenium</e1> . "
Other
Comment:

900	There are 3 types of indications: specific (for the treatment of some forms of  <e0>magnesium</e0>  deficit i.e. acute), pharmacological (i.e. without alterations of  <e1>magnesium</e1>  status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism). "
Other
Comment:

1600	Lastly local use of the mucocutaneous and cytoprotective properties of  <e0>magnesium</e0>  is still valid, in  <e1>cardioplegic solutions</e1>  and for preservation of transplants particularly."
Other
Comment:


100	Interaction between  <e0>glycine</e0>  and  <e1>glutamate</e1>  in the development of spontaneous motility in chick embryos.
"
effect(e0,e1)Comment:

500	The successive application of  <e0>glycine</e0>  (5 or 10 mg/kg egg weight (e.w.) and  <e1>glutamate</e1>  (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of  glutamate  alone. "
effect(e0,e1)Comment:

501	The successive application of  <e0>glycine</e0>  (5 or 10 mg/kg egg weight (e.w.) and  glutamate  (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of  <e1>glutamate</e1>  alone. "
Other
Comment:

502	The successive application of  glycine  (5 or 10 mg/kg egg weight (e.w.) and  <e0>glutamate</e0>  (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of  <e1>glutamate</e1>  alone. "
Other
Comment:


1200	The EC50 values for  <e0>isoproterenol</e0> , which is not a substrate for  <e1>norepinephrine</e1>  uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. "
Other
Comment:

1300	The uptake inhibitors  <e0>cocaine</e0>  and  <e1>desipramine</e1>  (3 mumol/liter) potentiated the positive inotropic effects of  norepinephrine  in nonfailing myocardium (p lt; 0.05) but not in functional class IV myocardium. "
Other
Comment:

1301	The uptake inhibitors  <e0>cocaine</e0>  and  desipramine  (3 mumol/liter) potentiated the positive inotropic effects of  <e1>norepinephrine</e1>  in nonfailing myocardium (p lt; 0.05) but not in functional class IV myocardium. "
effect(e0,e1)Comment:

1302	The uptake inhibitors  cocaine  and  <e0>desipramine</e0>  (3 mumol/liter) potentiated the positive inotropic effects of  <e1>norepinephrine</e1>  in nonfailing myocardium (p lt; 0.05) but not in functional class IV myocardium. "
effect(e0,e1)Comment:

1400	Radioligand binding experiments using the uptake inhibitor hydrogen-3  <e0>mazindol</e0>  revealed a significant decrease by approximately 30% in  <e1>norepinephrine</e1>  uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p lt; 0.05). "
Other
Comment:

1700	This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as  <e0>cocaine</e0>  and  <e1>desipramine</e1> , in the nonfailing heart only. "
Other
Comment:

1800	Compromised  <e0>norepinephrine</e0>  uptake-1 in functional class IV cannot be further increased by  <e1>cocaine</e1>  and  desipramine . "
Other
Comment:

1801	Compromised  <e0>norepinephrine</e0>  uptake-1 in functional class IV cannot be further increased by  cocaine  and  <e1>desipramine</e1> . "
Other
Comment:

1802	Compromised  norepinephrine  uptake-1 in functional class IV cannot be further increased by  <e0>cocaine</e0>  and  <e1>desipramine</e1> . "
Other
Comment:


100	[A pharmacological analysis of the effect of  <e0>angiotensin</e0>  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  <e1>angiotensin 1</e1>  and  angiotensin 2  on  pentagastrin - and  histamine -induced gastric acid secretion. "
Other
Comment:

101	[A pharmacological analysis of the effect of  <e0>angiotensin</e0>  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  angiotensin 1  and  <e1>angiotensin 2</e1>  on  pentagastrin - and  histamine -induced gastric acid secretion. "
Other
Comment:

102	[A pharmacological analysis of the effect of  <e0>angiotensin</e0>  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  angiotensin 1  and  angiotensin 2  on  <e1>pentagastrin</e1> - and  histamine -induced gastric acid secretion. "
Other
Comment:

103	[A pharmacological analysis of the effect of  <e0>angiotensin</e0>  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  angiotensin 1  and  angiotensin 2  on  pentagastrin - and  <e1>histamine</e1> -induced gastric acid secretion. "
Other
Comment:

104	[A pharmacological analysis of the effect of  angiotensin  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  <e0>angiotensin 1</e0>  and  <e1>angiotensin 2</e1>  on  pentagastrin - and  histamine -induced gastric acid secretion. "
Other
Comment:

105	[A pharmacological analysis of the effect of  angiotensin  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  <e0>angiotensin 1</e0>  and  angiotensin 2  on  <e1>pentagastrin</e1> - and  histamine -induced gastric acid secretion. "
Other
Comment:

106	[A pharmacological analysis of the effect of  angiotensin  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  <e0>angiotensin 1</e0>  and  angiotensin 2  on  pentagastrin - and  <e1>histamine</e1> -induced gastric acid secretion. "
Other
Comment:

107	[A pharmacological analysis of the effect of  angiotensin  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  angiotensin 1  and  <e0>angiotensin 2</e0>  on  <e1>pentagastrin</e1> - and  histamine -induced gastric acid secretion. "
Other
Comment:

108	[A pharmacological analysis of the effect of  angiotensin  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  angiotensin 1  and  <e0>angiotensin 2</e0>  on  pentagastrin - and  <e1>histamine</e1> -induced gastric acid secretion. "
Other
Comment:

109	[A pharmacological analysis of the effect of  angiotensin  on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of  angiotensin 1  and  angiotensin 2  on  <e0>pentagastrin</e0> - and  <e1>histamine</e1> -induced gastric acid secretion. "
Other
Comment:

200	It was established that both angiotensins inhibited gastric acid secretion stimulated by  <e0>pentagastrin</e0>  but not by  <e1>histamine</e1> . "
Other
Comment:

300	Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of  <e0>angiotensins</e0>  suggested the mediation of  <e1>angiotensin</e1>  influence through the modulation of cholinergic reactions of parietal cells in the stomach."
Other
Comment:


100	Interaction of  <e0>gentamycin</e0>  and  <e1>atracurium</e1>  in anaesthetised horses.
"
int(e0,e1)Comment:

200	Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by  <e0>atracurium</e0>  infusion in 7 horses anaesthetised with  <e1>halothane</e1> . "
Other
Comment:

400	 <e0>Atracurium</e0>  was again given by infusion to maintain 40% twitch for a second hour, then 2 mg  <e1>gentamycin</e1> /kg bwt were given i.v. "
Other
Comment:

800	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for  <e0>atracurium</e0>  alone and 11.5 +/- 2.7 min for  <e1>atracurium</e1>  plus  gentamycin  (P = 0.03). "
Other
Comment:

801	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for  <e0>atracurium</e0>  alone and 11.5 +/- 2.7 min for  atracurium  plus  <e1>gentamycin</e1>  (P = 0.03). "
Other
Comment:

802	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for  atracurium  alone and 11.5 +/- 2.7 min for  <e0>atracurium</e0>  plus  <e1>gentamycin</e1>  (P = 0.03). "
effect(e0,e1)Comment:

900	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for  <e0>atracurium</e0>  alone and 13.7 +/- 1.2 min for  <e1>atracurium</e1>  plus  gentamycin . "
Other
Comment:

901	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for  <e0>atracurium</e0>  alone and 13.7 +/- 1.2 min for  atracurium  plus  <e1>gentamycin</e1> . "
Other
Comment:

902	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for  atracurium  alone and 13.7 +/- 1.2 min for  <e0>atracurium</e0>  plus  <e1>gentamycin</e1> . "
effect(e0,e1)Comment:

1000	At 75% recovery of fade, hoof twitch was 87 +/- 3% for  <e0>atracurium</e0>  alone and 82 +/- 4% for  <e1>atracurium</e1>  plus  gentamycin . "
Other
Comment:

1001	At 75% recovery of fade, hoof twitch was 87 +/- 3% for  <e0>atracurium</e0>  alone and 82 +/- 4% for  atracurium  plus  <e1>gentamycin</e1> . "
Other
Comment:

1002	At 75% recovery of fade, hoof twitch was 87 +/- 3% for  atracurium  alone and 82 +/- 4% for  <e0>atracurium</e0>  plus  <e1>gentamycin</e1> . "
effect(e0,e1)Comment:

1200	It was concluded that, although  <e0>gentamycin</e0>  did augment the neuromuscular blockade of  <e1>atracurium</e1> , the effect was minimal."
effect(e0,e1)Comment:






100	Acid-catalyzed ethanolysis of  <e0>temazepam</e0>  in anhydrous and aqueous  <e1>ethanol</e1>  solutions."
mechanism(e0,e1)Comment:

200	The  <e0>benzodiazepines</e0>  are a family of  <e1>anxiolytic</e1>  and  hypnotic drugs . "
Other
Comment:

201	The  <e0>benzodiazepines</e0>  are a family of  anxiolytic  and  <e1>hypnotic drugs</e1> . "
Other
Comment:

202	The  benzodiazepines  are a family of  <e0>anxiolytic</e0>  and  <e1>hypnotic drugs</e1> . "
Other
Comment:

400	In addition to this pharmacological interaction, this report describes a novel chemical reaction between  <e0>temazepam</e0>  (a  <e1>benzodiazepine</e1> ) and  ethanol  under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. "
Other
Comment:

401	In addition to this pharmacological interaction, this report describes a novel chemical reaction between  <e0>temazepam</e0>  (a  benzodiazepine ) and  <e1>ethanol</e1>  under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. "
mechanism(e0,e1)Comment:

402	In addition to this pharmacological interaction, this report describes a novel chemical reaction between  temazepam  (a  <e0>benzodiazepine</e0> ) and  <e1>ethanol</e1>  under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. "
Other
Comment:

600	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume  <e0>alcohol</e0>  and  <e1>3-hydroxy-1,4-benzodiazepine</e1>  on a regular basis. "
mechanism(e0,e1)Comment:

